var title_f17_23_17776="Endotrach tube neck movement";
var content_f17_23_17776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Endotracheal tube with movement of the neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 218px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADaAgkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5/XvE8Gg6xp1tqlvLDp98fKTUSR5Mc5OFik7ru7MeCeOpGegqtqdhaapp9xY6jbx3NncIY5YZV3K6nqCKALNFcd4Dkl0u+1bwtd3U9w+mMktlJcNukezkX5Mt/FtdZY88nCKScmuxoAKKKKACiiigAooooAKKKKACiiigAooooAKzfEWt2Hh7SZtR1WfybaPA4BZnYnCoijlmJwAo5Jo8Ra3Y+HtIn1LVZvKtosDhSzOxOFRFHLMxIAUckmua8O6Jf63q8PifxdD5VzHk6ZpRIZdPUjG98cNOR1booO1e5IB02g39zqWnrdXmmXGmO7HZb3LIZAnYsEJCk+mTjvWjRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWDqOq3EfjHRdJtSpSe3uLm5G3JVE2Kpz2yzj64PoaAN6iiigAooooAKKKKACiiigAooooAKKKKACmLIjSOiupdMblB5XPTI7U+uQjL6X8UZIy2bbXNP81cj7s1syqQD/tJMpwf+eZoA6+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5fxlpF5NPp2t6FGG1vTZPljLhBdW7kCaBieOQAyk9HRT0zU+h+LbDVNQfTZ4rnS9YRd7affqqSlf7yEErIvYsjMAeDiuhrN17QdK8QWgtta0+2vYVO5BMgJRv7ynqp9xg0AaVFcYfDevaL83hbX3ngXpp+tbrmP6LP8A61PqxkA9Ks6V4xjfUoNK8Q6fc6Hq85KwxTkPBckDJEM6/K5wM7Ttf/ZoA6qiiigAooooAKKKKACiiigAoorL8Uaumg+HdR1SSNpRawtIsSD5pGA+VB7k4H40Ac9p8P8AwkvjvUb68PmWHh+cWljDj5PtLRI8s59WUSCNf7vz9zx1un3ttqNpHdWMyTW8mdkidDgkH9Qa881DSrrSvBnh/wAMvdtHqOu34h1C5gYq7s4kuboow5XcEkUHPygjHQV6Fptja6Zp9vY6fbx21nboI4oY12qigYAAoAs0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVykR8z4rXAX/lhosRf28yeTb/AOimrq65HRz5fxQ8SpNxLNp1jJCf70StcAj6hy2f94etAHXUU2OVJN3lur7WKttOcEdj706gAooooAKKKKACiiigAooooAKKKKACuV8Rf8j34R/7fP8A0UK6quQ+I6y2VppviK2V2fQ7kXMyICxe1YFJxgdcIxcD1jFAHX0VHbzxXNvFPbyJLDKoeORGyrqRkEEdQRUlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcT8XZrP/hFUsrgJJfXl1AlhBt3ySTCRWBQDnKgFiR0AJJFdbqc01vpt3NaRedcRxO8UeCd7BSQOPU1yXwz0XSzoem+Ilf8AtPWNQtI5Z9VuGMkrllBZVLZ8tMkjy1wBjGMigDtqKKKACiiigAooooAKKKKACuV+KP8AyImp/wDbL/0aldVXJ/FR1TwLqO9gu5oUXJxljMgAHuSQAKAF8SDd468Hg8hWu3AzxnycZ/Jj+ddXXKeOB5Oq+Eb5MeZDqwiP+0ksMsZH5srfVRXV0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcd4sP9k+MPDeuthbZ2k0i6bP3ROUMTH/trGqf9ta7Gs3xJpEGv6Df6VdM6RXUTR+Yhw0ZPR19GU4I9wKAMDw8y6V498Q6TIzxpqGzVbRHOVf5Vjn2H2ZUJXt5gP8AFXY150W1DxP4bWVFih8b+G7k5TO1WuFXlfaKeNuD2EgPVcDsfDOu2XiLR4dR05yY3+WSNuHgkH3o5B/C6ngg9DQBqUUUUAFFFFABRVOHUYJrgQrvBYsFcrhXK9QD37/lXE2uqeNdesm1nQv7Ft7FXn+zWNyjtJdqshRQ8gYCIsFJBAbBYZzg0AehUVm+G9Xh17QbDVLZJI47qJZPLkGGjJ6ow9Qcg+4qjqHjLw9p2rHTb7VraC9V0jaNyQEd8bFZsYBO5cAnuPWgDoKKKKACgjIwelFFAHAWcM3gDWLazSTzPB+oTiC3Vyd2lzufkjB/54u3yqD9xmVRwQF7+qWt6Za61pN3puox+ZaXUbRSLnBwR1B7EdQexrnfBuo6laardeGPEc63WoWkK3FpfY2m9tixXcwHAkQ4V8cHcrDG7AAOvooooAKKKKACiiigAooooAKKKwfFmq3VtoWqjQES71yK3kNrb5HzShSVHPBPfGefagDVhv7Oe6ltoLu3kuYv9ZEkgLp9QDkVPI6RRtJIyoigszMcAAdSTXl+meEvD+ufDqym8I+SNVtU8y01Rotl0t2py5mIIcMzgiRSeckGtfVZ/GWtaJPpaaDZ6bPeQmCW9mvlkSAMpDOqKpLkZOFOBnGTQBW0z4gX6aZb614g0M2vh29Ikt9QtZjKIImbEbXEbKrICMNuXcoDc4AzXolZN/o8c3hS40WHaYnsms0875gQYyg3evvVL4eakuqeDtMkKtHcwRC0uoXOWhni/dyI3uGU89xg96AOjoorL1XxBpGkv5eo6jbQS9REzgyH6IPmP4CgDUrhfh0bI674uOhc6N9uXy/Lz5H2jZ+/8vt9/wC9t43bu+ayfiR47VvBurRaJb3wmuIGt47t4TEsbP8AKGVWw7MM5GF7V5DoHxh8YaR9gtn0rRtO0q3jWGPTxZywIgJCoN5ZjwSBkDHJOKh1IrUG7bn1dRXjqfGi4KL5nhScPgbgt9GQD7HAyPwFWbX41WSlzq3h/VbWMDIkgMdwOOxAYMPwBH0rNYmi9FJfeR7SPc9ZoqK0nW6tYbiMMElRZFDDBAIzyOxqWtywooooAKKKKACuNv1j1/4j2dk482z0CAX0qnlftUpKw59SiLK2D0LoeoFdLrep2ui6Pe6nqEnl2lpC00rdSFUZOB3PoO5rF+H2m3dnost9q6eXrGrTNqF6n/PJ3ACxf9s41RP+Ak96AF+INnfXGi291pVubu8027hv0tQQDcCNvnRSSAGKltueM4zxWtoGsWevaRbalpshktZwSu5SrKQSGVlPKspBBB5BBFaFcDql1B4E8XLfSzRQ6Br86x3KswUW16cKswH9yThX9GCN/ExoA76iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKgvbSG9gMNym+MnOMkfyoAnorJ/4RzSv+fX/yI/8AjVi80myvPL+0w7/LXavzsMD8DQBz/i3w5dyahH4h8LyR23iO3TyyshxDfxA58ibH1O1+qE9wSDn2unJ4ltIvFXheWTQdflDR3CugeOV42KPDdRg4cqysu4EMMcNjg9Zb6Hp1tOk0NvtkQ5U72OD+Jrl/D+l2cvizxdZXkBcpdxXcJ3MuI5oVyOCB/rEmOfegC1ovjmzZ47DxQq6BroOxrW7bZHM3PMErYWVTgkYO4dwDXYA5GR0rMXQNLEE8DWUckM67JI5MurD0IbIrA1X4daLeQxpZS6jpJjACHT7pkVQOg8ttyf8AjtAHZUjglWCnaSMA+lfN1pq3i+5/tGwtvFWiWllZ30kAtdZtVjuvkbhpAhXG4YIwBkEHvXY6Rq93Ks0cvh3S9UeNhifTNVIQqQOquSVOc9zQBuDx7oUGr2mg30r2VxaXK2zXFxGyW8kwAGyOUjazncOMg8n3pnwb1pribxZoNzGkF1pGrT4gVs7IpZGdSPQFvMKj+7t+g56z0Oa/8QeINQ17SrKy0W9WJhZtcGUiRECvK2AFAYKgxz9zPUmqHwRsLV/HGq3kN7c6hBNC8tvNM2cxrKEjYEAFhtyAxznHWgD0G28OeJPD4Nv4Y1mzn0w+YUtdVt9xtyzbhtePaWUEt8rc4I+birCeH7HQ/A2swa1s1ZbhLi81OSVAgunYFnyvIUYAVRk7VVRnjNbtxoenXM7zTW+6RzljvYZP4GsDx1oMY8Da9DpNuv2ia1YGNpSBMo5MeScDcMr+NAGl8P0vY/A2gJqsgkvlsYRK4JO47BySQMn1OBznit+uO0KXwjrWl2l9YyQiG5QOiSTNG4z/AAspbII6Yro/7JsvsP2Pyf8AR927Zvbr9c5oAvUVk/8ACOaV/wA+v/kR/wDGrF5pNleeX9ph3+Wu1fnYYH4GgCrrvibRdBkgj1fUbe2mnz5ULNmSQDqVQZYgdyBgVztpdy+KPG+k6lp+nXUOk6XBPm+u4XgM7yhV2RI6hio27ixAB+XGeoTwDomnHUtd1A2iG9h1SeBJzneI127Vz3A9DXU3Gh6dczvNNb7pHOWO9hk/gaANKqUGq2M+q3WmRXUTahbIkk1vn50Rs7Wx6HB59qSz0mys/M+zQ7PMXa3zscj8TXM+LPAtpqNg02i4sNbhG62udzEEg58uTnJjY8MPxHIFAHYXE0dvbyzzNtiiUu7YzgAZJqLTb611PT7e+0+4jubO4QSRTRtuV1IyCDXNeE9S0jxBpb6ebZrO/ttpvdKndlmtpD655Zc5w4+VhyDWDLo6+ENQvnuNIn1DwzPL50UtmzvNp+QNytCOXi3BmDJuYbiCuBmgD0yisa2j0XxHYWt7aSQ31oUxDNDKWUj6g1Pb6Hp1tOk0NvtkQ5U72OD+JoA0qKzbjQ9OuZ3mmt90jnLHewyfwNSWek2Vn5n2aHZ5i7W+djkfiaAL1cN4z8SaX4Q8OXc+uStbGKYvBJjmR2YlSp7nsR7HtWzfab4d08Ib829sHyFM1yU3Y9MtXnnxU8XeFV8L3nh3QZH1nXZBvtLPSGNxLBNn5ZWYBhGFJBO7t2NAHGReN7Tw78QrrxZourG48O6jcRJrunzFVktS6gJcoo+/H0+ZcnAYHPG36UR1kRXjYMjDKspyCPUV87a14WsI/h1aT6no1pbeJ544lRLO2LlrtsYj2A/MCeGGcYyc8Zr0z4YwLq/gnT7bXod2qaSW025TeQUaI4XOD1KbG55+agDv6wP7C0rSdbvvESzSWLzIDeATbIJSowJHXpuA43cHAGc4FXbfQ9Otp0mht9siHKnexwfxNeeeMFsNR8SXrO3/ABL7FMXHznZJN95t3rsUL07k9xUTmoR5mCVy9r/iq41OGU2M0mm6Mg3PeNlJpl/2M8ov+0fmPbHU1/Dnhi+voPPtY49HspfmDyxeZczg/wARBPy59W3H1AqTwh4Rj1OVNV1W1aKw4a1spCcv6SyA/mq9up5xjtf+Ec0r/n1/8iP/AI1nGm5+9U+4d+xlxeBNGYIb/wC2ag6kMGubhsZ9di7Vz+FUvGXg3Tb3wjqukaNpumrfzw70RwFMhDA/M+CwBxt3c4zXU/2TZfYfsfk/6Pu3bN7dfrnNcZ4r8NSadq1lruj2EmoW0KGC902Jv3skRyfMiZmHzq235ScMMgc4rZRS2EUPCXg/wB4k0954PDcdtdQOYLuynZxNazDqjjd75BHBBBBINLqnwZ0GXe+jXup6TIW3qkU3nRL6jZJu4PoCMdsVa0xNH8QeOba/slE1jfaFFcKyll3gSkIWAP3gGI55HTtXZ2+h6dbTpNDb7ZEOVO9jg/iamVOElZoTinuX4ldYkWR97hQGbGNx9cdqfWbcaHp1zO801vukc5Y72GT+BqSz0mys/M+zQ7PMXa3zscj8TVjL1FZP/COaV/z6/wDkR/8AGrH9k2X2H7H5P+j7t2ze3X65zQBeorJ/4RzSv+fX/wAiP/jUXiddIsdIuNS1lMWljCXZgzZCgdAAeSegHc0AYvib/io/F+m+HE+awsdmq6n6NtY/ZoT/AL0imQj0hH96u1rjPh74aFlpMOo6tbeXrd45vJ13H9wWOVh68iNdqc5yQT3rZ1rw9aX9temNPLvJo3CTb2G1yMBuD2OKAMXUfiV4ftZriO2a+1L7Lv8AtL6faSTpDtJDBnA2kgg/KCTweK574k+HbLxfb6R4m06xh8S6esDRTWaeW/n2z4fzISxGJFdUOARuGR1xWXZLqPgzRLQ694ce2sURILu+trsXKxnHMrrw2wt1bHGcnAyQ8eHvD2rW8y+H9Ua1LxZQ6XeAKjE5Eu1SVY9OWBBFAF34WeLVg1O18NXd897p97ai80G9mbMksOPmt5CeTInUZ5K5zypz3/irxHp3hyyhl1O/tbN7mVbe3+0PtEkjdAPWvnmfzdB8SS+HfG7RQaPdhr3TNXsovKFrMCocg/N5Wd2TuyoJ6lWwvVa74Yt4PD2r6lrmsvfCPT3WCZ1SFIPlJ8wY43k7eenAwKAPYAJY7uzWK9lneXLyZKlDHjk4A45IAx61iat45Wy1G/itNE1TUrLTGCajeWioy27FQ+0IWDyEKwLBAcA9zxXlnhzUXj01v7aus/2FpV27zyZV7ht0awBwOpXLLgD5mI4zxXo9pYab4I+H41m5sLia60+x+13Pz/vZZQm52bJC7ickk4A57CgDtNNvrXU9Pt77T7iO5s7hBJFNG25XUjIINWa43wb4OhsNBjXWI4pNRnkkup1hZliieRy5jjAP3FLbR64z3rpLPSbKz8z7NDs8xdrfOxyPxNAF6isn/hHNK/59f/Ij/wCNWP7JsvsP2Pyf9H3btm9uv1zmgC9RWT/wjmlf8+v/AJEf/GrF5pNleeX9ph3+Wu1fnYYH4GgC9RWbb6Hp1tOk0NvtkQ5U72OD+JrLvv7Cl8Ux6TLbyzapPC104j3lYowcBnIOF3EEL6kHHQ0AdNRVGz0mys/M+zQ7PMXa3zscj8TS2Gl2dg7NaQ+WzDBO4nP5mgC7RRRQAUUUUAFFFFABXI2WP+Fs6v5OP+QLZ/aOvXz7nyvbp5v6V11cp4eGfHvi5zktts0yT0AjYgfmxP40AdXWF418QL4a8Pz34ge6uiRDa2yA5nnbiNOOgJxk9hk9q3a5v4haLc654Ymg00qNTgkju7Mu+xfOjYMoJweGwVPB4Y0AcHq3hvVvEUDr4g1ayLXAAuPsWmRo23PKJI+5wMfLnOcenZmn+C/BcUSadY6XpYltBg+TtE6+u5l+bnjOTVbWdLntks7bxLJqWs+I9SJuhounXn2a0giQr8sj8HywSoLHJck4XHApXHwzt9ZNq2sCz02K2WQRWuhRtblS5DMZJyS8vI9FHOcZoAk8YeENAsbXT7w6W8tnBfQm8iWZyHgZtjBlZsMPmBI9q9H8OxRj4g+KXCgNFbWNtGoGAkSrIwUDsNzv/kV5FrXw90bwnDba9BLf3cFhcRzXVvf3zvFJBuw+cg4K53g8cr1xXonizU5dB8XXV9YtGDq2iYhkxuXzbeX5T7nbdE+4T2oA2vEXix7a/k03RYIrq+jH76WViIbcnoGxyzHrtGOOpHFcQ6trl6zSRzeItQDhSRHmCE+g/wCWcYGfUt9TVq00oXF1p+ixSyJFdO73M+4+Y6gbn5/vOeCe2SfSvVLK1gsbSK1s4Uht4lCJGgwFA7AVzRvX95uyK2PNG8MamykN4csiD1Bmj5/Sqp0TUtLbMej6pZL2fTLnKD6ojD/0EivW6KpUIra6+YrnlFt4n1aymSEauxduEg1iyMbN7A4jJP51na58aYINUsPDok07SdYvHaN9Qu5fMsrcAffBGCzE5AVtgB6t6+xXlpb3tu9veQRXED/ejlQMp+oNeRfE/wCFOjP4a1e90yWLT0itpJpIJ1D252qTnB+6R2PIHYCrjFxe90B6Z4U0e00LQbWysJGnjAMj3Ltue4kc7nlZu7MxLE+/HFa9fI3gvV/EvgJNOtEluNJvGRWbTL5T9jvF4y0WcgEjnMZBB+8O1e6+CPijp+v38el6rato+sS/6mKSTzIbjjJEUuBkjn5WCt3AIqIV4ylyPR9mZqabt1PRKKKK3LMLxN4Zs9d8icyTWWq2uTaajakLNAT1APRlPdGBU9x0rGTxRqfh7EHjaxbyFOF1nT4mktnHYyxjLwHpnO5P9vtXbUUAeetF4O1O7fV/D3im30q7uTma50m/hCzt6yRsGjdh0yylu2ccVcu5vE/h+Bbh9X0XWLI4wNQxYyn6SpujY46Dy1+vp0t3oWkXkjyXelWE8j/faW3Ri31JHNZdj4D8J2NwZrTw3pMUhyARaphAeoUYwoPcDGaAKlrqvi3Vo1n07TtCtLUj5Xnv2uGkPsI12ge+4/QVFd6B4v1K1mF74tSxkZG2R6TYpEobHG55TIxGcZK7T9KTxN4F006df3vhqzTStfWNpba4sSYN0wU7d6oQJATgENnI49K6Xw5qsWu+H9N1a2GIb62juUHoHUNg+4zQB43YeFNb0mwkvde0HT77UvKH2vV9d1hZEUKOTvMbFI8jO0KB61l2k+t3upWtt4Q1nSUWcmW9mstGb7Jbx4+RVkYgyucH0HPQV6V8V286bwzp13uGk3eoj7ThCyyOil4Y2PQKZFU89SgHeuN8W/EB7G7XTfDmm3Gp6i8jwh1hcxLIhUOoxjzGUNlgCFXgMy5FAFyXwDBdXlpfalruu3WoW24xzfavLCMwIZkVAFQ4JAKgEDvWLYaqvwx+KDooZvC2s2iPdZkaR7SWPK+exYkldpUMTzjnolV7Twz8QtTRo9Q8UvpdlO7SSrEqPc8j7oKjbEAcYCs2B/ESa2rOxu/AFq15bW2h6jYEol15tl5N0ysyozecCxkO08hwc460AewanqEVlo11qIZXhgt3uNwOQyqpbOfTAryvSNPF1LoWiXB3tcP514vd1UGSQn2Z8Kf96rPjXw5qnhfw3JaeFNQQ6NdTJb/2VfqWjgDuOIZV+aNO21g4AOFC8Cqvg648XXfiS+ez0nSLSSG1jjke5vXlUb3YgqEjG77ncr29eMKi5qkV8xrY9iorkm0PxTef8f8A4uFoCOV0nTo4sf8AApzN+eB+FOHg1sfP4m8Sux5LG9Az+AUAfgK3EdXXB+PfiFouk6deafp+oJf+I54XjstO09vOuXlKnb8qZKDPO44AxWB4x8GaTqmq2HhiIX+oX11i5vrq/vZbn7NZq/zELIxRWkI8tQFH8bfw13XhDwX4d8H2zw+G9JtrEPxJIgLSSf70jZZvxNAGF8NPDmqaelne6xbWmnfZ9Ni06206BvMaJFOS0kmcM5PZRgf3mJzXfUUjEKpZiAoGST2oAWuWtbybW/GDmznlTSdIDRSlHIW4uWGCpxwyxrnI/vMP7tV7vWbrxPLJp/haQx2XKXWsAZRPVIP779t33V9zxXS6Tp1rpOnQWOnwiG1hXaiD9ST3JPJPcmsr+0emyO/2f1SD9p8clZLsnu35taJb9dNL3KKKK1OAK4vWkPibxtbaMedK0cR6hfDtNOSfs8R9l2mUj1EfrXT63qdrouj3up6hJ5dpaQtNK3UhVGTgdz6Duaxvh9pt1ZaG95qsQi1fVZm1C9TqY3fG2PPfy0CR/wDAKAOmrzb4njV7rW9Os47fWn0D7PI9yNK3B5pCwCxu6sCq4ycDrnr67/jXxvp/hWeztJ4pLrULxXeG2jkjj+VSoZ2aRlVVBYd8nsDXJQeIfEeuzNs8SaNpckg/d2Wnol28Y7kyOfmb6IFGOhoAxDa+E4547XVdP1LR55zsi+3m4thIT0CS7tpb2DbvbpTh4Ov/AA9qg1fwveG8lEIglsdQcYmQEnCyhdyvnHLBs4565rQ1LwBourafc22tNqGpSXIxNc3V7I0jn14IUYwMAAKPSqMa+KPBuhLGgtfEOnWEbfM8jQ3ZiVSRuLEo7DAGflyOeDQBS1zVNN+ImiWGj6LDa3OrakzRqLhgH0p0XMkjj7yunQAfeOBnaSa7jT/hP4W0y4tLyf7XMlliRYLi7c2qFTuGIidiqrZYL0Bx6DGj8MNAh0/wxY313b2zaxfBr25uVUMxeYlyobAO0BgoHHCiuW8feI28S623hrSrRr7RrR/+JvJ5nlxTSDpal8H5c4aQKDkYTu2E5KKuwLWjaXpvizxRFrWiaNDb6ELsXtxqUgw+qyxhxFsXBJiV28wOSMsqlQRzXpOo2cWoafdWVyCYLmJoZAOu1gQf0NcBDrviOABkk0koAALUW7oiAdArhsj6kH6Cul8OeKbfV7lrK4gksdSVN5t5GDB17tGw4YD8CO4FRCrCbtFjtYx9Jfxvpul2ekf2XpNzNbKkA1SS9ZYpI1AHmNEE3ByByoOM/wAWK0/DWu6jNr+o6F4gt7SHUbaGK7iktHZopoJCyg/MMqwdGBB9iOpxe8UeI7Hw5aQy3omlnuJBBa2lum+a5kPRI14ycZJJIAAJJA5qj4H0q9txqWsa3CIdZ1afzZYg4f7PCvyww7hwdq8nHG93I61oI6eiiigAooooAw/FviS08Naek06S3N3cOIbOygGZrqU9EQfqSeAASSAKg8E6HcaXZXF5q7Ry69qUn2m/lTlQ+MLEh/uRrhV9cE9WNZnge1/tzUrvxhqCBp52ktdOjbB+y2iOV49HkKl2PpsX+Gu2oAKKKKACiiigAooooAKKKKACuT8Ff6RrnjG/6rLqogjP+xFbwoR/38EtbPifWIfD/h7UNWugWitIWl2L1cgcIPcnAHuRVbwPpUui+FdOs7shr0IZrtx0e4kYySt+Lsx/GgDcoorI8W6wdA8M6nqq28ty9pA0iQxLuaRgOFA9zigDyLWnvvDfiTxHcXMNro0VzcyXL6zdQC4a5jxGIoYEVw8khLMAp4UjocjNPTfBWq6/ctq3iXWvEFnIUUWdvDfiOSDqWZxGixhjlRtAYALgs3NVINXgtZE1W7Fvfa5ckNd63qsbxQwvwRb2y7S8hGcCOIH1Y5PMksHxJ8TCa6gu7LQ7NP8AjzhZHjknYfxyghmVTzhcqcdRxigC3d/DnWrxZI7zx7rdxbSDEkDIiq691bZtOD0OCM100uj3HxC+E+nrby2lp4gsGaOKRUZI4p4i0MkbLyyqy7lI5xuBGcCubOrfFEcf8Iz4fOO4v25/Su5+Ccl/N4b1OTWIIbfUG1W4M0UL70RsrwD3FAHD+HfHNva63oVx4jtZ9GfzHt5nuR/o4LKVyJh8nDgDDFTyeOK93ikSWNZInV42GVZTkEeoNeU+KdOjfVvElhCAI5gk6oQCFkdMlgPdl3fXNbujeDdLuNMs9T8PXOoeHWvYEuGTSphHCS6g58lw0WeeuzPrmsKNleC6Dfc7uiuOey8Z6SwksdVsvEEA+9b6jEtrMfdZol2Z9jH+IpY/H+mWreV4mgu/DlwOv9pIFhPus6kxEf8AAgfUCtxHYV5T4ou7i70TxJa6kzTNpOuW1xJaT/cns2kidFyOqkFuuRuQgjGa70eKvDxtzONe0nyAu/zPtke3HrnOMV5nrks/iaz1rUreGNYvFCxeHNIjYf62JWmZrtwcHAVppEH91Af4+AD1fWtI0/XNOlsNYsre9s5PvQzxh1Pvg9D6HqK8O8a/CG90yKJtAkn1fSfOQNZTn/SbUbuJIpQQWCnBwfnAGQxPFe928Xk28UW95Nihd8hyzYGMk9zUlZ1KUaitJEyipblPRrE6bpdrZG5ubswIE8+5kLySY7sx5Jq5RRWhQUUUUAFFFFABXKfCwBfAelqoAAEgAHYea9dTLIsUbySHaiAsx9AK5j4Wo6/Drw88oKyT2cdyyn+EyjzCPw3YoA1vEeh2HiLR59M1aHzrWbHQlWRgcq6sOVYHBBHIIrxPw/Znw/reu2mj6cxbTZJYm1LWLySG0s7XcpA8xg2SzbnIUfMeWYZBr2Lxr4ms/CWgTapfrJIqssUUMf3pZWOFQE8DJ7nAA5PArw7U/FWiyzvqfje6l1q7WZMW9kWmsbJ85WCJchZZBgEnDNnn5RgUATR/8Jz4knn1DQddtYrOEhbSVrbyba6bJ3ERkO7R9FDlhnllUDGTVT46v9Gv08U6fbx6e0Jjng0tIpt0ePnbEzjcepC8Yx3NTxfErVdVmabw94V1G402F1V5J4XSSXLANsABUYGTy2TwCBnNb2k+P9O1azmu7HTtZltYG2XEkdkzmAg4IdFy6kdSNucc0Adhr5t5vhfFLaTNcWwtbaaCY9XAKMj/AF4Bqt4HcxeKNTiHKT2sUp9mVmX9Qw/Ks7SYZLf4F20csElufswKxSIUZVMuVBU8j5SOO1aHg3/kbrj/AK8R/wCjKwn/ABY/MfQ72o7meK1t5bi4kWOGJC7uxwFUDJJ9sVJXGfEN21eTT/CNsx36wWa9K9Y7GPBmPtvysQ/66E9q3EP+G1vLdafdeJb5GS+191u9jDmG2AxbxfgnzH/ad66DWL27soo2stKudRZjhkgliQoPU+Yyj8qvqoVQqgBQMADoBS0mroqElGSbV/J3/RpnLnUPFd2NtrodjYf9NL683kf8AjBz/wB9CmnwpLqbh/FOpzaogORZxp5FqPqgJL/8DYj2rqqKj2SfxO51fXZQ/gxUPTf72218mhkMUcESRQxpHEg2qiDAUegA6U+iitDjbvqwooqlrep2ui6Pe6nqEnl2lpC00rdSFUZOB3PoO5oA5fxN/wAVH4v03w4nzWFjs1XU/RtrH7NCf96RTIR6Qj+9XTa/qtvoeh3+qXrBbazgedznGQoJwPc9BWH4GsptK0C61fXgIdV1J21LUNxz5OVG2LPpHGqJ/wABJ71heIfGVj4l06fSvD2jyeIIbhAss1wGtrJAcH5pGG5+xxGre5FAGVea9rGqyRHUNP8ABkF9Ig8u2vmaeaENyqtkKSeeQAOc/Wql94Ci1mOKPxDdxXEEbLIIrGxhsgXHO7egMg9trjg85qEeBBqFu9rqcWk2OnEsTZ6VZIPOJ6tLNKGdz7Db2zmsrS/h3rmi3ckWg+IpdP0+SRg7lmuJGiIO1dsnyq6k8OuOOobgUAbUngY6VrMGreEbx7K5SMxTWl1LLNbXCHHVS+VYYyGGfcHNUvEWq+JJdNfQ9S0RobnVZPsEF7p9yrxHewXJ34aM7Cx6H7vrip7Lwp4ptdXnmj8YTrZAsIYZoRcFgcY3liAMY/hwTk5ParNj/bl5498NaV4gW1EEU8t6lxZNtFyYoxt3RtuZAGfnDEfd55xQB6F421D/AIRfwDql7YKIhp9mTEOuwKMDr1wPX0rzb4faE1zpnh7Q5mKILRb3UG5DStlSy5znLyMST1wD616D8WbCfU/hp4mtLRd88lhKUTGd5Ck7ce+MfjXLeBdUjvta8O6nCwMWo2ckYweMsqyj8vLb9awq6zinsNHZv4K8PspA08IT/FHLIjD6ENkVx3inQJtEC3E0k9xpcb747xWIuLFvUsOSvP3uw+8COa9TpHVXVldQysMEEZBFaSpxkK55T4FuzJ8Qr6fxOwn1J4I7fSr11wjxYLSKn8KuTgtgDdgdhger15X4r8NJonyx5OgXMgVADhrCUn5Sp7Juxj+6SB0PHW+C9fl1KOSw1MKmrWqgyEfdnToJV9iRyOx9sZmE3fklv+Y2dPRRRWogpCQoJJAA5JNLWX4pZk8MauyMVZbOYgg4IOw0AZHwpO/4d6FPjC3NuLlP9yQl1/RhXV1keD0WPwlokcYCotjAoA7ARrWvQAUUUUAFFFFABRRRQAUUVleKNct/Duiz6hdK8mzCRQRjMk8rHakSDuzMQB9aAMDxIT4h8ZaX4ej5stPMerakR0JVj9miP+9IpkI9IR/ertK57wTos+k6XJNqjJLrWoSm71CVeQZWAGxf9hFCovsoPUmuhoAK8y+LPi+40fUrPSYtTXSLea2e6nu41ElzKAwQQ26EEGRmYc4JGRgZOR23ijxBa+G9Pju72O5lWSZII47ePe7u3QAfhXnGo6dqfjuOGbxciWWlh/Nh0eFVL4zkefNySTxlE2r2JagDg7Lx3ommPc30HhrWLzXbf5L65uphctbJnnfdM7KqjIyqnjPQY41dQ+Kk91byxeGNAvbzUbZ2+2CRN8EEaEiRhJEWWQgjACEk/hiu2h1fw7aXyeHYLrTobhIWYWEZUBIxnPyjhR14qDRfF3hS8aez0fWdKf7IDvihmQBFHUjtj3HFAHKJ4y8aO8t1Y+F4NV0dJDGk8EjQPNjq6pJ823OQDt5x2HzV6B8E7ybUPDep3d1ZTWE8uq3DPbTEF4zleDjjNZul+NPDOqxSSafr2mzJG218XCjB+hPT3rd+Ej/afDt7qEQP2S/1G4ubZzx5kRbarj2baSPUEHvQBV8XIqeM1deGksF8z32yNtP/AI81avhbUINJ+G1pqN+/l2VpZNcO/pCoLA/98gVyXie7E+oeJb+RiI4UNqh9FiQ5/wDH2krd8ZRM3hjw34fK7ZNTvLSzkQf884x50w+hjhdfxrCnrUm/Qb2LVvrHjDU4rd7Lw5Z6Yki+Yz6ne7mUEcL5cQPzc85YAY71P/xW/wD1Lf8A5HrqqK3EcE2ga+0hkbSfBZkJyWNtJnPrnFamkeG75tei1vxLqaX1/BG0drBbRGG2td33mVSzFnIwC7HoOAuSK6migAooooAKKKKACiiigAooooA5n4m3b2Xw98RSwEC4axlihz08x1KJ/wCPMK39PtY7GwtrSHiK3jWJPooAH8q5b4iSC7fQNCi3NcajqcEpRTjEFvIs8jH/AGfkVT7yAd6k+K872/w81t4p5Lc+SFMsblGVWdVbDDkcE8igDgvi6Pt/ir7L4h0ma80CG3T7NFNdrb2kkxLNJLKzuq/Iu0AEMeSQOa5bw1rekaXqNv8A8I54FlnG0K11px88W8RPZ2AGDknarc9cV0NhceAIJTcW0VrPIRsE728k5wD0V2B4z6HFbFh440S+106VBPKLjyWmV5IWjjZVGWwzAcgHP5+hoAxX+LnhQW7Sx3F1MY8CaOO3YtAxbaFbtuJ6KMn2q/aSeC/Gd2Lu1ksby+2bSyMYrjZjIDD5Xx7H3rb0+20K5mNxp0GmSyxtkywJGzK3rkdDWZc/D7wrch/M0aDzG6TKzLKn3vuODuQfM3CkdaAJNAllk+EmsBri8ubSO6lhs5btmZ2gSRVX5m5YZBAJ6+9bfg3/AJG64/68R/6MrmPD1o+meAfF+nW9xczaLp9yttYrcMHdAFjaQBsZK72IGcnIbtiuh8Bzi58VXbojhVslBLDuXrGSbqRfqPoeh1x3glDqmueIPEkh3Lc3H9n2f+zb27MhI/3pTM2e421d+IGrTaV4bmXTxu1a+ZbGwTON1xJ8qnPYLy5PZUY1qeHtKg0PQtP0u0AEFnAkCYGMhVAz9TjNbCNCiiigAooooAKKKKACuHul/wCEw8Zy2LnfoGgSRvOg+7dX2N6o3qsSlHI7uy5+5iu4qlpGl2Oj2f2TTLaO2t97SFEHVmYszH1JJJJNAE19ax3tjcWk+7yp42ifacHawwcfnXmHh7QfHFjo0dtdtocMdmvkpLcyu7yRoMCRtgCrkdvbPtWxe+L9Yvta1C08M2WnNZafMbaW8vZX/ezAAuqIo6KTtLE/eBAHGaxNYsNU1qJ38Za6kemAnfYWGbW3IyuBJIWLuOORlQdx4oA424m8a69e2154R163urW1jeV7iSyNtZ3jt0ihDZZ1GP8AWnjOME5OLcHiD4iFYdUufDNuunQttn0+Nx9rnBXG5MsVAVuxOWGTxxW/N430HTpf7OsEu777OscKrp1q9xGrHG2LeoKhsc4JGByayb7XvEmg2Vn4h11T/ZMkzm90+K3DS2MDbvLYsuS5XCB8cZY9hmgC1pvirxOY573V/Bt3DppbMS28ySXSJzy8WeTwOFJPPSug+FF5D4n1vVvFEMFwtp5Men2bTx7GAVnabjqCX2gg/wDPNa53QvibpepRvdXdrdabpZkeOG/uADA5ViCHdciM8ZG4gEEYJ6V2/wAJZ4bnSdZmtpY5YZNXuGSSNgysPl5BHBoA7ivnrSLl/DHih9MuWC2UWryXGnNjASMXBSWH/gKPvUf3WIHC19C14d8SdEOqw+KrSJ/KvLa6+12kvTZJ5KOOfQ5ZT7E1jXdkm+40e41FFcwS3E0EU8Tzw7fNjVwWjyMjcOoyORmue0nxjpl54Bj8VSTbLBbQ3M/doio+eMj++GBXHqMVyXwCtr+50jW/E2qxGCfxBfvdLExyyoCVGT6dVXj7qqec1sI9Mv7SC/sp7S7jElvOhjkQ91Iwa8nka70HUQ0m+XUdFfcT/FdWrcE+5ZQf+Bp7V6/Xnfxp0H+0fDR1KAhbmx5cnGHiJG5TnjAOG59D61nUhzWa3Q0d9ZXUF9aQ3VpKk1vMoeORDkMD3FQa1qtlommT6hqk4gtIQC7lS3UgAAAEkkkAAAkkgCvBPgD408V6zZ32gx3WlXFxYkyQzXu/dNDu2Er5fy4VgMjtvFeqp4d1rWNfsL3xXc2L2Onnzreysi4R7gH5ZZN3LbRnaOgJz1AxadxE9t490druC31JL/RpLjH2c6ravbJMT/Crt8u7/YJDc9KtfEHU7XS/Ber3F3JhXtnhiVeWlkdSqRoO7MxAA9TW7d20F5bSW93BFPbyDDxSoHVh6EHg1gaf4F8M6dfW95ZaLaQzWzF4NqnbCcEZRM7V4JHAGM0wNXw/bSWeg6ba3ACzQW0UbgHOGVQDz9RV+iigAooooAKKKKACiiigAqle6XY315Y3d5axzXFk7SWzuM+UxXaWHvgkZ96u0UAFFFZPizVJtE8M6pqdrZy3txaWzzR20SlmkYAkLgc9fTnFAEPjXQI/E/hm+0t3WKWVd0ExQN5MyndHIAf7rAGvG9TtLjVby406O+PiLW0YyTyQztDpOmlhtRSqndK4Ul9hYknk7QVp9omjanG76v8A2r4o1y7Je4FvbXBQkjGxU4SOIDgBiB6kknO1qWp6h4R8Ovey+EYtM0yEDbCLuBHJPCosce4FycAKpOTwKAM1fhB4Rfw/Bpl1YGeRGaR70OUuJHf77M64+90K9MdqnsfCHgDV4X0yz0nS7kaS7QOiLlonP3lZupJwc5J5zWU91458Y3AsUi/4RTTHi3z3Ajd7kfMMRo52gEjOSB8vYmpNHt/DumWk8OqTX9prmmTjTPL0dWhmu4HdpIZGQkl8ln+fJ+bd3yKANHXfAmjafZ32p6JF/ZdzDa7gttHGYmMSnZujdWU8DB45H0Feu+H7gz+HdNuZtiGS1jkbaAqrlATgdhXlI0rWtY8O3lx4F1q21rSdQjMQi1VmW5s3IKSDIAyVPPlvtIIYbuletWWnpbaNBpxZnjit1ty3QsAu3NAHlGiqmsS6bZqyuNQvXupsf88/MaZsg84bhf8AgVdrcD+0/ijaIOYNF055n9POuHCp+ISGXj0ceoq/pnhPTtN1CC8tjP5sKsqhnBGCMHPFUvh2PtVvrWst8z6lqlwyt6xRN9njx7FYQwH+0T1JqIQ5L+Y2zraKKKsQUUUUAFFFFABRRRQAUUUUAFNd1jRnkYKiglmY4AHqadXnXxR16wZ18PXt4LXT2VJ9Zn5Oy2LYWAY5Mk7AoFGSVEmOcUAY8/ih7W7XxYLeGa81x/7O0KG6m8iKKzQM5nkbB2iQjfgDJHkrwc42bjVPF1zC8Nxa+GpYnGGRxMysPcHrTr3xdompWSQXnhLWLy2C4SGfSgVwRjG1zxxxg4965ddK00oPI+HEsMWMIjaqsbKOwwjkKfoTigDUuNN8Q6tbNaanrSabphO0WOiReQNm3G0ynLjJJJ27e345+sfDLwrqsMSz6YiSRyiYTocyMwGAGZs7lx2bIqpZ6R4rOqgadfXGjaMqYMF/cLqUpbn7jFQwA+X77tn0HU09R8OfEa9E1s3i7TktHyA9vZmCUjtyCSO2dpB9GHWgBNT+Gs8erte6JqkypPam1uYZpTHvXOQd0YGRywwwPXgjnJ4VHiDStYl8Nya1YQ3DFVsIdUSWZZU8sEGGbKl8FXDRt8w25DYIxJ4M1HU/DPgSGe+0uW58PWMssQ1SOVVYwrKy+c0TtuC5GSck4+bFdVeuNV8W+GNNtMyMtx/ac0iqSscEaNhs9Ms7Io56Fj2oA7Twh4fXw9on2KW5a9uJZZLi5uHTb50sjFmO3JCrzgL2AA561rwW8NuCIIY4geoRQufypmo3cVhp9zeXBxDbxNM59FUEn9BXJ/CDxJL4p8DWd/dPuu1kkhn5zhgxx/46VreOGnKjKuvhTS++/wDkQ5pSUOrJLsDU/irYxEBotF017pvaa4fy4z9QkM4+j12Fcl4JAu9b8W6pj/Xal9ljP/TOCJIyP+/nnH8a62sCwooooAKKKKACiiigAooqO5njtreWedwkMSF3Y9FUDJNAHExfDHR44mgW/wBbWzeRpGtkv3jRtzFmHy4bBJOcHnJrkNQg8OT3F1beBvC1pqN/bym3Gq3qiWytZBgMV3sWkZcnhBjIKlhzWhNqWreNre5u57270PwvMmILeLbFcXMWDmSVyC0SsOQq7WA5J5wFTxF4X0O1g0+zvLRY4Yv3VpZAzMqDjhIwTjt05PvQBoeF9DtvDujQ6fakuFLSSSsoDSyMxZ3bAAySScDgdBwK1q577Z4s8hNT/wCEWb+ymYL9m+0j+0ApP+sMWNmP9jfux7/LT7LRPEfiW/mvmudQ8M2NugSzgkjid7mQk73mQ7sJgAKuVbljxxQBsW9tBbReVbwxQxkk7I0CjJ6nApfhRFHDpmtxwosca6vcgKgwB93tVQ6D41VCi3vh2RgMCYwTLn32bjj6bvxrpvB2gDw5oos3umvLmSWS4ubll2ebK7FmIXJ2jnAGeAAOetAG5Xl3i4Y17xHgYzbxk+58s/4CvUa8v8X/APIe8Rf9e0f/AKLNYYn+GNbnG/Gi1vfD3gqyutAuI7e38QS2dtewMDtWZdsguVx0O2Ehx3UA5BXJ930fT7fSNJstNsk2WtnAlvEvoiKFA/IV51400O08TW/hDQ9SYra31ncw5B5Vza4DL/tAFiPxpfhp4tm0bTLPwp8Qp49N8S2S+RHLdSBY9RjXhJYXJw5243DO4HqBmtxHp9chrniq3uL2/wBC0rR73xBdRx+Xdx2rRpDDvB+SSV3UAkc7VywBHHIqj8VfGNro+iXmjabcR3HivUYWttP0+Ft0zSyAhWIH3VGSxZsDCnmtL4Y+D7fwP4QtdIhaOSfc091NGmwSzOcswHYdFHsooA+f/B32n4d+ONKh1q2ihOkzfY7kRMXRLe4UbJFY8sqkpuz/AHG7ivquvA/j5ocSeLLO7aP/AEbWLKSzuMOeXj5UlTxyjsMj+7z2r1b4Z6pca14A0G/vTuupbRBM3991+Vm/Egn8a5qHuznT7a/f/wAEzho3E6aiiiuk0Oe8ZXU1vBpMVrK8U1zqltF8rYLKH3uv0KI2fauhrk1b+3PHavH81joSMpYdGu5Bggf7kec+8ntXWVnB3bZ2YmKp06dPra7+e34WfzCiiitDjCiiigAooooAKKKKACiivM/HurS6lr1zojX8ulaFp1us+qXSTCFpi/3IhJncibQxZgQTlQD1oA3vFPjrTtIm/s/Tdmr6+7iNNNtpl3qf70p58pBg5Zh2wATxXO/2fqms6zZar4qnsZXslc2llaRMIoJGwDIWYkyOACA2FwGbjms3SvEfhXS9Ojt9CQ+RgeVb6fYyOZSem0KvzE+vfrnvWtBJ4o1eYrpGhCwt0+9c6w/l7jjokSbmPblto9M0AbVZ95o2m3uqWWo3dlbzX9nu+zzugLxbhg4NY7SeK9Yto9Ji0O+0jUpXEV1fkxtb2qBgHkiYnMhK52Db1I3AYNa9x4Z8T6Q+7SNTg1y0A/499UxBOv8AuzRptbjsyZ4GW60AZGt6VYW3iXw9qdtaQwahLqkEctxEux5VO7KuR94fXNetV51ZeH/Ees6xp9zrENlpOnWFylysCSG4nndQcZYYWNef9onHavRaACuR+FkqnwfFanK3Flc3FpOh6pIkzgj8sEeoIPeuurjLfOhfEueD7tj4ig+0J6C8gUK4+rxbD/2xY0AdnRRRQAUUUUAFFFFABRRRQAUUUUAFcT4j+H1pqcv22wu3s9XGoHUVu5IxcDzPJ8kKUYjKhMAAEEY4Iya7aigDza50/wAb2Mccps9G1VQcSQ2kr28hGDyvmZXrjgkdevFQHXrpYt8nhjxImFyy/Yt5HqMKxyfpn2zXqFFAHAaPqllrFil5ps6z27EruAIIYHBVgcFWBBBBAINXaZq/gP7Tq97faTrmoaQuoMHvYbZImWRwFXzE3qdjlVAJGQeuM81i+ING1jwfjU9NutQ1zRV/4/bKfEtzAv8Az1hYAFwP4ozkkcrzwQDAm8Halp/k3uk6vcXdzp7E2NldNstzEXdpIJNmNwcOV3MDjCnBwc9d8J9I8PJZS6xoFrf2csoNpJZ3crN9hKOS0CKThVDMfu8EYwcYrJ1nxNanwnLqeg3Vveyz4t7Hy3DiW5chY0477iMjqBnPSu/8KaFb+G9BtdMtWaTygWlmc5eeVjueRj3ZmJJ+tADPGWiyeIvDGo6RDd/YnvI/KM/l+ZtUkbvlyM5GR171yHwK8Ky+GfDM7NqP2uG+l85Y/J2eUykoedxzkKvpjHevSa5/wB/yKVh/20/9GNXoU8VVjgp0E/dco3Vl2fXfov6bMZU4uqp9bMqfC4f8UTZSEkvNNczyE/xO9xI7H8WYmurrkPh062seuaG3yy6Xqc4VD/zxmczxEe22XaP9wjtXX155sFFFFABRRRQAUUUUAFQX1rHe2NxaT7vKnjaJ9pwdrDBx+dT0UAcFpfwx02OC1i8QX9/4gitlVYre9KLbqFAC5ijVVc4HV93OcYrs7HTrLTw4sLO3tg+CwhiVN2PXA5q1RQAUUUUAFFFFABXm/iWLHjDU4Zl+W4toZF/2l+dCPwK/qK9Irzvx9dJZ+KbWWYN5bWZTcOgO/OCfwNY14uVNpDW4txZ3uq/C/RbzT0MutaSkN5arnBllhG1k/wC2ieYn/A63r3TfDfxE8K2kmo2Ntqmk3sSzwiZOVDDOQeqNzjggjkVN4CRk8IaYHBB8snB9CxI/nWX4QP8AYPiTWPDM2UhlkfVNMz0aGRgZkHukzMcdllStUIb4M+F/hLwdNHPomlBLtGZhczSvLJkgqTlif4SRx2J9TXa0UUwKV9pdjf3FtPe2kNxLbFmhaRQ3lkjBIz7VahijhjEcKJHGvRUGAPwp9Z2tam2mQxtHYX19JI2xY7SMMc+5JAUe5IpNqOrKhB1JKMd2aNcxr2uTz3j6H4cZZdXIHnT4DR2KH+N+xb+6nU9TxUT2viXXflvZk0GwPDQ2sglunHoZMbY/+Agn3Fb2j6TZaNZLaabbrBCCWIHJZj1ZieWJ9TzWbcp6LRHbGFLDe9NqcuiWqXq9n6K6fV9GzQNJttE0uGxtNxRMs0jnLyuTlnY92JySa0aKK0SSVkcU5yqSc5u7YUUUUyQooooAKKKKACiiigArD1Lwl4f1PWYtV1HR7K61CIKEmmiDEbc7evBI3HBPTPFblFABRRRQAUVwHj7x2PDXifRtPW4sI4H2zXy3EgWQxPKsKeWMjJBZ3PX5YiMciu/oAKKKKACuW+JFjcXPhs32nRmTVNIlXUrRF6u8eS0Y/wB9C8f/AAOupooAraXfW+qabaX9jIJbW6iSeJx/EjAEH8jVmuQ+HuNO/tnw4cL/AGTeN5C/9O0372LH+yu54x/1yP1rr6ACiiigAooooAKKKKACiiigAooooAKKKKACiub+IWr3eieGWvNOIFybyztgTEZSFmuoomIQEbjtc4Hrim+BNau9YtdSTUiBdWV41uQbdreTZtVkZ42J2khs8EgjB4OQAC4PCugDX/7cGjWA1fH/AB9iBfMz65x97HGeuOM4raoooAKq6XYw6bYx2lqGEMedoY5PJJP6mrVFPmdrdAt1OM18/wBh+PdG1kYWz1RP7IvT0AfJe2c/8CMkf1lWuzqhr+k2uu6NeaZfqWtrmMxttOGX0ZT2YHBBHIIBrM8B6ldajoATVHD6pYzSWN2wXbvkiYr5mO29drgejikB0VFFFABRRRQAUUUUAFFFFABRRRQAUVyNhd6zrupatJZahBYW2n3ps44GthKZdqoWaQ7gRksQAuMDBJOcDrqACiiigArK1+9+xpYoYY5kuruO3ZX6ANnn9K1a5/xh/wAwT/sKQf8As1bYeKnUSkTN2V0dBXJfEqEw6HHrtuhN5oUy6ghQEsYl4nQY67ojIMeu084FdbTZESWNo5FV0YFWVhkEHqCKxKCKRJY0kiYPG4DKynIIPQinVx3w8Mmlf2l4UuGLHRnT7G7HJeyk3GDPuu14vfys967GgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDMu9B0y8Gqi6tRKNUgFtebmY+bEFZQnXgYZumPvE9TWjGoRFQbiFGBuJJ/Enk06igAooooAKKKKAOO8UA6N4v0PxAnFvcsNHvv92Rs27n/dlOwf9dzXY1h+NtJn1zwrqOn2ciR3cse6B3XcokUhkyMjjco7itazaZrSBrtES4KKZFQ5VWxyAfTNAE1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAUNb0mz1vT2stRjeS3MkcuI5XiYPHIsiMGQhgQyKeD2pNH0ey0eKZLGOQGeTzZZJZnmkkfAXLO5LNwqgZPAAHQVoUUAFFFFABRRRQAVyNn/AMSn4k31v9231y0W9j44+0QbYpfxMbQY/wCubfh11cl8SoHj0S31m1ikkvdFuo7+MRIWcxg7ZkAXk7omkGOecHBxQB1tFR280dxbxTwtuilUOjYxkEZBqSgAooooAKKKKACiiigAooooAxLvwtpN1qE168VxHPMytN5F3NCkxUAAyIjBXOABlgeAB04rboooAKKKKACvEf2iNb8R6Hf+H5NFvGitZnJWMQxvi4Q/K2WUnkP06cdK9urn/GHhqDxIuki42j7BfxXoyPvbM5X6HNejlWJpYXFRq1oqUVe6av0MMRCVSm4xdma+mJcx6baJfS+ddrCizSYA3uANzYHAycnjirNFFefJ3dzdaHPXOlXq+O7LV7UxGzeyks7tGGGGGDxspzzyWBGO/wCfQ0UUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A shows the position of the tip of the endotracheal tube with the neck in neutral position. The tip of the tube follows the movement of the chin. The tube moves away from the carina with extension of the neck (B) and toward the carina with flexion (C) of the neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17776=[""].join("\n");
var outline_f17_23_17776=null;
var title_f17_23_17777="Supraclavicular brachial plexus block";
var content_f17_23_17777=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Supraclavicular brachial plexus block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 506px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The needle is inserted one centimeter superior to the midpoint of the clavicle (red dot), parallel to the patient's head and neck and advanced until it contacts the first rib. The needle is walked posteriorly along the rib until paresthesias are elicited, and then local anesthetic is injected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17777=[""].join("\n");
var outline_f17_23_17777=null;
var title_f17_23_17778="Angiodysplasia endosc";
var content_f17_23_17778=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50137%7EGAST%2F73541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50137%7EGAST%2F73541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Angiodysplasia in the colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 253px; height: 206px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADOAP0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UopRRQAlFLRQAlFLRQAlFLS/hQA2ipFXceelTLEvek3Y0jTcirRVzykx92kMaj+GkpJlexZUoq6IhsB8nPvmhYPWOhySF7FlKitA24/5509bZMZMefxpe0RX1eRmUVsxWcD9Ux+NTDT4T/yx/wDHql1oof1eRgUV0K6bAePLyfTNObTbdf8AlgRx61Pt4h9Wkc5RW+dNh/554+ppDp8IH3Fz9f8A69P28R/VZmDRW79giz/q/wBaDpsTcAFaarRYpYeSMKitC4sHjBKAsB7VSK4OGGDWiknsYyi4vUZRTsc0lMkSilNJQAUUUUAKKWkFLQAUUUUAFFFHpTQCgZqeOL5QxBpiL3q0JGaMR4GBzkdaiTOinDZsZGvPSpNtOHQAdKVeTispM64oYQe1OWMlgAM9zU6R5qxDAXlRFXcCQDjsKzcxtJalAo2CDnGeKlRRnBH0rY1KOI3QFvA0MaYGx+Tx1PQdev41XWE4zipdQcNdiFE/2RipY7fcwIX9KsxRj+7zVlEAAxwKxdQ1SKLQAcAYNPhVSgyoBqebLHCDd9Kmit2kxlSKjmvuNKxCiAN8oyateSpA79/xqQWpRgy546gVYhRXBOCPaoY7X2KewAjApJIQfpWg0BwDjim+Qc5UEj3OKzc7Cs11Mx7bIwBjPtVdomXrkqK31iVh0IOPu4yRVmGzhLMJwQoGRjjJpRrWBvucpt7E1VvLKObHB3f3hXQXNgAMkMpHWsu4j2MVHIrpp1tdCJ0lNHKTxNDIVcEemR1qP2rp7q1jntyHUl9vynvXMspUkEYIOK9GlUU0eXUpuDGmkpx6U2tDMKKKKAFFLSCloAKKKKAClQZNJUsQpMuCuyVRxU0K5b8KETp0q3DF9OlYykego6EBXnipI0wee9WVj596mWHJFYOZokQxx89K0LDYt5bPIqsiOu4OoYEZ9/pUccPzYq0YHjAVyBuGQcdiKycglG6NTxbFp/8Aa0zaRP8AaIG+YZjSJlPcBEJGMjjnoayIlVnzkc9u/wCI7VrX4tJbK2j0+zu45UjUzTXEu5WcZyVXHA6d/WqFqMvkDOPXtUNhSi1uSJCDyOKlEQPy9Pwp6/Lk7c1YRN6ZzgHsKxbNkQ2luNx4/KtSO3DAcY/Cm20YC85q/AhdgqnB9TUSkTJXKj24jQkAdcVRdQJgY8nFdELTzThm4YZAom0+JEXAwc84qedhDRmNF8w56nrQkojfb0x9P61emtgHGwEACofJUkggbvWpbudEYX1HWwV0IWFGYnIc53fmP8KumzMZO5txxndmi2iARNmeexFXFTapGByMHIrGUrbETiinqVpaCztvIUi4Yt5yj+Fex6/0Fc1dWivKxGTgkciunmXjBBI9j1+tU2h/eHA5PrTjUaJhT5Uc61mArMBkrzXK+I7DyZPtK8I5A2474Pf8K9Eng25OOe9ct40VV0qLaMfvh/6C1d+DrPnt3OTFU9LnEGkpx702vaZ5gUUUUgFFLSCloAKKKKACrNuAVGarVdtF3RDPrUzdkbUFeRaVMkYz0q5GucDGKIolB4qzlfSuGctT0lEFUYx3qZV4pikE9M1NyI+Dj2rJyK5RBtAzhs1YMkjxKrfMo6Z6iquasQu6rggEHpxSK5R5kckFpGIxgndUtmQeFzx60kEYO4utWY1G8hD83aoky1EkB9cbe9PVwr/Lwv8AOmm2MvJYgDqBTGR7blBvT0NZN3KUbmtbMuMEjNSLc+VcxhhhTgY9Kx2mKYaI7c9c9qnEhkZXbqOaTVzX2Nzr0K+WDjDY6+tCfOSG5x3qnp8u4IpO3dzzTru6S3uoY4o8Fm5561k30I9hqWWiU4yDg56Uy4s0CHAHIyDUqyh7hUY8OucelTTABHHUr0FZOVnY0UGjL09iYX3/AOsXP4gVp2zCdAAAM9zWB5jJO7BtrHI21o6UhWKMnLsx459zUyOh4e8blxbYODjg/Sq93ZYXdn5vpXRRRB4iygA9KatmrFt/Jrn5zm5TlzACvzDmuJ+IduItLjccAzgf+OtXp9za7Nwx+lcD8U026FBx/wAvK/8AoD134Cd6yRx4r4GeWNTacelNr6VnihRRRSAUUtIKWgAooooAK1dNXMCH/aNZVbOlj/RFPuayq/CdOF+M0kBGMdP/AK9SBNz0cDHJ6etNDnfg/pXAz0ok2MCpNrFeKakbMM54qwq+WMgk+1ZssgRQp561PGd2eMYpTH5jqAmSRyMdKmaNVymCNgPB9aCebmFtwZHAB4FaaW+CCO9bWm+DLk2NjdC+sFW7gadFaRgRguMNx/sH8xWdakyY+YMh6HIJ984FZSZUZdBFRV602dCVUx8U6+hKJlWNQWs+F2SHB7EmoWpvCPUpXqZOGGD60ywVxKqM3BrQvpEcqCAwqjMhjdDG3yZGD3/OqOuBqWcki3LwgE7M459Ks3l4WNv8m1lbOc1T01jHqsfmfMW4z+Fa+pWSh0dODnO2snua2TlqLHOWuIHUtuKEGuhmhQQebIgztzk1zdkJJJti/KY+9bdzdk25jmKsoXB55rCW5cqb6GEsPmTNI6hQxznFa+jqrBjKMlR8uOKoO4aSNRjYMYGavWxAheZypVBnYvU0p7G0oS5Dq7GDEIy2eTVkwKY+gzWdp9zIsW51GCcYAq+sqyLgAhupOa5OU86pS1M+7hIyCK82+LsQTw/CwHJuV/8AQHr1p0WVMrng15p8a4xH4Zt/U3i/+gPXVgnbEQXmcGLVqbR4kelNpzU2vrDwQooooAUUtIKWgAooooAK39JGbGPPdjWBXQaQV+wRA5+8ayrfCdGG+MvEgYNLGq7gx70zgt3xUiAHGTXns9SOxcB2j5RQjfNnvSwqJM8kAChovLTduzWYluSrM3IHB9e9NjLeYWJLMeDuOanghzCG7mpRA0YBwMGpbNIwRJCzJGASdvYelaEU43Luz7mqEki8DjK4yOc/y966/TfBOt6hez2ltaLJcQIJJF81FUAjI5J9PasZSszVQitTILK7DK5Qcmqt7Ak7jZwo6Cm3KvE8kWSHRtjrnof8iqzzmNQMkMOhpanVTgmRS2plYDcV28ECny2EkMeXfgVbspVd2dycn24rRuJIrqIKBz9KfMacvK9DnkaRFHQkdDnmtq2vXlQLKx46HFR/Yl56VCtuLZ9zHcPSldPQ2g090alvcpDJnG5j3NQPdqfNbBLk8cVR84GUttyOwqxGQ8i/wE8Y61nJdTsgtC9p1q0zJ5rfIecCuptLODyT8vzIM8DFQaLp4VFlJAQfnU321PtLyR8RfdxjrWEpNk1ZNq0TodLtF+zNJJ0BoukXzF8sY4qrb3Rt9PYSkn5uMVagkDiKRRuUjiuZs5J02tySNMqEUBexrzT45IP+EZt2BOPtqrj/AIBJXqNygBLIpx1znFeWfG4sPDFuDnb9sU8/9c5K3wX+8Q9TzsbT/cyZ4c3TimU89DTK+vPmegUUUUAKKWkFLQAUUUUAIOa3dKXNnH/vGsIcVvaUT9jjx/eNZ1fhOjDfGaW0Ko9aVOWyBihAWwWHtVpIQHFebJ7npx2FT5Bx3qQlxFgkYz6U8xgdelKPmQg1lcqwkM5A254FTo00p44X60ttAGxwPer8MIGVUDNROVh2sVTNKoKYPoRuO1h7irUWp3cM/mxSOshGNwbBAx6iphAoUnHFNFsfMYjadgyR6UJcyuzSMkVn1G4ZtzjJ7ljkmmtMtzw6hW/OtJLRHcK2M9TVwadBsyE3EdTUyZ0QqKJkwzxoAjKD7gVPLFsUzRHEdJf6WxYtAdoHUZrLWeeEhXYlB1U9KElY3jUuzbsrsbCOuR1Ip18EaDIHNZyXce3Krj2xUrXiSptAI7Hip5bO5om1IhTg4zxWjtYmPYox6nrWYrqsm052Hnirab5OjnYOmDg0NXOqE9DbS7uNpiWTZGePXFT2Ee4qhYsAcg4xWXDGqRgZYt6nmus0q0V4R5Z+cLnkVhP3EbRlbUsaZGzEmTLRnruNbNhCrTFbVSWUcqWwB9Kh0yxZ4pZJpG2pj5R3NbWmxSR5SMRqOpPf2rz5ysYV6iS0LsdkHjQuSeOxxmvLP2h7RYPB9pIoxm/Rcf8AbOSvYY9ynJCgHnA7V5N+0i5bwXZjHH9op/6Klq8FUf1qmvM8PHVG6TR83sc0ynGm19sfOhRRRQAopaQUtABRRRQAVt6W+20j/wB41iVsaYha1jx/eNZ1fhOjDfEb0Un7sYHNWreLd87v82OlZsLlAAwP41ejmycDgeteXJanpx2J5TtPtSIGA5FRvID17VaiwwGBzWbLWpNaNnjoa17WEMoYtt/rWRHGd/JxWpavhAu76e9Y1DRRTL0qDyjHFgbmBOR274rqvCXgyLWvDuram9/HHLYwiV4TCWPO7AJ6dF7Zrl1BADnn0ra8O3lxYXwnj3vDHhpICT5c6g/ccDgg+/FEZtaCq03y3gZ726na8ce3dwRnqf8AJqxboFQkHBH3h2r0r4u6KkejafrzPapLJtjFtZxYQBgWLFupwcDn1968ta5EcQdsqp4P19KqcL7GVCrzaDbi6jSXYVIP8WK53XEQDehznHUVb1bURLGqoqljn5s4rDnbzwkZODgck0QXc9SnT6siVuRjGT2p6uGcAcduKuQ6dIlsJGXp0461XkhKSAnjmqb6G1ky5EF2LuHNX7GBnjLRvtGelZqMU255GKvWd2FmZF+7nj3qJNmkHpY2LJPMcRt8r+tdZbsLCKJ0X94SF2/3q5RX2jzkHI5q7YXsszHzc7VYMufrXPLU1hFno1rcp9nMhAxJkDjuKGvsQEIQsgPDY7Vzsd9K8GxFQFck8cU603zTgvkgZ+Zeg9q8updK7J9ikryOutLhvJTedxIyWrzX9o51bwPYgdf7QjP/AJClr06wtkAwSy8dWHWvNP2kl2+B7HkH/iYxj/yFLU5dJyxlP1PEzG3I7HzYehptOPem19+fOhRRRQAopaQUtABRRRQAV0OiAGzjz/eNc9W/ozBbJfqayrfCdGG+M1XVCB60IcShexpdwY5wKese45BwexrzWz0ovQnii8wkelXYI9wOzqOaoxyFOAOnU5q7aTFASvOaxbNIl2CBpXVW+XIzu7D61YVDDOyErJsOAy9Dz1HtUFvJI5JUqo71PESZHHU9KynqbRNSAZKmY4Trt9K6u1gsrW3E4uQVZCGQrnPH6VzylLq2hjEUayKNmV+85yf8f0ouftMMRVldccbWPp7Vmwk3sjpW8VXEng680fVV+2NKVNtczPk24G3oPoK4W582WIJGSybjluxIxV4tI0WXAIxjFRo6qhG0DB4HYVopO1jGMY0ndGDeQCDG472HOKoIAZkJGVzW7qlo90Q0OFHf1NJcWwjW3iaOBfL25dBy3Xr61SuejTqrlLcTLNbNGSAFGQBWJLGXlA5K571pz7kZnjAG44wo4ptxGLdFIG/eOWx901L0ZpB63IZ4ESBTwDgdapWrbDv2klT+FaDIHti0jMXBwo9qzyDAcM3Dc4NUthp2ZvS3X+jgINpIzUmnzPuCg7mPYVnQATMnLHj1rc0+y8qUyY7etc9SSidMKtupsWjzRxEOfnJxj2rb0mV2UQFETOW3d6xbUGVcsTk9x2rZ0mN9xyPnHGT6dv0rzJu6sy5VFKJ2EUm1ByTjue9eXftGOz+CLLPT+0U/9FS13oumQBSSSK88/aElEngqyGeft6HH/bOSnl0bYqHqeDmC/dtnzu3Q02nNTa+6PnQooooAUUtIKWgAooooAK2dLYi1QD+8axq0dPk2w4HUHNZ1PhN8O7SN6JsjB61aicqSOOB3rPSTGCTU6zjpxk150o7nemXGaNGffu56EVLZuBuWRzyOOKzzJvJyegzUu4h+CcqeahR7mkWa8EpB2jd9av28gU53AmsCGV88kn6Gr8JYJuB5PPNYyjY2jI6Syvfs0iShgXVtwyoPP0q5d3E1xullfzHl5CgAZPsBwP0rlkklJHcd81rG8k+yIFUeYOQfQ1ny3G/hbPRfHnhW38O+HdLvI/tnm3m0nzggjX5MkDDE559OgNefO4Cc4JPpXrXxb1CDVvhv4c1CwuHlsoHRHWRl37jECowO+Aa8Ye5Vwu0EcZGauyRx0nKW5chkZwc/eHSqmp3BMTEgBweNtNin2yctjNLPE0wP3ee4pXsztg3G1ybTW8wRifB6Eg9av39v5sDPCh2oc4rOtY2RgcnI9q1Xlf7O0RJDMMrsHX6is567GzqWd0ZcU8YH76MfL8uKyr9zcXJ8tcItaksQMbBgQ+7n1P4VRi27plKgsT3oTsawlzFnTm2yxrySa6yIgkJ0GK5yK1aB4pTjZgV0Wnr5jB3Py4rkrzFVbjsb2m2iFSFGV6/jWzbwiJcng+1Z+mSIFODgZq9JOoUHdxXnuMupnGs3oJPIVdcDOTXnnx4kVvCVqAfmF8nH/bOSu7nmVgCpGRXm3xsmEnhi2HGftinP/AHrty+P+0Q9Tnxsuak0eJNTacabX2R8+FFFFACilpBS0AFFFFABU9rLsbB6VBQODmk1dFRlyu5tNPkjB461MsuWB6VlRucDmrcMgzzXNKFj0ITvY1rfG8FhuXuM4rfN7ZvoEtvDpiG5MwZr5mJdVxjYBwOTzmuYjmG3ANTw3bojRgna5G4dq5pRubbl2NCqja3X3rRtt+0Ix5rKt7heQy/T2rUtzuRWBJAHWsKiZSZorHhOM5PenMHVQSDj60+He8CyBCEPG7+H86JWJQgsBwDzx17c1ySTRanbQlk1K8lsEsZLuZrJSGW33nYGAwDj1xxUAQMv3cHGPwqFvkIOM56EHNSwOXyCOlJXZXMlsiNl3NkZGKtQOcAHnI9ahUgMQ1IXKY29hTUWwvcsiYqe/wCdWPtBMbEkhx0YHkVliTOMnnvT3l4wDmnylXLy5aPexzk8k9aqLCTMXQZUmpbdt6Ac4rStLZSAeevSok7ItT5S1JEsiJEB/DnjtWtYQA22F4wO9Q20AJz/ABYxWpBHiPCjHFcdTUc6nMiolw1rIELcGrsN4sgGW4rG1M+XOCSTxVYX4j46Uezvsc93E3ZbnaSASfSvPfi7cxyeHbeLcPN+1q2M8ldj811Ut2rouHw2MjH9a8d8bay2qapIsZP2aIhFHuM8/qa78tw7dZStscmKre7Y5rsabTz0NMr6V7nmhRRRSAUUtIKWgAooooAKSlooAfG2DzViNzu46VU7VJG+KlxubU6lmX4mO4GraN3rMjkyeGGanWbAwRmsJQudkahpLJx1Gau2t60abTjFYSye9TRzcdc1jKkacx2UOq7rAQF8xKdwXA9c9evc12ltpOnf8IJNrV7qzw3YQNDZeUG85izADI6cDv615HbzEOpGMDsK1I9QdkWM5KrwAcfzrlnRVwkm9jaL5HChRjsc80okZVwvU1kx3bA9PrT3uPMTGcE96xcLGiTS1NQSqVByCSM46GojN820EYPeoLu+N5BbhkVDFHtyuSTVVuMEHmjlKTsX590QG4qQemKhWTZwOAahjJbcOpPtSMpjwTmnYpSNrTpcLz3ro7I/us1yemS7uMV0Vu7BVx0rCpHcm+pu28nzYrRjIEZx1rEt5gp6ir6zKVAB5PT3rjlEUpWKuq/MN54IHANc3eSFG+YYJPA9a19Zv4LaIy3M0cMYH+sdhg+w9TXnHijxSkrGDTWWTn5pmGB+ArrweGnOVmtDmq17bFrxJ4pNrDNY2oVpXUq79dvt9ev515+TmlZsknrnnNNr6KlRjRVkedKbk7sD0ptOPSm1oIKKKKAFFGaSigBc0ZpKKAFzRmkooAXNGaSigBwbBqRZiO1Q0UFRm47Fj7R/s04XQH8H61VoqeVF+2n3L8d+EbPl5/Gp11cA8wA/8CrJoqXSi90P29Tuba64F6W//j//ANanf29/07n/AL+f/WrCopewp9g+sVO5vp4i2j/j2P8A38/+tR/wkTf8+5/77/8ArVgUUvq9PsH1ip3OiTxJtP8Ax6kn/rp/9anS+Jg4x9kI/wC2v/1q5uil9Wpdg+sVO50tt4oEDZ+yFv8Atrj/ANlrUj8elFx/Z2f+23/2NcNRQ8NSf2R/Wavc70fEIgH/AIlv/kf/AOxqK6+Id7IZFtrSCGJxjDZcj8eK4eipWDoL7JLr1HuzQ1TVbrU7v7TeyebNjaG2BePoKpM25snk0yiuhJLYyFzRmkopgLmkoooAKKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Angiodysplasia appears endoscopically as peripherally expanding dilated capillaries with a central origin measuring between 0.1 to 1.0 cm in diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rome Jutabha, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colon angiodysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of T Edward Bynum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17778=[""].join("\n");
var outline_f17_23_17778=null;
var title_f17_23_17779="Eyelid laceration with orbital fat prolapse";
var content_f17_23_17779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eyelid laceration with orbital fat prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The presence of orbital fat in an eyelid laceration indicates damage to the orbital septum and possibly to the underlying levator muscle. Ophthalmology consultation should be obtained.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter A D Rubin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17779=[""].join("\n");
var outline_f17_23_17779=null;
var title_f17_23_17780="Vitek MIC test";
var content_f17_23_17780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Miniaturized minimum inhibitory concentration test module for automated susceptibility instrument",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For automated susceptibility testing, microdilution trays such as this are inoculated with known quantities of bacteria. Photometers or fluorometers monitor reactions in each well and can report changes in 3 to 24 hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Jane Ferraro, PhD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17780=[""].join("\n");
var outline_f17_23_17780=null;
var title_f17_23_17781="Teacher questionnaire A";
var content_f17_23_17781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56349%7EPEDS%2F69113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56349%7EPEDS%2F69113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Speech and language evaluation teacher questionnaire",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 673px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Speech-Language Pathology Department, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Speech and language evaluation teacher questionnaire (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 681px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Speech-Language Pathology Department, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17781=[""].join("\n");
var outline_f17_23_17781=null;
var title_f17_23_17782="General guidelines for use of anti-tumor necrosis factor alpha agents in ankylosing spondylitis and axial spondyloarthritis";
var content_f17_23_17782=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General guidelines for use of anti-tumor necrosis factor alpha agents in ankylosing spondylitis and axial spondyloarthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/23/17782/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/23/17782/contributors\">",
"     David T Yu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/23/17782/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/23/17782/contributors\">",
"     Joachim Sieper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/23/17782/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/23/17782/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/23/17782/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The very high cost of anti-tumor necrosis factor (TNF)-alpha therapies is a major impediment to their widespread use. In order to control health care costs, government agencies and health insurance payers impose restrictions. These policies vary by payer. In some countries, such as the United States (US), each health payer formulates its own rules regarding patient characteristics that are required to have the cost of anti-TNF therapy covered. In other countries where health care costs for all citizens are borne by the governments, committees of national specialists in ankylosing spondylitis (AS) have been requested to setup guidelines to identify patients eligible for reimbursement.",
"   </p>",
"   <p>",
"    Other than recognized contraindications to anti-TNF therapy (eg, untreated latent tuberculosis, active infection, and moderate or severe heart failure), there are no convincing evidence-based indications to exclude any patients with AS from the treatment. Many of the existing guidelines affect practice in a particular region or the patients covered by a particular payer. Clinicians in each region need to consult the regulatory or insurance guidelines of their own country, region, insurer, or other payer to determine the criteria that patients must meet to have anti-TNF therapies approved by the responsible agency or insurer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17782/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Assessment in Ankylosing Spondylitis (ASAS) working group, an organization of approximately 100 international experts, first published a set of guidelines for use of anti-TNF agents in AS in 2003, updated them in 2006 and in 2010, and plans to update them further [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17782/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. The guidelines address patient selection, monitoring, and discontinuation of these drugs in patients with AS and other axial spondyloarthritis (SpA). The ASAS guidelines represent a consensus opinion. Most other guidelines (eg, from individual countries) also follow the major parameters of the ASAS guidelines.",
"   </p>",
"   <p>",
"    This topic reviews the guidelines proposed for the cost-conscious use of TNF inhibitors in patients with well-defined AS and axial spondyloarthritis. Detailed reviews of the overall approaches to diagnosis and management of AS and SpA, including the use of TNF inhibitors as well as other agents, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=see_link\">",
"     \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are being considered for anti-TNF therapy should have a clinical diagnosis of AS or axial spondyloarthritis (axial SpA). These patients should:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meet either of two classification criteria, the modified New York criteria for definitive AS or the Assessment in Ankylosing Spondylitis (ASAS) criteria for axial SpA (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=see_link&amp;anchor=H32243117#H32243117\">",
"       \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\", section on 'Modified New York criteria'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=see_link&amp;anchor=H9478399#H9478399\">",
"       \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\", section on 'ASAS classification criteria for axial SpA'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Have disease that has been active for at least four weeks (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Active disease'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Have back pain for more than three months, with an age at onset of less than 45 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, either of the following criteria should be met, depending upon the diagnostic category and criteria set:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definitive AS &mdash; The criteria for definitive AS include the requirement for patients to have radiographic changes of sacroiliitis of grade II bilaterally or of grade III or grade IV unilaterally. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=see_link&amp;anchor=H21#H21\">",
"       \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\", section on 'Imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ASAS criteria for axial SpA &mdash; For the ASAS criteria for axial SpA, an MRI of the sacroiliac joints should be obtained if the plain radiographs of the sacroiliac joints are negative. Changes of bone marrow edema (BME) (on short T inversion recovery, STIR, or T2 with fat absorption images) in the subchondral or periarticular areas are required to diagnose active sacroiliitis by MRI; such lesions should not be present in the T1-weighted images. T1-weighted images might show sclerosis or erosions.",
"      <br/>",
"      <br/>",
"      In patients with negative imaging studies, criteria for axial SpA are also met if the patient has a positive test for HLA-B27 and more than two other features of SpA, such as high acute phase reactant levels and a good response to nonsteroidal antiinflammatory drugs (NSAIDs). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link&amp;anchor=H27#H27\">",
"       \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\", section on 'Axial SpA'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ASAS recommendation to include patients without evidence of sacroiliitis on plain radiographs increases the number of patients with axial SpA who would be considered eligible for anti-tumor necrosis factor (TNF)-alpha therapy. These radiographically-negative axial SpA patients with axial symptoms and undifferentiated spondyloarthritis were designated previously as having or &ldquo;early ankylosing spondylitis,&rdquo; but the term &ldquo;early ankylosing spondylitis&rdquo; has been replaced by the term &ldquo;non-radiographic axial SpA&rdquo; (nr-axSpA) because many of these patients do not appear to progress to develop the characteristic changes of classic AS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17782/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=see_link\">",
"     \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=see_link&amp;anchor=H9478399#H9478399\">",
"     \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\", section on 'ASAS classification criteria for axial SpA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also a very small number of patients with early inflammatory back pain who do not have radiographic or MRI changes in the sacroiliac joints but who show MRI changes of inflammation in the spine [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17782/abstract/8\">",
"     8",
"    </a>",
"    ]. How to best classify this group has not been determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\", section on 'Axial radiographs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACTIVE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, only patients with active disease should be considered candidates for treatment with anti-TNF agents. Radiographic changes of the spine by themselves do not constitute an indication for such therapy, since there is no evidence that anti-TNF agents can arrest the progression of radiographic changes in the spine. Active disease as indicated by both the Bath ankylosing spondylitis disease activity Index (BASDAI) score and a physician global assessment should be present to warrant anti-TNF therapy. The guidelines of several countries require more stringent or additional criteria for active disease compared with the ASAS guidelines, such as elevated acute phase reactants. The definition of \"active disease\" for each index is given below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     BASDAI score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BASDAI is an instrument for the assessment of disease activity that is presented in a questionnaire format. The BASDAI instrument is available for healthcare professionals on several sites on the world wide web, including",
"    <a class=\"external\" href=\"file://www.spondylitis.org/physician_resources/assesment.aspx?PgSrch=basdai\">",
"     www.spondylitis.org",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.asas-group.org/\">",
"     www.asas-group.org",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Each of six questions has a visual analog or numerical scale. The final BASDAI score (range 0 to 10) is computed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sum the values for the first four BASDAI questions",
"     </li>",
"     <li>",
"      Add",
"      <span class=\"nowrap\">",
"       one/half",
"      </span>",
"      of the sum of the last two BASDAI questions",
"     </li>",
"     <li>",
"      Divide the result by five",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A BASDAI score of &ge;4 (on a scale of 0 to 10) is indicative of active disease that warrants consideration of anti-TNF therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physician global assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disease should be in an active stage as assessed by expert opinion. An expert is defined for the purpose of these criteria as a doctor familiar with inflammatory back pain and use of biological agents. An expert can simply decide that the disease is active or provide a physician global assessment. Disease is usually regarded as active if the score is &ge;2 on a Likert Scale (range 0 to 4: 0 = mild, 2 = moderate, 3 = severe, 4 = very severe).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FAILURE OF TRADITIONAL DMARD THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with AS or other axial SpA with symptomatic peripheral arthritis, failure of NSAIDs, local injections with glucocorticoids, and at least one traditional disease-modifying antirheumatic drug (DMARD), preferably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , is a criterion for use of anti-TNF therapies. Patients with only pure axial disease need not try a DMARD to be deemed treatment failures, because traditional (nonbiologic) DMARD therapies have not been shown to be effective for patients with only pure axial disease. In 2012, the TNF inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    received regulatory approval in Europe for use in severe axial SpA in patients who do not have structural changes of sacroiliitis by plain radiographs but who have objective signs of inflammation, including either an elevated C-reactive protein or evidence of inflammation on MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17782/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     NSAID failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to respond to at least two different NSAIDs during four weeks of treatment, as defined by the lack of adequate response (BASDAI remains &gt;4) or intolerability, is a criterion for anti-TNF therapy. Each NSAID should have been used at the maximum tolerable dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     DMARD failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with predominantly peripheral arthritis should normally have had a therapeutic trial of a DMARD, preferably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    . Failed treatment (ie, BASDAI remains &gt;4) with &ge;1 disease modifying antirheumatic drug (DMARD) is a criterion for treatment with anti-TNF therapy.",
"   </p>",
"   <p>",
"    Failure is defined as either a lack of response or an inability to tolerate a DMARD. It is understood that some rheumatologists prefer other nonbiologic DMARDs to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    . Failure of other nonbiologic DMARDs is also a criterion for failure of DMARD therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Glucocorticoid injection failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local glucocorticoid injection of one or more symptomatic peripheral joints or enthesitis sites is warranted before initiating anti-TNF therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link&amp;anchor=H39#H39\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\", section on 'Glucocorticoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contraindications to TNF inhibitor use are the same as those for use in other diseases, such as rheumatoid arthritis. (See individual drug information topics) and (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'TNF inhibition'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Briefly summarized, the contraindications to the use of anti-TNF therapies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Active infection",
"     </li>",
"     <li>",
"      Latent (untreated) tuberculosis",
"     </li>",
"     <li>",
"      Demyelinating disease (eg, multiple sclerosis, optic neuritis)",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Pregnancy and breastfeeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    for AS is 25 mg subcutaneously twice a week or 50 mg once a week. The usual maximum dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    is 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously every six weeks. The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    is 40 mg subcutaneously every two weeks. The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    is 50 mg subcutaneously every four weeks. Patients with low disease activity may also be adequately treated on an on-demand (as needed) basis, using the biologics only when required for relief of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17782/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link&amp;anchor=H26#H26\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\", section on 'Tumor necrosis factor alpha antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of anti-TNF agents in patients with AS and non-radiographic axial SpA is supported by multiple randomized trials that compare these agents with placebo using composite outcome measures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17782/abstract/2\">",
"     2",
"    </a>",
"    ] The number-to-treat (NNT) to achieve a partial remission is estimated to be from 2.3 to 5.9.",
"   </p>",
"   <p>",
"    There are limited data that suggest that adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    to an anti-TNF agent does not result in a higher response rate. This was illustrated in a study that randomly assigned 38 Chinese patients to receive either methotrexate or placebo in combination with three monthly infusions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    . No significant differences in clinical or magnetic resonance imaging features were noted between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17782/abstract/10\">",
"     10",
"    </a>",
"    ]. The proportion of ASAS20 responders at 30 weeks (eight weeks after the last of three infliximab infusions) were 68 and 63 percent in the placebo plus infliximab and methotrexate plus infliximab groups, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MONITORING OF RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with AS do not respond to anti-TNF therapy. Periodic reevaluation is necessary to assure that treatment is discontinued if it is ineffective; the initial assessment of the response to treatment should be performed after at least 12 weeks of anti-TNF therapy.",
"   </p>",
"   <p>",
"    Use of both of the following assessment tools is recommended in clinical practice:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BASDAI and physician global assessment (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Active disease'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Assessments in ankylosing spondylitis (ASAS) working group core set for clinical practice (",
"      <a class=\"graphic graphic_table graphicRef76447 \" href=\"UTD.htm?27/57/28571\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17782/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Improvement is defined as either a 50 percent improvement of the BASDAI score or an absolute change of &ge;2 on a scale of 0 to 10 and an \"expert\" opinion that a particular patient has improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DURATION OF ANTI-TNF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-TNF agent should be discontinued if the response criteria are not met or if adverse effects limit usage. Use of another anti-TNF agent may be indicated in such circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17782/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients will relapse within weeks if anti-TNF therapy is discontinued after achieving disease remission [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17782/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3955560\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guidelines have been proposed by international experts in spondyloarthritis (SpA) for the cost-conscious use of tumor necrosis factor (TNF) inhibitors in patients ankylosing spondylitis (AS) and other axial SpA. The consensus of these experts is that patients who are being considered for anti-TNF therapy should have a clinical diagnosis of AS or axial SpA according to formal classification criteria. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Only patients with active disease, who have failed to respond to at least two different nonsteroidal antiinflammatory drugs during four weeks of treatment, should be considered candidates for treatment with anti-TNF agents. Disease activity should be assessed by both the Bath ankylosing spondylitis disease activity Index (BASDAI) score and a physician global assessment. A BASDAI score of greater than or equal to four (on a scale of 0 to 10) is indicative of active disease that warrants consideration of anti-TNF therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Active disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'BASDAI score'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Physician global assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with predominantly peripheral arthritis should generally have had an unsuccessful therapeutic trial of at least one disease-modifying antirheumatic drug (DMARD), preferably",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , prior to the use of a TNF inhibitor. Additionally, glucocorticoid injection of one or more symptomatic peripheral joints or enthesitis sites is warranted before initiating anti-TNF therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Failure of traditional DMARD therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dosing and contraindications to TNF inhibitor use in SpA are similar to those in rheumatoid arthritis and other conditions. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Contraindications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Periodic reevaluation is necessary to assure that treatment is discontinued if the response is inadequate; the initial assessment of the response to treatment should be performed after at least 12 weeks of anti-TNF therapy. Use of another anti-TNF agent may be indicated in patients who do not respond to the initial drug chosen. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Monitoring of response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Duration of anti-TNF therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17782/abstract/1\">",
"      van den Berg R, Stanislawska-Biernat E, van der Heijde DM. Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide. Rheumatology (Oxford) 2011; 50:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17782/abstract/2\">",
"      Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford) 2012; 51:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17782/abstract/3\">",
"      Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17782/abstract/4\">",
"      Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17782/abstract/5\">",
"      van der Heijde D, Sieper J, Maksymowych WP, et al. Update of the ASAS recommendations on the use of TNF-blockers in ankylosing spondylitis. Arthritis Rheum 2009; 60:S670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17782/abstract/6\">",
"      van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17782/abstract/7\">",
"      Kiltz U, Baraliakos X, Karakostas P, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) 2012; 64:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17782/abstract/8\">",
"      Blachier M, Coutanceau B, Dougados M, et al. Does the site of magnetic resonance imaging abnormalities match the site of recent-onset inflammatory back pain? The DESIR cohort. Ann Rheum Dis 2012.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency. Committee for medicinal products for human use. Summary of opinion (post authorisation). Humira (adalimumab). 21 June 2012. file://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000481/WC500129074.pdf (Accessed on September 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17782/abstract/10\">",
"      Li EK, Griffith JF, Lee VW, et al. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford) 2008; 47:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17782/abstract/11\">",
"      Miceli-Richard C, van der Heijde D, Dougados M. Spondyloarthropathy for practicing rheumatologists: diagnosis, indication for disease-controlling antirheumatic therapy, and evaluation of the response. Rheum Dis Clin North Am 2003; 29:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17782/abstract/12\">",
"      Rudwaleit M, Van den Bosch F, Kron M, et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010; 12:R117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17782/abstract/13\">",
"      Haibel H, Sieper J. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker? Curr Opin Rheumatol 2010; 22:388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7788 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17782=[""].join("\n");
var outline_f17_23_17782=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3955560\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACTIVE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BASDAI score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physician global assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FAILURE OF TRADITIONAL DMARD THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NSAID failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DMARD failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Glucocorticoid injection failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DOSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MONITORING OF RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DURATION OF ANTI-TNF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3955560\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7788\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7788|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/57/28571\" title=\"table 1\">",
"      AS clinical assessment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=related_link\">",
"      Diagnosis and differential diagnosis of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_23_17783="Nephrology pattern 6 answer";
var content_f17_23_17783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 6 answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Moderate FGS. Light micrograph in focal segmental glomerulosclerosis shows a moderately large segmental area of sclerosis with capillary collapse on the upper left side of the glomerular tuft; the lower right segment is relatively normal. Focal deposition of hyaline material (arrow) is also seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17783=[""].join("\n");
var outline_f17_23_17783=null;
var title_f17_23_17784="Fenofibrate: Drug information";
var content_f17_23_17784=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fenofibrate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/61/38868?source=see_link\">",
"    see \"Fenofibrate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Antara&reg;;",
"     </li>",
"     <li>",
"      Fenoglide&reg;;",
"     </li>",
"     <li>",
"      Lipofen&reg;;",
"     </li>",
"     <li>",
"      Lofibra&reg;;",
"     </li>",
"     <li>",
"      TriCor&reg;;",
"     </li>",
"     <li>",
"      Triglide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Feno-Micro&reg;;",
"     </li>",
"     <li>",
"      Apo-Feno-Super&reg;;",
"     </li>",
"     <li>",
"      Apo-Fenofibrate&reg;;",
"     </li>",
"     <li>",
"      Ava-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      Dom-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      Feno-Micro-200;",
"     </li>",
"     <li>",
"      Fenofibrate Micro;",
"     </li>",
"     <li>",
"      Fenofibrate-S;",
"     </li>",
"     <li>",
"      Fenomax;",
"     </li>",
"     <li>",
"      Lipidil EZ&reg;;",
"     </li>",
"     <li>",
"      Lipidil Micro&reg;;",
"     </li>",
"     <li>",
"      Lipidil Supra&reg;;",
"     </li>",
"     <li>",
"      Mylan-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      Novo-Fenofibrate Micronized;",
"     </li>",
"     <li>",
"      PHL-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      PMS-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      PRO-Feno-Super;",
"     </li>",
"     <li>",
"      Q-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      ratio-Fenofibrate MC;",
"     </li>",
"     <li>",
"      Riva-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      Sandoz-Fenofibrate E;",
"     </li>",
"     <li>",
"      Sandoz-Fenofibrate S;",
"     </li>",
"     <li>",
"      Teva-Fenofibrate S",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F170300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, Fibric Acid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F170266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     At least 2-3 months of therapy is required to determine efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertriglyceridemia:",
"     </b>",
"     Oral: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antara&reg; (micronized): 43-130 mg once daily; maximum dose: 130 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fenoglide&reg;: 40-120 mg once daily; maximum dose: 120 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fenomax&trade; [CAN; not available in U.S.]: 160 mg once daily; maximum dose: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipidil EZ&reg; [CAN; not available in U.S.]: 145 mg once daily; maximum dose: 145 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipidil Micro&reg; [CAN; not available in U.S.]: 200 mg once daily; maximum dose: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipidil Supra&reg; [CAN; not available in U.S.]: 160 mg once daily; maximum dose: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipofen&reg;: 50-150 mg once daily; maximum dose: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lofibra&reg; (micronized): 67-200 mg once daily; maximum dose: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lofibra&reg; (tablets): 54-160 mg once daily; maximum dose: 160 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TriCor&reg;: 48-145 mg once daily; maximum dose: 145 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triglide&reg;: 50-160 mg once daily; maximum dose: 160 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypercholesterolemia or mixed hyperlipidemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antara&reg; (micronized): 130 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fenoglide&reg;: 120 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fenomax&trade; [CAN; not available in U.S.]: 160 mg once daily; maximum dose: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipidil EZ&reg; [CAN; not available in U.S.]: 145 mg once daily; maximum dose: 145 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipidil Micro&reg; [CAN; not available in U.S.]: 200 mg once daily; maximum dose: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipidil Supra&reg; [CAN; not available in U.S.]: 160 mg once daily; maximum dose: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipofen&reg;: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lofibra&reg; (micronized): 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lofibra&reg; (tablets): 160 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TriCor&reg;: 145 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triglide&reg;: 160 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F170267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antara&reg; (micronized): 43 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fenoglide&reg;: Adjust dosage based on creatinine clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lipidil EZ&reg; [CAN; not available in U.S.]: 48 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lipidil Micro&reg; [CAN; not available in U.S.]: Adjust dosage based on creatinine clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lipidil Supra&reg; [CAN; not available in U.S.]: Adjust dosage based on creatinine clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lipofen&reg;: Adjust dosage based on creatinine clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lofibra&reg; (micronized): 67 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lofibra&reg; (tablets): 54 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     TriCor&reg;: Adjust dosage based on creatinine clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Triglide&reg;: Adjust dosage based on creatinine clearance",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F170268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Monitor renal function and lipid panel before adjusting.",
"     <b>",
"      Note:",
"     </b>",
"     Use in severe renal impairment (including patients on dialysis) is contraindicated (see specific product labeling):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antara&reg; (micronized):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Initiate at 43 mg once daily (contraindicated in severe impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fenoglide&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;80 mL/minute or eGFR &ge;60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-80 mL/minute or eGFR 30-59 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Initiate at 40 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute or eGFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fenomax&trade; [CAN; not available in U.S.]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;20-100 mL/minute: Initiate at 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lipidil EZ&reg; [CAN; not available in U.S.]:",
"     <b>",
"      Note:",
"     </b>",
"     Interrupt treatment in patients with an increase in creatinine concentrations &gt;50% the upper limit of normal (ULN).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;20-50 mL/minute: Initiate at 48 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lipidil Micro&reg; [CAN; not available in U.S.]:",
"     <b>",
"      Note:",
"     </b>",
"     Interrupt treatment in patients with an increase in creatinine concentrations &gt;50% the upper limit of normal (ULN).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;20-85 mL/minute (women) or &ge;20-95 mL/minute (men): Initiate therapy with Lipidil EZ&reg; formulation with a dose of 48 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lipidil Supra&reg; [CAN; not available in U.S.]:",
"     <b>",
"      Note:",
"     </b>",
"     Interrupt treatment in patients with an increase in creatinine concentrations &gt;50% the upper limit of normal (ULN).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;20-100 mL/minute: Initiate at 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lipofen&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;80 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-80 mL/minute: Initiate at 50 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lofibra&reg; (micronized):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;80 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-80 mL/minute: Initiate at 67 mg once daily",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lofibra&reg; (tablets):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;80 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-80 mL/minute: Initiate at 54 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     TriCor&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;80 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-80 mL/minute: Initiate at 48 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Triglide&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;80 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-80 mL/minute: Initiate at 50 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14224085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipofen&reg;: 50 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral [micronized]: 43 mg, 67 mg, 130 mg, 134 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antara&reg;: 43 mg, 130 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lofibra&reg;: 67 mg, 134 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 48 mg, 54 mg, 145 mg, 160 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fenoglide&reg;: 40 mg, 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lofibra&reg;: 54 mg, 160 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TriCor&reg;: 48 mg, 145 mg [contains soybean lecithin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triglide&reg;: 50 mg, 160 mg [contains egg lecithin]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Micronized capsule, tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F170241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antara&reg;, TriCor&reg;: May be administered with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fenoglide&reg;: Administer with meals. Swallow whole; do not crush, dissolve, or chew tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lofibra&reg;, Lipofen&reg;: Administer with meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Triglide&reg;: May be administered with or without food. Swallow whole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Canadian products [not available in U.S.]:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fenomax&trade;, Lipidil Micro&reg;: Administer with meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipidil Supra&reg;: Administer with meals. Swallow whole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipidil EZ&reg;: May be administered with or without food. Swallow whole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F170239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary therapy for the treatment of adults with elevations of serum triglyceride levels (Fredrickson types IV and V hyperlipidemia); adjunct to dietary therapy for the reduction of low density lipoprotein cholesterol (LDL-C), total cholesterol (total-C), triglycerides, and apolipoprotein B (apo B), and to increase high density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb hyperlipidemia)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F15796012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy for the treatment of hyperuricemia in patients with gout",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6053352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       TriCor&reg; may be confused with Fibricor&reg;, Tracleer&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F170298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Hepatic: Liver function tests increased (dose related; 3% to 13%; ALT/AST increased &gt;3 x ULN: 5% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Urticaria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (5%), constipation (2%), nausea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (3%), CPK increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory disorder (6%), rhinitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal vision, acute renal failure, agranulocytosis, allergic reaction, alopecia, amblyopia, anemia, angina pectoris, anorexia, arrhythmia, arthralgia, arthritis, arthrosis, asthma, atrial fibrillation, bronchitis, bursitis, cataract, cholecystitis, cholelithiasis, cholestatic hepatitis, cirrhosis, colitis, conjunctivitis, contact dermatitis, cyst, cystitis, deep venous thrombosis, diabetes mellitus, diarrhea, duodenal ulcer, electrocardiogram abnormality, eosinophilia, esophagitis, extrasystoles, fatty liver deposits, gastritis, gastroenteritis, gout, gynecomastia, HDL-C decreased (paradoxical), hepatitis, hernia, herpes simplex, herpes zoster, homocysteine increased, hyper-/hypotension, hypersensitivity pneumonitis, hypersensitivity reaction, hypertonia, hyperuricemia, hypoglycemia, infection, leukopenia, lymphadenopathy, maculopapular rash, MI, migraine, myasthenia, myopathy, myositis, neuralgia, pancreatitis, peptic ulcer, photosensitivity reaction, pneumonia, pregnancy (unintended), prostate disorder, pulmonary embolus, rectal hemorrhage, refraction disorder, rhabdomyolysis, skin ulcer, Stevens-Johnson syndrome, tachycardia, tenosynovitis, thrombocytopenia, toxic epidermal necrolysis, urinary frequency, urolithiasis, vaginal moniliasis, vasodilatation, weight gain/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F170244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fenofibrate or any component of the formulation; hepatic dysfunction including primary biliary cirrhosis and unexplained persistent liver function abnormalities; severe renal impairment (including patients on dialysis); pre-existing gallbladder disease; breast-feeding (Fenoglide&reg;, Lipofen&reg;, TriCor&reg;, and Triglide&reg;)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Pregnancy; breast-feeding; known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     Lipidil EZ&reg;; Lipidil Micro&reg;; Lipidil Supra&reg;: Additional contraindications: Allergy to soya lecithin or peanut or arachis oil; chronic or acute pancreatitis; patients &lt;18 years of age; coadministration with HMG-CoA reductase inhibitors in patients with a predisposition for myopathy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F170228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholelithiasis: May cause cholelithiasis; discontinue if gallstones are found upon gallbladder studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HDL cholesterol (HDL-C): A paradoxical, severe, and reversible decrease in HDL-C (as low as 2 mg/dL) with a simultaneous decrease in apolipoprotein A1 has been reported within 2 weeks to years after initiation of fibrate therapy; clinical significance unknown. Monitor HDL-C within a few months of initiation of therapy and discontinue if HDL-C becomes severely depressed; do not restart therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemogloblin/hematocrit/WBC effects: May cause mild-to-moderate decreases in hemoglobin, hematocrit and WBC upon initiation of therapy which usually stabilizes with long-term therapy. Agranulocytosis and thrombocytopenia have been reported (rare). Periodic monitoring of blood counts is recommended during the first year of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Hepatic transaminases can become significantly elevated (dose-related); hepatocellular, chronic active, and cholestatic hepatitis have been reported. Regular monitoring of liver function tests is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Rarely hypersensitivity reactions (eg, severe skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis) may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Has been associated with rare myositis, myopathy, or rhabdomyolysis; patients should be monitored closely. Risk increased in the elderly, those receiving concomitant HMG-CoA reductase inhibitors or colchicine, and patients with diabetes mellitus, renal failure, or hypothyroidism. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal effects: Increases in serum creatinine (&gt;2 mg/dL) have been observed with use; clinical significance unknown. Fenofibrate has been shown to increase creatinine production (unknown mechanism) resulting in an equal increase of creatinuria thereby demonstrating that the increase does not reflect a reduction in creatinine clearance (Hottelart, 2002). Monitor renal function in patients with renal impairment and consider monitoring patients with increased risk for developing renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Venous thromboembolism (VTE): Use has been associated with pulmonary embolism (PE) and deep vein thrombosis (DVT).  Use with caution in patients with risk factors for VTE.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with mild-to-moderate renal impairment; dosage adjustment required. Contraindicated with severe renal impairment including those receiving dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants: Use with caution in patient taking oral anticoagulants (eg, warfarin); adjustments in anticoagulation therapy may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HMG-CoA reductase inhibitors: Use caution with HMG-CoA reductase inhibitors; may lead to myopathy, rhabdomyolysis. No incremental benefit of combination therapy on cardiovascular morbidity and mortality over statin monotherapy has been established. In combination with HMG-CoA reductase inhibitors, fenofibrate is generally regarded as safer than gemfibrozil due to limited pharmacokinetic interaction with statins.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Due to a higher incidence of renal impairment, use with caution in the elderly; dosage adjustment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Type 2 diabetes mellitus: In two large randomized controlled clinical trials, neither fenofibrate monotherapy (Keech, 2005) nor the addition of fenofibrate to simvastatin (ACCORD Study Group, 2010) compared to placebo has been shown to reduce cardiovascular disease morbidity and mortality in patients with type 2 diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peanut or arachis oil: Some products may contain peanut or arachis oil; use is contraindicated in patients with a peanut or arachis allergy for applicable formulations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Soya lecithin: Some products may contain soya lecithin; use is contraindicated in patients with a soya lecithin allergy for applicable formulations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Optimal response: Therapy should be withdrawn if an adequate response is not obtained after 2-3 months of therapy at the maximal daily dose. In patients with severe hypertriglyceridemia, the occurrence of pancreatitis may represent a failure of efficacy, a direct effect of the drug, or obstruction of the common bile duct due to biliary tract stone or sludge formation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F170295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2A6 (weak), CYP2C8 (weak), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Fibric Acid Derivatives. Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Fibric Acid Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any fibric acid derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the nephrotoxic effect of Fibric Acid Derivatives. Fibric Acid Derivatives may decrease the serum concentration of CycloSPORINE (Systemic). Management: Careful consideration of the risks and benefits should be undertaken prior to use of this combination; extra monitoring of renal function and cyclosporine concentrations will likely be required.  Adjustment of cyclosporine dose may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ezetimibe: Fibric Acid Derivatives may increase the serum concentration of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Fenofibrate may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Fibric Acid Derivatives may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): May enhance the nephrotoxic effect of Fenofibrate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Fibric Acid Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Fibric Acid Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Fenofibrate may enhance the anticoagulant effect of Warfarin. Fenofibrate may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F170234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F170247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal toxicity was observed in pregnant rats at doses approximately equivalent to the human dose; adverse events were not observed in reproduction studies done in rabbits. Reports of using fenofibrate during pregnancy are limited (Goldberg, 2012; Sunman, 2012; Whitten, 2011). Other agents are generally preferred if treatment for hypertriglyceridemia during pregnancy (Berglund, 2012) or treatment of lipid disorders in women of reproductive age (NCEP, 2001) is required. Use during pregnancy is specifically contraindicated in Canadian product labeling; some products recommend using effective birth control when treating women of reproductive age and discontinuing therapy several months prior to conception if planning a pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F170272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F170248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if fenofibrate is excreted into breast milk. Some products are specifically contraindicated in nursing women. According to the manufacturers, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F170249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fenoglide&reg;, Lofibra&reg; (capsules [micronized] and tablets), Lipofen&reg;: Take with meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antara&reg;, TriCor&reg;, Triglide&reg;: May be taken with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Canadian products [not available in U.S.]:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fenomax&trade;, Lipidil Micro&reg;, Lipidil Supra&reg;: Take with meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipidil EZ&reg;: May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F170246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Antara Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     43 mg (30): $78.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     130 mg (30): $230.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Fenofibrate Micronized Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     43 mg (30): $70.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     67 mg (100): $105.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     130 mg (30): $207.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     134 mg (100): $195.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $242.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Lipofen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (90): $194.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (90): $426.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Lofibra Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     67 mg (100): $145.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     134 mg (100): $281.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $437.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fenofibrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     48 mg (90): $171.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     54 mg (90): $71.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     145 mg (90): $515.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg (90): $213.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fenoglide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (90): $263.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (90): $790.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lofibra Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     54 mg (90): $131.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg (90): $394.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tricor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     48 mg (90): $209.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     145 mg (90): $629.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Triglide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $239.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg (30): $239.70",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F170236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic blood counts during first year of therapy. Total cholesterol, LDL-C, triglycerides, and HDL-C should be measured periodically (6-8 weeks after initiation; if dose increased [or if combined with another agent], monitor again at 6-8 weeks until goal met, then every 4-6 months [NCEP, 2001); if only marginal changes are noted after 2-3 months of initiation, discontinue fenofibrate. Monitor LFTs regularly and discontinue therapy if levels remain &gt;3 times normal limits. Monitor renal function in patients with renal impairment or in those at increased risk for developing renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F170250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Feno-Micro (MY);",
"     </li>",
"     <li>",
"      Aterolis (UY);",
"     </li>",
"     <li>",
"      Colestrim (TH);",
"     </li>",
"     <li>",
"      Controlip (CR, EC, GT, HN, MX, NI, PA, PE, SV);",
"     </li>",
"     <li>",
"      Durafenat (DE);",
"     </li>",
"     <li>",
"      Durafenat Micro (DE);",
"     </li>",
"     <li>",
"      Eticer (CL);",
"     </li>",
"     <li>",
"      Febrate (TH);",
"     </li>",
"     <li>",
"      Fegenor (FR);",
"     </li>",
"     <li>",
"      Fendown (TW);",
"     </li>",
"     <li>",
"      Fenobrate (AR);",
"     </li>",
"     <li>",
"      Fenocor (IN);",
"     </li>",
"     <li>",
"      Fenofanton (DE);",
"     </li>",
"     <li>",
"      Fenofibrat-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Fenogal (PH);",
"     </li>",
"     <li>",
"      Fenoget (PK);",
"     </li>",
"     <li>",
"      Fenomed (TH);",
"     </li>",
"     <li>",
"      Fenopidil (KP);",
"     </li>",
"     <li>",
"      Fenosup Lidose (MY, SG);",
"     </li>",
"     <li>",
"      Fenox (TH);",
"     </li>",
"     <li>",
"      Fibrafen (PH);",
"     </li>",
"     <li>",
"      Hyperchol (ID);",
"     </li>",
"     <li>",
"      Katalip (HR);",
"     </li>",
"     <li>",
"      Lexemin (HK, MY, SG, TH);",
"     </li>",
"     <li>",
"      Lifen (ID);",
"     </li>",
"     <li>",
"      Linlip (TW);",
"     </li>",
"     <li>",
"      Lipanthyl (BE, BG, CH, CL, CZ, DE, EE, FI, FR, GR, HK, HU, ID, IT, LU, PH, PL, RU, SE, TH, TR, TW);",
"     </li>",
"     <li>",
"      Lipanthyl Penta (MY, SG);",
"     </li>",
"     <li>",
"      Lipantil (GB, PT);",
"     </li>",
"     <li>",
"      Lipidax (IT);",
"     </li>",
"     <li>",
"      Lipidil (AU, BR, CN, DE, HU);",
"     </li>",
"     <li>",
"      Lipidil Supra (KP);",
"     </li>",
"     <li>",
"      Lipiduce (PH);",
"     </li>",
"     <li>",
"      Lipilfen (KP);",
"     </li>",
"     <li>",
"      Lipofen (PT);",
"     </li>",
"     <li>",
"      Lipolin (TW);",
"     </li>",
"     <li>",
"      Lipsin (AT);",
"     </li>",
"     <li>",
"      Lipway SR (PH);",
"     </li>",
"     <li>",
"      Lofibra (PH);",
"     </li>",
"     <li>",
"      Low-Lip (TW);",
"     </li>",
"     <li>",
"      Lowpirol S (KP);",
"     </li>",
"     <li>",
"      Naftilan (CL);",
"     </li>",
"     <li>",
"      Nofibal (HU);",
"     </li>",
"     <li>",
"      Nopid (KP);",
"     </li>",
"     <li>",
"      Normolip (CR, DO, GT, HN, NI, PA, PE, SV);",
"     </li>",
"     <li>",
"      Notricol (CO);",
"     </li>",
"     <li>",
"      Nubrex (PH);",
"     </li>",
"     <li>",
"      Qualipantyl (HK);",
"     </li>",
"     <li>",
"      Redose (KP);",
"     </li>",
"     <li>",
"      Secalip (FR);",
"     </li>",
"     <li>",
"      Secalip Supra (ES);",
"     </li>",
"     <li>",
"      Stanlip (IN, TH);",
"     </li>",
"     <li>",
"      Sulnit (PY);",
"     </li>",
"     <li>",
"      Trichek (PH);",
"     </li>",
"     <li>",
"      Trolip (HK, ID, PH);",
"     </li>",
"     <li>",
"      Versamid (CY);",
"     </li>",
"     <li>",
"      Zumafib (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F170227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fenofibric acid, an agonist for the nuclear transcription factor peroxisome proliferator-activated receptor-alpha (PPAR-alpha), downregulates apoprotein C-III (an inhibitor of lipoprotein lipase) and upregulates the synthesis of apolipoprotein A-I, fatty acid transport protein, and lipoprotein lipase resulting in an increase in VLDL catabolism, fatty acid oxidation, and elimination of triglyceride-rich particles; as a result of a decrease in VLDL levels, total plasma triglycerides are reduced by 30% to 60%; modest increase in HDL occurs in some hypertriglyceridemic patients.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F170243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Increased when taken with meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely to most tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Tissue and plasma via esterases to active form, fenofibric acid; undergoes inactivation by glucuronidation hepatically or renally",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Fenofibric acid: Mean: 20 hours (range: 10-35 hours); half-life prolonged in patients with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% as metabolites); feces (25%); hemodialysis has no effect on removal of fenofibric acid from plasma",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACCORD Study Group, Ginsberg HN, Elam MB, et al, &ldquo;Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 362(17):1563-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/20228404/pubmed\" id=\"20228404\" target=\"_blank\">",
"        20228404",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(9):2969-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/22962670/pubmed\" id=\"22962670\" target=\"_blank\">",
"        22962670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bonds DE, Craven TE, Buse J, et al, \"Fenofibrate-Associated Changes in Renal Function and Relationship to Clinical Outcomes Among Individuals With Type 2 Diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Experience,\"",
"      <i>",
"       Diabetologia",
"      </i>",
"      , 2012, 55(6):1641-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/22450889/pubmed\" id=\"22450889\" target=\"_blank\">",
"        22450889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Lorgeril M, Salen O, Paillard F, et al, &ldquo;Lipid-Lowering Drugs and Homocyst(e)ine,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1999, 353(9148):209-10.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farnier M, Bonnefous F, Debbas N, et al, &ldquo;Comparative Efficacy and Safety of Micronized Fenofibrate and Simvastatin in Patients With Primary Type IIa or IIb Hyperlipidemia,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1994, 154(4):441-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/8117177/pubmed\" id=\"8117177\" target=\"_blank\">",
"        8117177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feher MD, Hepburn AL, Hogarth MB, et al, &ldquo;Fenofibrate Enhances Urate Reduction in Men Treated with Allopurinol for Hyperuricaemia and Gout,&rdquo;",
"      <i>",
"       Rheumatology (Oxford)",
"      </i>",
"      , 2003, 42(2):321.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/12595630/pubmed\" id=\"12595630\" target=\"_blank\">",
"        12595630",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldberg AS and Hegele RA, \"Severe Hypertriglyceridemia in Pregnancy,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(8):2589-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/22639290/pubmed\" id=\"22639290\" target=\"_blank\">",
"        22639290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hottelart C, El Esper N, Rose F, et al, \"Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine,\"",
"      <i>",
"       Nephron",
"      </i>",
"      , 2002, 92(3):536-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/12372935/pubmed\" id=\"12372935\" target=\"_blank\">",
"        12372935",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keech A, Simes RJ, Barter P, et al, &ldquo;Effects of Long-term Fenofibrate Therapy on Cardiovascular Events in 9795 People With Type 2 Diabetes Mellitus (The FIELD Study): Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005, 366(9500):1849-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/16310551/pubmed\" id=\"16310551\" target=\"_blank\">",
"        16310551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahley RW and Bersot TP, &ldquo;Drug Therapy for Hypercholesterolemia and Dyslipidemia,&rdquo;",
"      <i>",
"       Goodman and Gilman's The Pharmacological Basis of Therapeutics",
"      </i>",
"      , 10th ed, Hardman JE and Limbird LE, eds, New York, NY: McGraw-Hill, 2001, 993-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(11):913-27; published erratum appears in",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(12):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/16971976/pubmed\" id=\"16971976\" target=\"_blank\">",
"        16971976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mychaleckyj JC, Craven T, Nayak U, et al, \"Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(5):1008-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/22432114/pubmed\" id=\"22432114\" target=\"_blank\">",
"        22432114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitori CR, Montanari G, Gianfranceschi G, et al, &ldquo;Correlation Between Plasma Levels of Fenofibrate and Lipoprotein Changes in Hyperlipidaemic Patients,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1985, 28(6):619-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/3840743/pubmed\" id=\"3840743\" target=\"_blank\">",
"        3840743",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sunman H, Canpolat U, Sahiner L, et al, \"Use of Fenofibrate During the First Trimester of Unplanned Pregnancy in a Patient With Hypertriglyceridemia,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2012, 46(2):e5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/22253190/pubmed\" id=\"22253190\" target=\"_blank\">",
"        22253190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taskinen M, Sullivan DR, Ehnholm, et al, &ldquo;Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate,&rdquo;",
"      <i>",
"       Arterioscler Thromb Vasc Biol",
"      </i>",
"      , 2009, 29(6):950-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/19325138/pubmed\" id=\"19325138\" target=\"_blank\">",
"        19325138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whitten AE, Lorenz RP, and Smith JM, \"Hyperlipidemia-Associated Pancreatitis in Pregnancy Managed With Fenofibrate,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(2 Pt 2):517-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/23/17784/abstract-text/21252809/pubmed\" id=\"21252809\" target=\"_blank\">",
"        21252809",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8935 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17784=[""].join("\n");
var outline_f17_23_17784=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170261\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170262\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170300\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170266\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170267\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170268\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14224085\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170238\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170224\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170241\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170239\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796012\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6053352\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170298\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170244\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170228\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170295\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170233\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170234\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170247\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170272\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170248\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170249\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170246\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170236\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170250\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170227\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170243\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8935\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8935|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/61/38868?source=related_link\">",
"      Fenofibrate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_23_17785="High resolution manometry";
var content_f17_23_17785=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   High resolution manometry",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/23/17785/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/23/17785/contributors\">",
"     Peter J Kahrilas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/23/17785/contributors\">",
"     John E Pandolfino, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/23/17785/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/23/17785/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/23/17785/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/23/17785/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/23/17785/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22510745\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal manometry is indicated in the evaluation of dysphagia and noncardiac chest pain in patients without evidence of mechanical obstruction, ulceration, or inflammation. It is also an important tool in the evaluation of gastroesophageal reflux disease (GERD), both for correct placement of pH electrodes and as an essential part of preoperative evaluation prior to antireflux procedures.",
"   </p>",
"   <p>",
"    High resolution manometry (HRM) with esophageal pressure topography (EPT) plotting combines improvements in pressure sensing technology with a greatly increased number of pressure sensors and an analysis paradigm that displays data as a topographic plot that morphs anatomy and physiology.",
"   </p>",
"   <p>",
"    This topic review will discuss the critical features that distinguish HRM with EPT from conventional manometry, novel metrics for EPT, a classification scheme of motility disorders developed for EPT (Chicago Classification[CC]), and will detail the diagnostic criteria within this classification scheme. The indications for motility testing, technical aspects of conventional manometry, and the clinical manifestations and management of specific motility disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=see_link\">",
"     \"Motility testing: When does it help?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13096?source=see_link\">",
"     \"Diffuse esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link\">",
"     \"Clinical manifestations and diagnosis of achalasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=see_link\">",
"     \"Overview of the treatment of achalasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510752\">",
"    <span class=\"h1\">",
"     HIGH RESOLUTION MANOMETRY (HRM) WITH ESOPHAGEAL PRESSURE TOPOGRAPHY (EPT)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H544147912\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fundamental difference between conventional manometry and high resolution manometry (HRM) is the number of pressure sensors used and the spacing between them (",
"    <a class=\"graphic graphic_figure graphicRef86104 \" href=\"UTD.htm?1/43/1722\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=see_link&amp;anchor=H2#H2\">",
"     \"Motility testing: When does it help?\", section on 'Esophageal manometry'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to conventional manometry where sensors are spaced at 3 to 5 cm intervals, in HRM sensors are spaced no more than 1 cm apart along the length of the manometric assembly. Catheters with up to 36 sensors distributed longitudinally and radially in the esophagus allow for simultaneous pressure readings within both sphincters and the esophageal body.",
"   </p>",
"   <p>",
"    Esophageal pressure topography (EPT) is a three-dimensional plotting format devised for depiction of HRM studies. EPT interpolates pressure values between sensors to create a pressure continuum. Pressure magnitude is converted into a color scale using cold colors to denote low pressures and hot colors to denote higher pressures (",
"    <a class=\"graphic graphic_figure graphicRef86104 \" href=\"UTD.htm?1/43/1722\">",
"     figure 1",
"    </a>",
"    ). In an EPT plot, time and location within the esophagus are continuous variables and pressure magnitude is indicated at each x-y coordinate by color. The result is a seamless isobaric contour (IBC) map spanning from above the upper esophageal sphincter (UES) to below the esophagogastric junction (EGJ). This also allows for the depiction of real-time luminal pressure gradients and spatial transition points of contraction amplitude or propagation velocity along the esophagus that correlate with anatomical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physiological landmarks.",
"   </p>",
"   <p>",
"    Both EPT analysis and conventional manometry aim to characterize peristalsis and EGJ function. However, the types of measurements obtained differ substantially. Several novel metrics and nomenclature have been devised specifically to quantify esophageal function in EPT (see",
"    <a class=\"local\" href=\"#H22510787\">",
"     'Analysis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22510878\">",
"     'Classification of motility disorders by esophageal pressure topography (EPT)'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510766\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technical aspects of performing HRM studies mirror that of conventional manometry in terms of preprocedure patient preparation and transnasal intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=see_link&amp;anchor=H2#H2\">",
"     \"Motility testing: When does it help?\", section on 'Esophageal manometry'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In HRM, once the manometric catheter is positioned across the EGJ, no further repositioning is required. Simultaneous assessment of sphincters and body with a single series of swallows is possible with the catheter in a single, fixed position. This is in contrast to conventional manometry where pull-though maneuvers and repeated catheter repositioning are required to separately assess the sphincters and different esophageal regions.",
"   </p>",
"   <p>",
"    The data acquisition period with HRM also tends to be shorter than with conventional manometry, possibly increasing study acceptability and tolerability among patients.",
"   </p>",
"   <p>",
"    Similar to conventional manometry, HRM is not dependent on any specific hardware and can be accomplished with different pressure transduction technologies such as water-perfused systems, solid state strain gauge devices, or Tact-array technology. However, as performance characteristics of each pressure transduction technology are unique, HRM requires its own set of reference values developed for each specific system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510773\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications to perform HRM are the same as those described for conventional manometry and include the evaluation of dysphagia, gastroesophageal reflux disease (GERD), noncardiac chest pain, and systemic diseases of the smooth muscle or autonomic nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/3\">",
"     3",
"    </a>",
"    ]. Studies using HRM suggest enhanced performance and accuracy for assessing pressure changes, especially in the sphincters&nbsp;compared with conventional manometry [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Therefore, when available, HRM is the preferred manometric technique for the assessment of motility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=see_link&amp;anchor=H2#H2\">",
"     \"Motility testing: When does it help?\", section on 'Esophageal manometry'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510780\">",
"    <span class=\"h2\">",
"     Protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the manometric catheter is positioned, the patient undergoes a 10-swallow protocol in the supine position consisting of 10 swallows, each using 5 mL of water.",
"   </p>",
"   <p>",
"    Although upright and provocative swallows with viscous and solid food challenges can be added to the basic protocol, there are currently few validated metrics to determine the significance of swallow patterns associated with these challenges [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510787\">",
"    <span class=\"h2\">",
"     Analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both HRM with EPT analysis and conventional manometry aim to characterize peristalsis and EGJ function. However, the types of measurements obtained differ. The HRM metrics utilized in EPT to define esophageal motor function and the corresponding measures in conventional manometry are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef86119 \" href=\"UTD.htm?38/24/39308\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22024797\">",
"    <span class=\"h3\">",
"     Pressure topography landmarks",
"    </span>",
"    &nbsp;&mdash;&nbsp;EPT plots have several stereotypic features reflective of unique features of esophageal anatomy, physiology, and pathophysiology that are crucial to the accurate interpretation of these studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510801\">",
"    <span class=\"h4\">",
"     Anatomic sphincters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The upper and lower esophageal sphincters are usually easily visualized with EPT. Sphincter margins are characterized by an abrupt change in pressure along the luminal axis where a distinct high-pressure zone or pressure band can be identified. These high-pressure zones, together with sphincter relaxation and peristalsis with swallowing, allow for easy localization of the esophageal sphincters.",
"   </p>",
"   <p>",
"    The EGJ is subject to substantial morphological variability in EPT plots largely due to potential laxity in the attachment between the lower esophageal sphincter (LES) and the crural diaphragm (CD) (",
"    <a class=\"graphic graphic_figure graphicRef86107 \" href=\"UTD.htm?36/53/37720\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With a completely normal EGJ (Type I), the CD is completely superimposed on the LES, making it possible to identify the CD only on the basis of its inspiratory contraction (",
"      <a class=\"graphic graphic_figure graphicRef86107 \" href=\"UTD.htm?36/53/37720\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      With a Type II EGJ, there is slight separation between the LES and CD, but there is no low pressure gap between the two (",
"      <a class=\"graphic graphic_figure graphicRef86107 \" href=\"UTD.htm?36/53/37720\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With a Type III EGJ, there is complete separation between the LES and CD, permitting the independent assessment of either constituent. The distinction between Type IIIa and Type IIIb is based on the location of the respiratory inversion point (RIP); with Type IIIa, the RIP is associated with increased pressure at and below the CD, whereas with Type IIIb, the RIP extends up to the LES (",
"      <a class=\"graphic graphic_figure graphicRef86107 \" href=\"UTD.htm?36/53/37720\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some individuals have been observed to transition between morphologic types during prolonged manometric recordings, emphasizing the laxity of the LES-CD attachment that can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510808\">",
"    <span class=\"h4\">",
"     Contractile segments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal peristalsis consists of a progressive sequence of segmental contractions demarcated by three pressure troughs (proximal, middle, and distal) (",
"    <a class=\"graphic graphic_figure graphicRef86104 \" href=\"UTD.htm?1/43/1722\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/12\">",
"     12",
"    </a>",
"    ]. The first contractile segment is continuous with the pharyngeal and UES contraction, while the fourth contractile segment is the LES. The second and third contractile segments, comprising most of the tubular esophagus, are not always distinct and sometimes merge as a seamless contraction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510815\">",
"    <span class=\"h4\">",
"     Transition zone",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stereotypical morphologic feature of peristalsis is the major pressure trough between the first and second contractile segments, alternatively labeled the \"transition zone\" [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Physiological studies have concluded that this is the region of transition from central nervous system (CNS) control of peristalsis to enteric nervous system (myenteric plexus) control. Transition zone defects may be related to dysphagia in a small percentage of patients (&lt;4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510822\">",
"    <span class=\"h4\">",
"     Contractile deceleration point (CDP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conduction velocity, a defining feature of an esophageal contraction, is measured on EPT by the slope of the 30 mmHg IBC (",
"    <a class=\"graphic graphic_figure graphicRef86108 \" href=\"UTD.htm?43/23/44406\">",
"     figure 3",
"    </a>",
"    ). Conduction velocity is not constant along the length of the esophagus and is more rapid proximally than distally. Physiological studies have demonstrated that the transition from rapid to slow propagation correlates with the formation of the phrenic ampulla (",
"    <a class=\"graphic graphic_figure graphicRef86108 \" href=\"UTD.htm?43/23/44406\">",
"     figure 3",
"    </a>",
"    ), a transient structure composed of the effaced, elongated, and elevated LES [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The contraction deceleration point (CDP) demarcates the proximal region in which the conduction (peristaltic) velocity is fast from the distal region where conduction velocity is slow, reflecting the progression of ampullary emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/17\">",
"     17",
"    </a>",
"    ]. The CDP location is determined on EPT plots by defining the intersection point between two tangent lines of the 30 mmHg isobaric contour: one extending distally from the transition zone and the other extending proximally from the EGJ when it reestablishes its normal postdeglutitive position (",
"    <a class=\"graphic graphic_figure graphicRef86108 \" href=\"UTD.htm?43/23/44406\">",
"     figure 3",
"    </a>",
"    ). The CDP is localized within 2 cm of the proximal margin of the EGJ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510829\">",
"    <span class=\"h3\">",
"     Novel EPT metrics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several novel metrics and nomenclature have been devised specifically to quantify esophageal function in EPT (",
"    <a class=\"graphic graphic_table graphicRef86119 \" href=\"UTD.htm?38/24/39308\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510836\">",
"    <span class=\"h4\">",
"     Integrated relaxation pressure (IRP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Integrated relaxation pressure (IRP) is a measure for assessing the adequacy of EGJ relaxation with swallowing.",
"   </p>",
"   <p>",
"    Abnormal deglutitive LES relaxation is the most fundamental abnormality of esophageal motility [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/18\">",
"     18",
"    </a>",
"    ]. However, using intraluminal manometry, LES pressure cannot be distinguished from other contributions to intraluminal pressure at the level of the EGJ, most notably, the CD. Additionally, outflow obstruction caused by stenosis or extrinsic compression can lead to elevated intrabolus pressure that is indistinguishable from impaired LES relaxation. Consequently, the metric developed to distinguish normal from impaired EGJ relaxation was termed the IRP.",
"   </p>",
"   <p>",
"    IRP is defined as the average minimum EGJ pressure for four seconds of relaxation (contiguous or noncontiguous) within 10 seconds of swallowing (upper sphincter relaxation).",
"   </p>",
"   <p>",
"    The IRP is a complex metric as it involves localizing the margins of the EGJ, demarcating the time window following deglutitive upper sphincter relaxation within which EGJ relaxation will occur, applying an e-sleeve measurement within that 10-second time box, and then determining the four seconds during which the e-sleeve value was least. IRP is the mean pressure during those four seconds.",
"   </p>",
"   <p>",
"    The published upper limit of normal for the IRP is 15 mmHg which represents the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile in a series of 75 asymptomatic controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/18\">",
"     18",
"    </a>",
"    ]. However, normal values are specific for specific manometric apparatus (sensor types and arrays). Additionally, the threshold value for defining a swallow as pathologic may require some degree of latitude based on the fact the concurrent contractile pattern may affect the intrabolus pressure generated at the EGJ [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/19\">",
"     19",
"    </a>",
"    ]. Depending on these mitigating factors, the upper limit of normal for the IRP can be as low as 10 mmHg or as high as 20 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510843\">",
"    <span class=\"h4\">",
"     Peristaltic integrity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peristaltic integrity is defined by whether or not there are gaps (and the length of those gaps) in the 20 mmHg IBC spanning from the upper sphincter to the EGJ (",
"    <a class=\"graphic graphic_figure graphicRef86115 \" href=\"UTD.htm?8/46/8934\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on observations in patients with abnormal bolus transit and normal EGJ anatomy and function, peristaltic integrity is classified as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intact &ndash; no break greater than 2 cm in the 20 mmHg IBC",
"     </li>",
"     <li>",
"      Weak contraction &ndash; small defect; break between 2 and 5 cm",
"     </li>",
"     <li>",
"      Weak contraction &ndash; large defect; break greater than 5 cm",
"     </li>",
"     <li>",
"      Failed peristalsis &ndash; minimal (less than 3 cm) of contractile integrity distal to the proximal pressure trough",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510850\">",
"    <span class=\"h4\">",
"     Distal latency (DL)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal latency (DL) is a measure of peristaltic timing and is dependent on the integrity of deglutitive inhibition rather than peristaltic velocity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/21\">",
"     21",
"    </a>",
"    ]. DL is defined as the interval between UES relaxation and the CDP (",
"    <a class=\"graphic graphic_figure graphicRef86108 \" href=\"UTD.htm?43/23/44406\">",
"     figure 3",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H22510822\">",
"     'Contractile deceleration point (CDP)'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Based on the DL, contractions are defined as premature or of normal latency. In normal subjects, the median DL is 6.2 seconds with a minimal value of 4.6 seconds, thereby establishing 4.5 seconds as the lower limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510857\">",
"    <span class=\"h4\">",
"     Contractile front velocity (CFV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The esophageal contraction prior to the CDP is quantified as the contractile front velocity (CFV) (see",
"    <a class=\"local\" href=\"#H22510822\">",
"     'Contractile deceleration point (CDP)'",
"    </a>",
"    above). CFV is measured as the slope of the best-fit tangent to the 30 mmHg IBC (",
"    <a class=\"graphic graphic_figure graphicRef86108 \" href=\"UTD.htm?43/23/44406\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/17\">",
"     17",
"    </a>",
"    ]. The upper limit of normal for the CFV is 9",
"    <span class=\"nowrap\">",
"     cm/second.",
"    </span>",
"   </p>",
"   <p>",
"    In",
"    instances of increased intrabolus pressure, trapped between the distal esophageal contraction and the EGJ, the CFV should be determined at an IBC pressure exceeding EGJ pressure so as not to mistake compartmentalized esophageal pressurization for a simultaneous contraction (see",
"    <a class=\"local\" href=\"#H22510871\">",
"     'Pressurization patterns'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510864\">",
"    <span class=\"h4\">",
"     Distal contractile integral (DCI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal contractile integral (DCI) is a summary measure of the vigor of the distal esophageal contraction. The DCI is essentially a composite of the mean distal contractile amplitude, length of the distal esophagus, and contractile duration.",
"   </p>",
"   <p>",
"    The DCI is measured for the segment spanning from the proximal to distal pressure troughs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/4\">",
"     4",
"    </a>",
"    ]. A box is constructed to delineate the contractile activity relegated to the second and third contractile segments (",
"    <a class=\"graphic graphic_figure graphicRef86116 \" href=\"UTD.htm?14/5/14424\">",
"     figure 5",
"    </a>",
"    ). The DCI is then calculated by summing the pressure measurements at each enclosed coordinate. To exclude the effects of vascular artifacts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intrabolus pressure in the DCI computation, the first 20 mmHg is discounted. Therefore, the DCI value is greater than zero only when foci of intra-esophageal pressure exceed 20 mmHg.",
"   </p>",
"   <p>",
"    Swallow patterns based on DCI values are defined as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypercontractile (jackhammer) &ndash; any swallow with DCI &gt;8000 mmHg-s-cm",
"     </li>",
"     <li>",
"      Hypertensive (nutcracker) &ndash; mean DCI &gt;5000 but less than 8000 mmHg-s-cm",
"     </li>",
"     <li>",
"      Weak peristalsis &ndash; DCI &lt;450 mmHg-s-cm",
"     </li>",
"     <li>",
"      Failed peristalsis &ndash; DCI &lt;150 mmHg-s-cm",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510871\">",
"    <span class=\"h4\">",
"     Pressurization patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distinction between an esophageal contraction and pressurization is that while a contraction signifies a lumen-obliterating squeeze of the circular muscle clamping down on the pressure recording device, pressurization is recorded within an open chamber, for example, in the esophageal lumen between the closed upper and lower sphincters [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In EPT, pressurization is evident by vertical bands of increased pressure \"blocked\" at either end by a greater, obstructing pressure.",
"   </p>",
"   <p>",
"    When pressurization involves the entire esophagus, it is termed as \"panesophageal pressurization\" (",
"    <a class=\"graphic graphic_figure graphicRef86117 \" href=\"UTD.htm?36/59/37815\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/25\">",
"     25",
"    </a>",
"    ]. This pattern is pathognomonic for type II achalasia (see",
"    <a class=\"local\" href=\"#H22510922\">",
"     'Achalasia'",
"    </a>",
"    below). A more limited region of pressurization, termed \"compartmentalized pressurization\", can occur between an esophageal contraction and the EGJ in the setting of hiatus hernia, a CD contraction, after fundoplication surgery, or after bariatric surgery (",
"    <a class=\"graphic graphic_figure graphicRef86117 \" href=\"UTD.htm?36/59/37815\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/26\">",
"     26",
"    </a>",
"    ]. Proximal compartmentalized pressurization (",
"    <a class=\"graphic graphic_figure graphicRef86117 \" href=\"UTD.htm?36/59/37815\">",
"     figure 6",
"    </a>",
"    ) can also occur in the setting of isolated, nonperistaltic distal esophageal contractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510878\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF MOTILITY DISORDERS BY ESOPHAGEAL PRESSURE TOPOGRAPHY (EPT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Chicago Classification (CC) of esophageal motility is an algorithmic scheme for diagnosis of esophageal motility disorders from clinical esophageal pressure topography (EPT) studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/7,27\">",
"     7,27",
"    </a>",
"    ]. A key feature of the CC is the hierarchical categorization of esophageal motility disorders into conditions never seen in normal individuals and those that are borderline, defined on the basis of being statistically outside of the norm (expected in about 5 percent of a \"normal\" population) but not necessarily indicative of pathology. The CC of esophageal motility diagnoses along with their diagnostic criteria are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef86120 \" href=\"UTD.htm?0/35/573\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Efforts have been made to link the CC diagnoses to conventional manometric diagnoses when possible. However, with the use of high resolution manometry (HRM), the CC has essentially redefined manometric diagnoses by characterizing EPT phenotypes of motility disorders with the intent that these phenotypes would be sufficiently physiologically homogeneous in order to guide management (see",
"    <a class=\"local\" href=\"#H22510915\">",
"     'EPT criteria for motility disorder subtypes'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510885\">",
"    <span class=\"h2\">",
"     Stepwise approach to EPT analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnostic algorithm, comprised of three major steps, can progressively identify physiological dysfunction as defined by the CC into the following: (i) achalasia, (ii) esophagogastric junction (EGJ) outflow obstruction, (iii) abnormal motility pattern, and (iv) borderline motor dysfunction (",
"    <a class=\"graphic graphic_algorithm graphicRef86118 \" href=\"UTD.htm?30/56/31616\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510892\">",
"    <span class=\"h3\">",
"     Step 1: Assess the EGJ",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      EGJ morphology &ndash; Although EGJ morphology (",
"      <a class=\"graphic graphic_figure graphicRef86107 \" href=\"UTD.htm?36/53/37720\">",
"       figure 2",
"      </a>",
"      ) is not a defining criterion for any of the motility disorders (",
"      <a class=\"graphic graphic_table graphicRef86120 \" href=\"UTD.htm?0/35/573\">",
"       table 2",
"      </a>",
"      ), determining the existence of a hiatus hernia is an important clinical finding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7527?source=see_link\">",
"       \"Hiatus hernia\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A hiatus hernia may cause the manometric catheter to not traverse the EGJ into the intra-abdominal space thereby distorting EPT metrics, and potentially compromising the study. Intra-abdominal location of the manometric catheter is verified by noting that inspiration augments the recorded pressure as opposed to decreasing the recorded pressure when the catheter is located in the mediastinum. The point of transition between the two is the respiratory inversion point (RIP), which is usually at the level of the crural diaphragm (CD) (except with a type IIIb EGJ) (",
"      <a class=\"graphic graphic_figure graphicRef86107 \" href=\"UTD.htm?36/53/37720\">",
"       figure 2",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H22510801\">",
"       'Anatomic sphincters'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      EGJ pressure &ndash; Similar to EGJ morphology, the measurement of basal EGJ pressure is not a defining criterion for any of the motility disorders (",
"      <a class=\"graphic graphic_table graphicRef86120 \" href=\"UTD.htm?0/35/573\">",
"       table 2",
"      </a>",
"      ), but a hypertensive or hypotensive EGJ pressure can be an important clinical finding pertinent to the diagnosis of achalasia or gastroesophageal reflux disease (GERD), respectively (see",
"      <a class=\"local\" href=\"#H22510922\">",
"       'Achalasia'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Integrated relaxation pressure (IRP) &ndash; The determination of normal or abnormal EGJ relaxation after swallowing is made based on the mean value of the IRP among the 10 test swallows (see",
"      <a class=\"local\" href=\"#H22510836\">",
"       'Integrated relaxation pressure (IRP)'",
"      </a>",
"      above). IRP is a major diagnostic criterion for all subtypes of achalasia and for EGJ outflow obstruction (",
"      <a class=\"graphic graphic_table graphicRef86120 \" href=\"UTD.htm?0/35/573\">",
"       table 2",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H22510922\">",
"       'Achalasia'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H22510930\">",
"       'EGJ outflow obstruction'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510900\">",
"    <span class=\"h3\">",
"     Step 2: Characterize esophageal contractility",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peristaltic integrity (",
"      <a class=\"graphic graphic_figure graphicRef86115 \" href=\"UTD.htm?8/46/8934\">",
"       figure 4",
"      </a>",
"      ) &ndash; Assessment of peristaltic integrity is a crucial step in the evaluation of esophageal contractility as the metrics below cannot be applied in instances of failed peristalsis or with a large break in the 30 mmHg isobaric contour (IBC) that obscures the location of the contractile deceleration point (CDP) (see",
"      <a class=\"local\" href=\"#H22510822\">",
"       'Contractile deceleration point (CDP)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22510843\">",
"       'Peristaltic integrity'",
"      </a>",
"      above).",
"      <br/>",
"      <br/>",
"      Each test swallow should be categorized as intact, weak, or failed. Only swallows that are sufficiently intact to permit analysis should be evaluated using metrics of propagation (distal latency [DL], contractile front velocity [CFV]) and contractile vigor (distal contractile integral [DCI]) (see",
"      <a class=\"local\" href=\"#H22510850\">",
"       'Distal latency (DL)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22510857\">",
"       'Contractile front velocity (CFV)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22510864\">",
"       'Distal contractile integral (DCI)'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      DL (",
"      <a class=\"graphic graphic_figure graphicRef86108 \" href=\"UTD.htm?43/23/44406\">",
"       figure 3",
"      </a>",
"      ) &ndash; Measurement of the DL requires that the CDP be identifiable since it is the interval between upper esophageal sphincter (UES) relaxation and the CDP (see",
"      <a class=\"local\" href=\"#H22510850\">",
"       'Distal latency (DL)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22510822\">",
"       'Contractile deceleration point (CDP)'",
"      </a>",
"      above).",
"      <br/>",
"      <br/>",
"      Premature contractions are of particular significance because these are never encountered in normal subjects and are important diagnostic criteria for type III achalasia and distal esophageal spasm (DES) (see",
"      <a class=\"local\" href=\"#H22510922\">",
"       'Achalasia'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H1871924\">",
"       'Distal esophageal spasm (DES)'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CFV (",
"      <a class=\"graphic graphic_figure graphicRef86108 \" href=\"UTD.htm?43/23/44406\">",
"       figure 3",
"      </a>",
"      ) &ndash; CFV is utilized to define one of the borderline motor abnormalities termed rapid contraction when it is not associated with weak peristalsis (",
"      <a class=\"graphic graphic_algorithm graphicRef86118 \" href=\"UTD.htm?30/56/31616\">",
"       algorithm 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H22510857\">",
"       'Contractile front velocity (CFV)'",
"      </a>",
"      above). However, many instances of rapid CFV are associated with peristaltic fragments of minimal clinical significance and are not indicative of spasm [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DCI (",
"      <a class=\"graphic graphic_figure graphicRef86116 \" href=\"UTD.htm?14/5/14424\">",
"       figure 5",
"      </a>",
"      ) &ndash; Although initially devised as a measurement to define hypercontractile disorders (eg, nutcracker or jackhammer esophagus), the DCI can be measured on any swallow and also used as an alternative means of identifying failed peristalsis (DCI &lt;150 mmHg-s-cm) or weak peristalsis (DCI &lt;500 mmHg-s-cm) (see",
"      <a class=\"local\" href=\"#H22510864\">",
"       'Distal contractile integral (DCI)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1561726\">",
"       'Hypercontractile (jackhammer) esophagus'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510908\">",
"    <span class=\"h3\">",
"     Step 3: Characterize pressurization patterns, if present",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Panesophageal pressurization, defined by the 30 mmHg isobaric contour, is pathognomonic for type II achalasia. Compartmentalized pressurization is a frequent finding in EGJ outflow obstruction (see",
"      <a class=\"local\" href=\"#H22510922\">",
"       'Achalasia'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H22510930\">",
"       'EGJ outflow obstruction'",
"      </a>",
"      below).",
"      <br/>",
"      <br/>",
"      These pressurization patterns (",
"      <a class=\"graphic graphic_figure graphicRef86117 \" href=\"UTD.htm?36/59/37815\">",
"       figure 6",
"      </a>",
"      ) are defined independently of the IRP, but are much more prevalent when the IRP is abnormal (see",
"      <a class=\"local\" href=\"#H22510871\">",
"       'Pressurization patterns'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22510836\">",
"       'Integrated relaxation pressure (IRP)'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510915\">",
"    <span class=\"h2\">",
"     EPT criteria for motility disorder subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achalasia, EGJ outflow obstruction, abnormal motility pattern, and borderline motor dysfunction, can be further classified into subtypes (",
"    <a class=\"graphic graphic_table graphicRef86120 \" href=\"UTD.htm?0/35/573\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510922\">",
"    <span class=\"h3\">",
"     Achalasia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPT criteria for achalasia subtypes (",
"      <a class=\"graphic graphic_figure graphicRef86439 \" href=\"UTD.htm?23/23/23924\">",
"       figure 7",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Type I: mean IRP &gt;upper limit of normal, 100 percent failed peristalsis, minimal pressurization within the esophagus",
"     </li>",
"     <li>",
"      Type II: mean IRP &gt;upper limit of normal, no normal peristalsis, panesophageal pressurization with &ge;20 percent of swallows",
"     </li>",
"     <li>",
"      Type III: mean IRP &gt;upper limit of normal, no normal peristalsis, preserved fragments of nonpropagating distal peristalsis or premature (spastic) contractions with &ge;20 percent of swallows",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical implications &ndash; With conventional manometry, achalasia was loosely subdivided into classic and vigorous subtypes; however, there was no consensus on diagnostic criteria or on whether or not such a distinction was meaningful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of achalasia\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With HRM, three discernible achalasic subtypes were defined based on distinct patterns of esophageal pressurization associated with lower esophageal sphincter (LES) dysfunction (",
"    <a class=\"graphic graphic_figure graphicRef86439 \" href=\"UTD.htm?23/23/23924\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The key significance of this observation is that each subgroup has distinct physiology and different likelihood of a favorable treatment outcome. Specifically, type II patients do particularly well with all available treatments, whereas type I patients do significantly better with Heller myotomy than with pneumatic dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/25,30,31\">",
"     25,30,31",
"    </a>",
"    ]. Type III patients have an inferior treatment response compared with the other subtypes. Conventional manometry cannot reliably distinguish the type II and III variants, a crucial distinction as the prognostic implications for these entities are distinctly different.",
"   </p>",
"   <p>",
"    Achalasia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=see_link\">",
"     \"Pathophysiology and etiology of achalasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link\">",
"     \"Clinical manifestations and diagnosis of achalasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=see_link\">",
"     \"Overview of the treatment of achalasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510930\">",
"    <span class=\"h3\">",
"     EGJ outflow obstruction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPT criteria &ndash; Mean IRP &gt;upper limit of normal, some instances of intact peristalsis or weak peristalsis with small breaks such that the criteria for achalasia are not met (",
"      <a class=\"graphic graphic_figure graphicRef86117 \" href=\"UTD.htm?36/59/37815\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Clinical implications &ndash; EGJ outflow obstruction does not meet diagnostic criteria of achalasia because some peristalsis is preserved. However, since the primary abnormality in both conditions is failure of LES deglutitive relaxation, the treatment is often similar. Therapy is typically directed towards lowering LES pressure with botulinum toxin, dilation, or surgical myotomy. Outcome data regarding this entity are limited.",
"      <br/>",
"      <br/>",
"      While EGJ outflow obstruction is likely a variant form, incomplete expression, or evolving case of achalasia in some instances, it has also been reported to occur in benign and malignant infiltrative disorders. Therefore, endoscopic ultrasound to rule out neoplasia should be performed as part of the evaluation of patients with EGJ outflow obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510938\">",
"    <span class=\"h3\">",
"     Abnormal esophageal motor function",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561669\">",
"    <span class=\"h4\">",
"     Absent peristalsis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPT criteria &ndash; Normal mean IRP, 100 percent of swallows with failed peristalsis (",
"      <a class=\"graphic graphic_figure graphicRef86115 \" href=\"UTD.htm?8/46/8934\">",
"       figure 4",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H22510836\">",
"       'Integrated relaxation pressure (IRP)'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Clinical implications &ndash; Absent peristalsis is associated with poor esophageal bolus transit and can be associated with dysphagia for both liquids and solids. The two main associated conditions are GERD and collagen vascular diseases (eg, scleroderma). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=see_link&amp;anchor=H7#H7\">",
"       \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\", section on 'Esophageal involvement'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with absent peristalsis and an impaired antireflux barrier are prone to very severe esophagitis from gastroesophageal reflux. Absent peristalsis is also encountered in patients with post-fundoplication dysphagia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1871924\">",
"    <span class=\"h4\">",
"     Distal esophageal spasm (DES)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPT criteria &ndash; Normal mean IRP, &gt;20 percent premature contractions (DL &lt;4.5 seconds) (",
"      <a class=\"graphic graphic_figure graphicRef86440 \" href=\"UTD.htm?11/13/11479\">",
"       figure 8",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H22510836\">",
"       'Integrated relaxation pressure (IRP)'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Clinical implications &ndash; Early iterations of the CC adopted \"simultaneous contractions\", as described in conventional manometry (CFV &gt;9",
"      <span class=\"nowrap\">",
"       cm/second)",
"      </span>",
"      as defining criterion for DES. However, subsequent evaluation demonstrated this to be a nonspecific finding because of regional variability in contractile velocity, the observation that regions of apparent rapid contraction velocity often occurred with weak peristalsis, and the lack of correlation between these &lsquo;spastic&rsquo; events and symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/28\">",
"       28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Consequently, the metric of DL was proposed as an alternative, more specific measure to define DES (see",
"      <a class=\"local\" href=\"#H22510850\">",
"       'Distal latency (DL)'",
"      </a>",
"      above) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/7\">",
"       7",
"      </a>",
"      ]. Reduced DL is a rare finding, encountered in only 24 of 1070 consecutive patients who underwent manometry in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/28\">",
"       28",
"      </a>",
"      ]. However, all 24 of these patients had a dominant symptom of dysphagia or chest pain and were diagnosed and managed as either DES (six patients) or spastic (type III) achalasia (18 patients). That study suggested that the diagnosis of DES based on an abnormal DL defined a distinct clinical phenotype. However, further studies evaluating the clinical outcomes of patients diagnosed with DES based on reduced DL are needed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13096?source=see_link&amp;anchor=H4#H4\">",
"       \"Diffuse esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter\", section on 'Diffuse (or distal) esophageal spasm'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561726\">",
"    <span class=\"h4\">",
"     Hypercontractile (jackhammer) esophagus",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPT criteria &ndash; At least one swallow with a DCI &gt;8000 mmHg-s-cm with single peaked or multi-peaked contraction (",
"      <a class=\"graphic graphic_figure graphicRef86441 \" href=\"UTD.htm?19/58/20390\">",
"       figure 9",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H22510864\">",
"       'Distal contractile integral (DCI)'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Clinical implications &ndash; Hypercontractile esophagus is a relatively rare disorder, accounting for just 4.1 percent of patients referred for manometric evaluation in a large consecutive series in tertiary referral centers [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/29\">",
"       29",
"      </a>",
"      ]. Patients usually have associated dysphagia. In conventional manometry, the nearest equivalent to hypercontractile (jackhammer) esophagus is nutcracker esophagus. (See",
"      <a class=\"local\" href=\"#H1871168\">",
"       'Hypertensive peristalsis (\"nutcracker esophagus\")'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13096?source=see_link&amp;anchor=H8#H8\">",
"       \"Diffuse esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter\", section on 'Nutcracker esophagus'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Hypercontractile esophagus may be a primary disorder of excessive excitation of the smooth muscle esophagus or potentially a reaction to a subtle EGJ outflow obstruction (see",
"      <a class=\"local\" href=\"#H22510930\">",
"       'EGJ outflow obstruction'",
"      </a>",
"      above) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/29\">",
"       29",
"      </a>",
"      ]. When this pattern is associated with a distal esophageal obstruction, the motility abnormality will resolve with resolution of the obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22510988\">",
"    <span class=\"h3\">",
"     Borderline esophageal motor function",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561819\">",
"    <span class=\"h4\">",
"     Frequent failed peristalsis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPT criteria &ndash; &gt;30 percent, but &lt;100 percent of swallows with failed peristalsis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinical implications &ndash; Unlike weak peristalsis, frequent failed peristalsis is not an established cause of dysphagia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/17\">",
"       17",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H1871148\">",
"       'Weak peristalsis'",
"      </a>",
"      below). It is clearly associated with impaired bolus transit, but if peristalsis is otherwise normal, the significance of this finding is unclear. Patients diagnosed with frequent failed peristalsis have a good long-term outcome and do not require any intervention focused on the motility abnormality [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/32\">",
"       32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients who border on absent peristalsis (more than seven failed swallows) may be at risk for progressing to absent peristalsis and follow-up manometry may be prudent if dysphagia develops (see",
"      <a class=\"local\" href=\"#H1561669\">",
"       'Absent peristalsis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1871148\">",
"    <span class=\"h4\">",
"     Weak peristalsis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPT criteria &ndash; Mean IRP &lt;15 mmHg and (a) &gt;30 percent swallows with small breaks in the 20 mmHg IBC (2 to 5 cm in length) or (b) &gt;20 percent of swallow with large breaks (&gt;5 cm) in the 20 mmHg IBC (",
"      <a class=\"graphic graphic_figure graphicRef86115 \" href=\"UTD.htm?8/46/8934\">",
"       figure 4",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H22510836\">",
"       'Integrated relaxation pressure (IRP)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22510843\">",
"       'Peristaltic integrity'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Clinical implications &ndash; Weak peristalsis is associated with impaired bolus transit through the esophagus and nonobstructive dysphagia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/17\">",
"       17",
"      </a>",
"      ]. In conventional manometry, the nearest equivalent to weak peristalsis was \"ineffective esophageal motility\" (IEM). IEM may be identified in EPT by the presence of 50 percent or more swallows associated with a distal contractile integral (DCI) &lt;450 mmHg-s-cm or 50 percent or more swallows with any combination of failed peristalsis, weak contraction with a small peristaltic break, or weak peristalsis with a large peristaltic break in the middle or distal esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H22510864\">",
"       'Distal contractile integral (DCI)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22510843\">",
"       'Peristaltic integrity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1561819\">",
"       'Frequent failed peristalsis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Although promotility drugs are often recommended to treat this family of borderline esophageal motor function, minimal controlled data or outcome studies exist supporting such interventions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H1959668#H1959668\">",
"       \"Medical management of gastroesophageal reflux disease in adults\", section on 'Prokinetic agents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1871159\">",
"    <span class=\"h4\">",
"     Rapid contraction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPT criteria &ndash; Rapid contraction (CFV &gt;9.0",
"      <span class=\"nowrap\">",
"       cm/second)",
"      </span>",
"      with &ge;20 percent of swallows, DL &lt;4.5 seconds (",
"      <a class=\"graphic graphic_figure graphicRef86440 \" href=\"UTD.htm?11/13/11479\">",
"       figure 8",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H22510857\">",
"       'Contractile front velocity (CFV)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22510850\">",
"       'Distal latency (DL)'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Clinical implications &ndash; The isolated finding of rapid contractions is of unclear significance. Rapid contractions can occur as a segment of rapid CFV within a seemingly normal swallow or as an artifact associated with breaks in the 30 mmHg IBC (see",
"      <a class=\"local\" href=\"#H22510857\">",
"       'Contractile front velocity (CFV)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22510843\">",
"       'Peristaltic integrity'",
"      </a>",
"      above). Consequently, rapid contractions are currently considered ancillary findings with weak peristalsis unless the DL is abnormal or approaches a borderline value, suggestive of DES (see",
"      <a class=\"local\" href=\"#H22510850\">",
"       'Distal latency (DL)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1871924\">",
"       'Distal esophageal spasm (DES)'",
"      </a>",
"      above) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1871168\">",
"    <span class=\"h4\">",
"     Hypertensive peristalsis (\"nutcracker esophagus\")",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPT criteria &ndash; Mean DCI &gt;5000 mmHg-s-cm, but not meeting criteria for hypercontractile esophagus (",
"      <a class=\"graphic graphic_figure graphicRef86441 \" href=\"UTD.htm?19/58/20390\">",
"       figure 9",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H22510864\">",
"       'Distal contractile integral (DCI)'",
"      </a>",
"      above) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinical implications &ndash; Hypertensive peristalsis represents a borderline increase in peristaltic amplitude, the clinical significance of which is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17785/abstract/29\">",
"       29",
"      </a>",
"      ]. The pattern of propagation is normal and thus, treatment options are directed at frequently associated conditions, especially GERD and visceral hypersensitivity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13096?source=see_link&amp;anchor=H8#H8\">",
"       \"Diffuse esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter\", section on 'Nutcracker esophagus'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22511052\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High resolution manometry (HRM) for the evaluation of esophageal motility disorders employs catheters with up to 36 sensors distributed longitudinally and radially allowing for simultaneous pressure readings within both sphincters and the esophageal body. (See",
"      <a class=\"local\" href=\"#H22510752\">",
"       'High resolution manometry (HRM) with esophageal pressure topography (EPT)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Esophageal pressure topography (EPT) is a three-dimensional plotting format devised for depiction of HRM studies wherein both time and location within the esophagus are continuous variables and pressure magnitude is indicated at each x-y coordinate by color. The result is a seamless isobaric contour (IBC) map spanning from above the upper esophageal sphincter (UES) to below the esophagogastric junction (EGJ) (",
"      <a class=\"graphic graphic_figure graphicRef86104 \" href=\"UTD.htm?1/43/1722\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22510752\">",
"       'High resolution manometry (HRM) with esophageal pressure topography (EPT)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The interpretation of clinical EPT studies required the development of novel metrics customized to highlight the key pathophysiological features of esophageal motor disorders.",
"      <br/>",
"      <br/>",
"      The most important of these are: the integrated relaxation pressure (IRP) for assessing the adequacy of EGJ relaxation with swallowing; the distal contractile integral (DCI) for characterizing the vigor of the distal esophageal contraction; and the distal latency (DL) to identify instances of premature distal esophageal contraction. (See",
"      <a class=\"local\" href=\"#H22510829\">",
"       'Novel EPT metrics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Chicago Classification (CC) of esophageal motility is an algorithmic scheme for diagnosis of esophageal motility disorders from clinical EPT studies. A key feature of the CC is the hierarchical categorization of esophageal motility disorders into conditions never seen in normal individuals and those that are borderline (defined on the basis of being statistically outside of the norm, but not necessarily indicative of pathology) (",
"      <a class=\"graphic graphic_table graphicRef86120 \" href=\"UTD.htm?0/35/573\">",
"       table 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      A diagnostic algorithm, comprised of three major steps, can progressively identify physiological dysfunction as defined by the CC into achalasia, EGJ outflow obstruction, abnormal motility pattern, and borderline motor dysfunction (",
"      <a class=\"graphic graphic_algorithm graphicRef86118 \" href=\"UTD.htm?30/56/31616\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22510878\">",
"       'Classification of motility disorders by esophageal pressure topography (EPT)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22510885\">",
"       'Stepwise approach to EPT analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The CC has clarified the diagnosis of achalasia, both by standardizing the diagnostic criteria and by defining three distinct subtypes based on the pattern of associated esophageal contractility: essentially no contractility in type I, panesophageal pressurization in type II, and either nonpropagating fragments of peristalsis or premature contractions in type III. Outcome analysis suggests type II, a pattern first recognized on the basis of EPT studies, to have the most favorable response to therapy. (See",
"      <a class=\"local\" href=\"#H22510922\">",
"       'Achalasia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HRM with EPT has also clearly defined the entity of EGJ outflow obstruction in which there is preserved peristalsis in association with EGJ outflow obstruction of sufficient severity as seen in achalasia. In fact, this syndrome can be a variant form of achalasia, but it also occurs in the setting of EGJ stenosis, whether it be inflammatory or neoplastic. An endoscopic ultrasound to rule out a neoplasia should therefore be performed in patients with EGJ outflow obstruction on HRM. (See",
"      <a class=\"local\" href=\"#H22510930\">",
"       'EGJ outflow obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The CC has clarified the diagnosis of distal esophageal spasm (DES), defining it on the basis of premature contraction (reduced latency relative to the timing of the swallow) in the distal esophagus as opposed to the very nonspecific finding of increased propagation velocity. (See",
"      <a class=\"local\" href=\"#H1871924\">",
"       'Distal esophageal spasm (DES)'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Criteria for hypercontractile (jackhammer) esophagus have also been established distinguishing this profound pattern of repetitive contraction usually associated with substantial dysphagia from hypertensive peristalsis (nutcracker esophagus), a motility pattern of unclear significance. (See",
"      <a class=\"local\" href=\"#H1561726\">",
"       'Hypercontractile (jackhammer) esophagus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1871168\">",
"       'Hypertensive peristalsis (\"nutcracker esophagus\")'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/1\">",
"      Clouse RE, Prakash C. Topographic esophageal manometry: an emerging clinical and investigative approach. Dig Dis 2000; 18:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/2\">",
"      Kahrilas PJ, Clouse RE, Hogan WJ. American Gastroenterological Association technical review on the clinical use of esophageal manometry. Gastroenterology 1994; 107:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/3\">",
"      Pandolfino JE, Kahrilas PJ, American Gastroenterological Association. AGA technical review on the clinical use of esophageal manometry. Gastroenterology 2005; 128:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/4\">",
"      Ghosh SK, Pandolfino JE, Zhang Q, et al. Quantifying esophageal peristalsis with high-resolution manometry: a study of 75 asymptomatic volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290:G988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/5\">",
"      Kahrilas PJ, Sifrim D. High-resolution manometry and impedance-pH/manometry: valuable tools in clinical and investigational esophagology. Gastroenterology 2008; 135:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/6\">",
"      Sweis R, Anggiansah A, Wong T, et al. Normative values and inter-observer agreement for liquid and solid bolus swallows in upright and supine positions as assessed by esophageal high-resolution manometry. Neurogastroenterol Motil 2011; 23:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/7\">",
"      Bredenoord AJ, Fox M, Kahrilas PJ, et al. Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol Motil 2012; 24 Suppl 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/8\">",
"      Spechler SJ, Castell DO. Classification of oesophageal motility abnormalities. Gut 2001; 49:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/9\">",
"      Pandolfino JE, El-Serag HB, Zhang Q, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 2006; 130:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/10\">",
"      Kahrilas PJ, Kim HC, Pandolfino JE. Approaches to the diagnosis and grading of hiatal hernia. Best Pract Res Clin Gastroenterol 2008; 22:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/11\">",
"      Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Intermittent spatial separation of diaphragm and lower esophageal sphincter favors acidic and weakly acidic reflux. Gastroenterology 2006; 130:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/12\">",
"      Clouse RE, Staiano A. Topography of the esophageal peristaltic pressure wave. Am J Physiol 1991; 261:G677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/13\">",
"      Fox M, Hebbard G, Janiak P, et al. High-resolution manometry predicts the success of oesophageal bolus transport and identifies clinically important abnormalities not detected by conventional manometry. Neurogastroenterol Motil 2004; 16:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/14\">",
"      Pohl D, Ribolsi M, Savarino E, et al. Characteristics of the esophageal low-pressure zone in healthy volunteers and patients with esophageal symptoms: assessment by high-resolution manometry. Am J Gastroenterol 2008; 103:2544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/15\">",
"      Ghosh SK, Pandolfino JE, Kwiatek MA, Kahrilas PJ. Oesophageal peristaltic transition zone defects: real but few and far between. Neurogastroenterol Motil 2008; 20:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/16\">",
"      Kwiatek MA, Nicod&egrave;me F, Pandolfino JE, Kahrilas PJ. Pressure morphology of the relaxed lower esophageal sphincter: the formation and collapse of the phrenic ampulla. Am J Physiol Gastrointest Liver Physiol 2012; 302:G389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/17\">",
"      Pandolfino JE, Leslie E, Luger D, et al. The contractile deceleration point: an important physiologic landmark on oesophageal pressure topography. Neurogastroenterol Motil 2010; 22:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/18\">",
"      Ghosh SK, Pandolfino JE, Rice J, et al. Impaired deglutitive EGJ relaxation in clinical esophageal manometry: a quantitative analysis of 400 patients and 75 controls. Am J Physiol Gastrointest Liver Physiol 2007; 293:G878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/19\">",
"      Lin Z, Kahrilas PJ, Roman S, et al. Improving the Integrated Relaxation Pressure (IRP) cutoff value for the diagnosis of achalasia using a classification and regression tree (CART) model (abstract). Gastroenterology 2012; 142(Suppl 1):S281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/20\">",
"      Roman S, Lin Z, Kwiatek MA, et al. Weak peristalsis in esophageal pressure topography: classification and association with Dysphagia. Am J Gastroenterol 2011; 106:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/21\">",
"      Behar J, Biancani P. Pathogenesis of simultaneous esophageal contractions in patients with motility disorders. Gastroenterology 1993; 105:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/22\">",
"      Roman S, Lin Z, Pandolfino JE, Kahrilas PJ. Distal contraction latency: a measure of propagation velocity optimized for esophageal pressure topography studies. Am J Gastroenterol 2011; 106:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/23\">",
"      Fox MR, Bredenoord AJ. Oesophageal high-resolution manometry: moving from research into clinical practice. Gut 2008; 57:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/24\">",
"      Kahrilas PJ, Ghosh SK, Pandolfino JE. Esophageal motility disorders in terms of pressure topography: the Chicago Classification. J Clin Gastroenterol 2008; 42:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/25\">",
"      Pandolfino JE, Kwiatek MA, Nealis T, et al. Achalasia: a new clinically relevant classification by high-resolution manometry. Gastroenterology 2008; 135:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/26\">",
"      Scherer JR, Kwiatek MA, Soper NJ, et al. Functional esophagogastric junction obstruction with intact peristalsis: a heterogeneous syndrome sometimes akin to achalasia. J Gastrointest Surg 2009; 13:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/27\">",
"      Pandolfino JE, Fox MR, Bredenoord AJ, Kahrilas PJ. High-resolution manometry in clinical practice: utilizing pressure topography to classify oesophageal motility abnormalities. Neurogastroenterol Motil 2009; 21:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/28\">",
"      Pandolfino JE, Roman S, Carlson D, et al. Distal esophageal spasm in high-resolution esophageal pressure topography: defining clinical phenotypes. Gastroenterology 2011; 141:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/29\">",
"      Pandolfino JE, Ghosh SK, Rice J, et al. Classifying esophageal motility by pressure topography characteristics: a study of 400 patients and 75 controls. Am J Gastroenterol 2008; 103:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/30\">",
"      Salvador R, Costantini M, Zaninotto G, et al. The preoperative manometric pattern predicts the outcome of surgical treatment for esophageal achalasia. J Gastrointest Surg 2010; 14:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/31\">",
"      Pratap N, Reddy DN. Can achalasia subtyping by high-resolution manometry predict the therapeutic outcome of pneumatic balloon dilatation?: author's reply. J Neurogastroenterol Motil 2011; 17:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/32\">",
"      Ravi K, Friesen L, Issaka RB, et al. The natural history of patients with normal and borderline motor function on high-resolution manometry. Gastroenterology 2012; 142:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17785/abstract/33\">",
"      Xiao Y, Kahrilas PJ, Kwasny MJ, et al. High-resolution manometry correlates of ineffective esophageal motility. Am J Gastroenterol 2012; 107:1647.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17125 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17785=[""].join("\n");
var outline_f17_23_17785=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22511052\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22510745\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22510752\">",
"      HIGH RESOLUTION MANOMETRY (HRM) WITH ESOPHAGEAL PRESSURE TOPOGRAPHY (EPT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H544147912\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22510766\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22510773\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22510780\">",
"      Protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22510787\">",
"      Analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22024797\">",
"      - Pressure topography landmarks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22510801\">",
"      Anatomic sphincters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22510808\">",
"      Contractile segments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22510815\">",
"      Transition zone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22510822\">",
"      Contractile deceleration point (CDP)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22510829\">",
"      - Novel EPT metrics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22510836\">",
"      Integrated relaxation pressure (IRP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22510843\">",
"      Peristaltic integrity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22510850\">",
"      Distal latency (DL)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22510857\">",
"      Contractile front velocity (CFV)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22510864\">",
"      Distal contractile integral (DCI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22510871\">",
"      Pressurization patterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22510878\">",
"      CLASSIFICATION OF MOTILITY DISORDERS BY ESOPHAGEAL PRESSURE TOPOGRAPHY (EPT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22510885\">",
"      Stepwise approach to EPT analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22510892\">",
"      - Step 1: Assess the EGJ",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22510900\">",
"      - Step 2: Characterize esophageal contractility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22510908\">",
"      - Step 3: Characterize pressurization patterns, if present",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22510915\">",
"      EPT criteria for motility disorder subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22510922\">",
"      - Achalasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22510930\">",
"      - EGJ outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22510938\">",
"      - Abnormal esophageal motor function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1561669\">",
"      Absent peristalsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1871924\">",
"      Distal esophageal spasm (DES)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1561726\">",
"      Hypercontractile (jackhammer) esophagus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22510988\">",
"      - Borderline esophageal motor function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1561819\">",
"      Frequent failed peristalsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1871148\">",
"      Weak peristalsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1871159\">",
"      Rapid contraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1871168\">",
"      Hypertensive peristalsis (\"nutcracker esophagus\")",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22511052\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/17125\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/17125|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?30/56/31616\" title=\"algorithm 1\">",
"      Chicago Classification stepwise algorithm interpretation of EPT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/17125|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/43/1722\" title=\"figure 1\">",
"      Conventional manometry and HRM with EPT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/53/37720\" title=\"figure 2\">",
"      Subtypes of EGJ pressure morphology on EPT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/23/44406\" title=\"figure 3\">",
"      Localization of the CDP and measurement of DL on EPT plot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/46/8934\" title=\"figure 4\">",
"      EPT manifestations of weak peristalsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/5/14424\" title=\"figure 5\">",
"      Computing the DCI using EPT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/59/37815\" title=\"figure 6\">",
"      Patterns of esophageal pressurization in EPT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/23/23924\" title=\"figure 7\">",
"      EPT plot of achalasia subtypes in the Chicago Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/13/11479\" title=\"figure 8\">",
"      EPT phenotypes of abnormal propagation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/58/20390\" title=\"figure 9\">",
"      DCI thresholds on EPT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/17125|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/24/39308\" title=\"table 1\">",
"      Definitions of esophageal pressure topography metrics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/35/573\" title=\"table 2\">",
"      High resolution manometry diagnostic criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=related_link\">",
"      Clinical manifestations and diagnosis of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13096?source=related_link\">",
"      Diffuse esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=related_link\">",
"      Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7527?source=related_link\">",
"      Hiatus hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=related_link\">",
"      Motility testing: When does it help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=related_link\">",
"      Overview of the treatment of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=related_link\">",
"      Pathophysiology and etiology of achalasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_23_17786="Prevention of recurrent variceal hemorrhage in patients with cirrhosis";
var content_f17_23_17786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/23/17786/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/23/17786/contributors\">",
"     Arun J Sanyal, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/23/17786/contributors\">",
"     Jasmohan S Bajaj, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/23/17786/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/23/17786/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/23/17786/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/23/17786/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/23/17786/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H70339949\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of cirrhosis following an episode of variceal hemorrhage has been defined from clinical trials in which \"control\" subjects did not receive any specific treatment to prevent rebleeding. The cumulative data indicate that over 70 percent of patients experience recurrent variceal hemorrhage within one year of their index bleed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The risk of rebleeding is greatest immediately after cessation of active bleeding and then declines, reaching close to baseline values by six weeks. Approximately 70 percent of all untreated patients die within the first year after their initial variceal bleed. The causes of death include recurrent variceal hemorrhage, liver failure, hepatic encephalopathy, and progressive ascites and infections.",
"   </p>",
"   <p>",
"    These data underscore the importance of preventing recurrent hemorrhage, sustaining liver function, maintaining an ascites-free state, and avoiding infections to achieve prolonged survival. At this time, orthotopic liver transplant (OLT) is the only treatment that achieves all of these objectives and prolongs long-term survival with any degree of certainty. However, some patients are not suitable subjects for liver transplants and, even when OLT is being considered, patients often have to wait several months before an organ becomes available. During this time, they are at risk for recurrent variceal hemorrhage and therefore require treatment to prevent this complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ideal treatment would be one that is universally effective, safe, freely available, easy to administer and inexpensive. Because such a treatment does not exist, the choice of a given modality of treatment over another involves consideration of its relative efficacy and safety, availability, and cost considerations. The major options are endoscopic sclerotherapy, endoscopic band ligation, pharmacologic therapy with beta blockers and oral nitrates, insertion of a transjugular intrahepatic portosystemic shunt, and surgery.",
"   </p>",
"   <p>",
"    This topic with will review the options for preventing recurrent variceal hemorrhage in patients with cirrhosis. The treatment of acute variceal hemorrhage is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link\">",
"     \"General principles of the management of variceal hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=see_link\">",
"     \"Endoscopic variceal ligation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70339956\">",
"    <span class=\"h1\">",
"     AASLD GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Association for the Study of Liver Diseases (AASLD) issued guidelines in 2007 for the prevention of variceal recurrent bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/3\">",
"     3",
"    </a>",
"    ]. The approaches recommended by the guidelines (nonselective beta blockers, endoscopic variceal ligation, transjugular intrahepatic portosystemic shunts, and liver transplantation), as well as other options for the prevention of recurrent variceal bleeding, are discussed in detail below.",
"   </p>",
"   <p>",
"    The AASLD recommends:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with cirrhosis who survive an episode of active variceal hemorrhage should receive therapy to prevent recurrence of variceal hemorrhage (secondary prophylaxis).",
"     </li>",
"     <li>",
"      Combination of nonselective beta blockers plus endoscopic variceal ligation is the best option for secondary prophylaxis of variceal hemorrhage.",
"     </li>",
"     <li>",
"      The nonselective beta blocker should be adjusted to the maximal tolerated dose. Endoscopic variceal ligation should be repeated every 1 to 2 weeks until obliteration, with the first surveillance EGD performed 1 to 3 months after obliteration and then every 6 to 12 months to check for variceal recurrence.",
"     </li>",
"     <li>",
"      Transjugular intrahepatic portosystemic shunts should be considered in patients who have Child A or B cirrhosis and experience recurrent variceal hemorrhage despite combination pharmacologic and endoscopic therapy. In centers where the expertise is available, surgical shunts can be considered in Child A patients.",
"     </li>",
"     <li>",
"      Patients who are otherwise transplant candidates should be referred to a transplant center.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70339962\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC SCLEROTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic sclerotherapy has been extensively evaluated for the long-term prevention of recurrent variceal hemorrhage. Compared with placebo, it decreases both the risk of rebleeding (40 to 50 percent versus 70 percent) and death (30 to 60 percent versus 50 to 75 percent) (",
"    <a class=\"graphic graphic_table graphicRef68177 \" href=\"UTD.htm?34/35/35388\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. However, it remains controversial whether these effects represent the benefits of repeated episodes of sclerotherapy or the beneficial effects of sclerotherapy for episodes of active hemorrhage. Only esophageal varices and gastric varices in direct continuity with esophageal varices are treatable by endoscopic sclerotherapy. Endoscopic sclerotherapy has been largely replaced by endoscopic variceal band ligation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70339968\">",
"    <span class=\"h2\">",
"     Technique and complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection of the sclerosing agent causes necrosis of esophageal tissues and mucosal ulcers (",
"    <a class=\"graphic graphic_table graphicRef71037 \" href=\"UTD.htm?33/41/34459\">",
"     table 2",
"    </a>",
"    ). Small ulcers appear within the first few days in most patients and larger ulcers develop in approximately 50 percent. Many patients have transient retrosternal discomfort. Patients who develop large ulcers are at risk for bleeding, delays in scheduled sclerotherapy treatments, and the development of strictures weeks to months later. Esophageal perforation is a rare complication.",
"   </p>",
"   <p>",
"    The incidence of symptomatic strictures varies from series to series, with 15 percent being a representative figure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/10\">",
"     10",
"    </a>",
"    ]. Postsclerotherapy treatment with a proton pump inhibitor such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    has been tried, but its efficacy in preventing ulcers and strictures is unproven. In one randomized trial, omeprazole was no more effective than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both intravariceal injections and paravariceal injections have been associated with equally good outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/12\">",
"     12",
"    </a>",
"    ]. The outcomes are also similar regardless of the type of sclerosant used [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/13\">",
"     13",
"    </a>",
"    ], the volume injected, or frequency of sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/14\">",
"     14",
"    </a>",
"    ]. The frequency of complications increases when sclerotherapy is performed weekly, while injections at two- to three-week intervals take longer to achieve variceal obliteration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most episodes of recurrent hemorrhage occur before variceal obliteration is achieved. Once varices are obliterated, there is a risk of recurrence over time, necessitating surveillance endoscopy every six months for the first year and annually thereafter.",
"   </p>",
"   <p>",
"    When used, it is this author's practice to start sclerotherapy sessions with intravariceal injections of up to 2 mL of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/21/43346?source=see_link\">",
"     sodium morrhuate",
"    </a>",
"    each, to a total of up to 20 mL per session. Sessions are repeated at two-week intervals and, as variceal obliteration is achieved, the total amount of sclerosant is reduced accordingly [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/16\">",
"     16",
"    </a>",
"    ]. This regimen appears to minimize complications without greatly prolonging the time to variceal obliteration. Endoscopic sclerotherapy has largely been replaced by other methods for prevention of recurrent esophageal variceal hemorrhage (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70339974\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC BAND LIGATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic band ligation was developed as an alternative to sclerotherapy. It is performed by attachment of a device loaded with rubber bands to the tip of the endoscope. A varix is suctioned into the device using the suction channel of the endoscope and then the rubber band is deployed around the base of the varix by pulling on a trip wire, which releases the rubber band. Devices that are loaded with 6 and 10 rubber bands are now commercially available. Small varices are often difficult to suction into the banding device and are not optimal for this procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=see_link\">",
"     \"Endoscopic variceal ligation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70339980\">",
"    <span class=\"h2\">",
"     Band ligation versus sclerotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated the relative efficacy of band ligation versus sclerotherapy for the management of variceal hemorrhage. A meta-analysis indicated that, compared with sclerotherapy, ligation reduced the rebleeding rate (odds ratio 0.47), the mortality rate (odds ratio 0.67), the rate of death due to rebleeding (odds ratio 0.49), and the development of esophageal strictures (odds ratio 0.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/17\">",
"     17",
"    </a>",
"    ]. Variceal obliteration was achieved in similar proportions with both techniques, but the number of treatments necessary to achieve obliteration was lower with ligation.",
"   </p>",
"   <p>",
"    These considerations have led the American College of Gastroenterology Practice Parameters Committee to recommend band ligation as the endoscopic treatment of choice for the long-term management of variceal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/18\">",
"     18",
"    </a>",
"    ]. Despite the seeming superiority of band ligation, a few words of caution are necessary:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Not all trials enrolled consecutive patients who were eligible for the study and were therefore free of enrollment bias",
"     </li>",
"     <li>",
"      The method of randomization in virtually all the studies was potentially subject to investigator bias",
"     </li>",
"     <li>",
"      The assessment of complications (eg, strictures) was subjective in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/19\">",
"       19",
"      </a>",
"      ], while the method of assessment was not well defined in others",
"     </li>",
"     <li>",
"      While one study claimed to have a lower incidence of complications in those treated by banding (14:1), this is misleading because five patients bled from banding-related ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Recurrence of varices may be more common with variceal ligation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In view of the data that are currently available, band ligation is the initial procedure of choice for prevention of recurrent variceal hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70339986\">",
"    <span class=\"h2\">",
"     Band ligation plus sclerotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating combination therapy for esophageal varices have produced heterogeneous results, depending in part upon the population that is studied (ie, active bleeding versus prior bleeding). Considering the available data, it appears that combining initial variceal band ligation with a session of sclerotherapy used for small residual varices could offer the benefit of reducing variceal recurrence while minimizing complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/22\">",
"     22",
"    </a>",
"    ]. However, such a practice has not evolved to be routine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=see_link\">",
"     \"Endoscopic variceal ligation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=see_link&amp;anchor=H13#H13\">",
"     \"Endoscopic variceal ligation\", section on 'Combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After a mean follow-up of two years, recurrent esophageal varices and variceal bleeding were significantly less common in patients treated with combined therapy (14 versus 43 percent and 8 versus 31 percent, respectively). One patient treated with band ligation alone developed an esophageal stricture.",
"   </p>",
"   <p>",
"    In contrast to these findings, most studies using strategies in which variceal ligation was combined with sclerotherapy during initial variceal obliteration have demonstrated decreased efficacy and a higher complication rate compared with band ligation alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=see_link\">",
"     \"Endoscopic variceal ligation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70339992\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the pharmacologic prevention of recurrent variceal hemorrhage have focused on the use of beta blockers, although other drugs have also been studied. The available data support combining beta blockers with endoscopic band ligation as primary therapy for secondary prophylaxis of esophageal variceal hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70339998\">",
"    <span class=\"h2\">",
"     Nonselective beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonselective beta blockers lower portal pressure and reduce the risk of first bleeding in patients with esophageal varices [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/23\">",
"     23",
"    </a>",
"    ]. For these reasons, they are the treatment of choice for primary prophylaxis in patients at high risk for variceal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple clinical trials have compared beta blockers with placebo for the prevention of recurrent variceal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/24-34\">",
"     24-34",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Approximately 75 percent of the patients enrolled had Child-Pugh class A cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"     table 3",
"    </a>",
"    ). Alcohol was the most common cause of liver disease and many patients were excluded from participation due to contraindications to use of beta blockers. The most important variation among studies was the timing of entry into the studies from the index bleed (one day to one month). The doses of the drug used were also variable (10 to 480",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ); the dose was generally titrated to achieve a 25 percent decrease in resting heart rate.",
"   </p>",
"   <p>",
"    With a few exceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/30,33\">",
"     30,33",
"    </a>",
"    ], an overall improvement in rebleeding rate was noted (",
"    <a class=\"graphic graphic_figure graphicRef70811 \" href=\"UTD.htm?10/15/10494\">",
"     figure 1",
"    </a>",
"    ),",
"    <strong>",
"    </strong>",
"    but a survival advantage was only shown in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/24\">",
"     24",
"    </a>",
"    ]. Meta-analysis of these data suggests that the risk of bleeding is decreased by approximately 40 percent, while the risk of death is decreased by 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/35\">",
"     35",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    has also decreased recurrent bleeding (35 versus 62 percent at one year) from portal hypertensive gastropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=see_link\">",
"     \"Uncommon causes of upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of a hepatoma, poor compliance, and continued alcohol use are risk factors for recurrence of variceal hemorrhage in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/37\">",
"     37",
"    </a>",
"    ]. Although acute hemodynamic changes after initiation of propranolol does not predict long-term outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/38\">",
"     38",
"    </a>",
"    ], the presence of a sustained portal hypotensive effect at one month after initiation of therapy appears to be an important predictive factor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, measurement of portal hemodynamics may be an important prognostic element of treatment. One study prospectively evaluated 69 patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    after an episode of variceal bleeding and measured the hepatic venous pressure gradient (HVPG) before and at three months. The HPVG fell by 20 percent or more in 25 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/40\">",
"     40",
"    </a>",
"    ]. During follow-up of 28 months, rebleeding was much less likely in these patients compared with patients who had lesser reductions in HVPG (8 versus 52 percent). Despite these encouraging data, the facilities for routine measurement of portal pressures are not widely available and the cost-effectiveness of portal pressure measurement for guidance of medical therapy appears to depend largely upon local costs, life expectancy, and rebleeding rates [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/41\">",
"     41",
"    </a>",
"    ]. These considerations have precluded its widespread use for this purpose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5066642\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are associated with numerous side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .) In patients with cirrhosis, the most clinically important adverse effects include bronchoconstriction, heart failure, and impotence. Beta blockers rarely induce liver failure from decreased portal blood flow because total hepatic blood flow is usually maintained by an increase in hepatic arterial flow [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/42\">",
"     42",
"    </a>",
"    ]. Despite the inability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    to cross the blood brain barrier due to its hydrophilic nature (in contrast to the highly lipophilic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ), central nervous system side effects of the two medications do not differ.",
"   </p>",
"   <p>",
"    The routine use of beta blockers in patients with cirrhosis with refractory ascites has been called into question based upon a prospective study of 151 patients with cirrhosis and refractory ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/43\">",
"     43",
"    </a>",
"    ]. Median survival was significantly longer in patients who did not receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    versus those who did (20 versus 5 months). Independent predictors of mortality in that study were Child-Pugh class C, hyponatremia, refractory ascites due to renal failure, and beta blocker therapy.",
"   </p>",
"   <p>",
"    Whether the beta blockers accounted for the increased mortality is uncertain, since the study was not randomized. In particular, patients who did not receive the beta blockers appeared to be less likely to have varices and to be sicker [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, approximately two-thirds of the deaths on beta blockers were due to hepatocellular cancer (HCC) or sepsis, and there is no clear pathogenic basis for beta blockers in HCC.",
"   </p>",
"   <p>",
"    However, preliminary results from a second study found no increased mortality in those receiving beta blockers. [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/45\">",
"     45",
"    </a>",
"    ]. The retrospective study included 194 patients with decompensated cirrhosis and ascites who did not have a history of variceal hemorrhage. Varices were present in 132 patients (68 percent). Predictors of decreased survival included higher Child-Pugh scores (hazard ratio [HR] 1.2) and the presence of varices (HR 1.2). Beta blocker use was not associated with decreased survival. However, the study was not limited to patients with refractory ascites, so whether the results apply to such patients is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70340004\">",
"    <span class=\"h2\">",
"     Beta blockers plus band ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with a beta blocker plus endoscopic band ligation is more effective at preventing rebleeding than band ligation alone or beta blockers alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. A meta-analysis of 23 randomized controlled trials (with a total of 1860 patients with cirrhosis and a variceal bleeding) reached the following conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination therapy reduced overall bleeding more than endoscopic therapy alone (RR 0.68, 95% CI 0.52-0.89) or beta blocker therapy alone (RR 0.71, 95% CI 0.59-0.86). Combination therapy also reduced variceal rebleeding and variceal recurrence.",
"     </li>",
"     <li>",
"      A reduction in mortality from combination therapy was not statistically different from endoscopic therapy (OR 0.78 95% CI 0.58-1.07) or beta blockers (OR 0.70, 95% CI 0.46-1.06).",
"     </li>",
"     <li>",
"      Withdrawals due to side-effects occurred almost exclusively in patients randomized to beta blockers; the overall rate of withdrawals was 7 percent in the subset of trials that reported relevant data.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current guidelines recommend the combined use of endoscopic variceal ligation and nonselective beta-blockers for the prevention of recurrent variceal hemorrhage, even in patients who have had a recurrent hemorrhage despite treatment with nonselective beta-blockers or endoscopic variceal ligation for primary prophylaxis. In patients who are not candidates for endoscopic variceal ligation, the strategy would be to maximize portal-pressure reduction by combining nonselective beta-blockers plus nitrates [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H70340022\">",
"     'Beta blockers plus oral nitrates'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70340010\">",
"    <span class=\"h2\">",
"     Beta blockers versus sclerotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several controlled trials and meta-analyses comparing beta blockers to sclerotherapy have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/46,47,49-62\">",
"     46,47,49-62",
"    </a>",
"    ]. The clinical issue is of decreasing importance given the preference toward band ligation and the relatively large body of data supporting band ligation in combination with beta blockers. (See",
"    <a class=\"local\" href=\"#H70340004\">",
"     'Beta blockers plus band ligation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70340016\">",
"    <span class=\"h2\">",
"     Beta blockers plus sclerotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination of sclerotherapy and beta blockade was more effective in preventing rebleeding than sclerotherapy alone in a number of trials and at least two meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. However, as noted above, band ligation is preferred to sclerotherapy. (See",
"    <a class=\"local\" href=\"#H70340004\">",
"     'Beta blockers plus band ligation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70340022\">",
"    <span class=\"h2\">",
"     Beta blockers plus oral nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have suggested that the combination of beta blockers and nitrates improves the hemodynamic response and may markedly lower the rate of rebleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. The mechanism of the improvement in hemodynamics appears to be a decrease in outflow resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/63\">",
"     63",
"    </a>",
"    ]. This was demonstrated in a study in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"     isosorbide mononitrate",
"    </a>",
"    was added to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    in patients who exhibited insufficient hemodynamic response to beta blockers. Poor responders were those who did not exhibit a decrease in HPVG to 12 mmHg or a percent decrease greater than 20 percent. The addition of isosorbide mononitrate to nadolol in these patients led to significant improvement in the percent decrease of HPVG from 9 percent to 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical trials of combination therapy with beta blockers have demonstrated a reduced rebleeding rate and a trend toward improved survival in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 86 patients who had survived an episode of variceal hemorrhage were randomly assigned to receive either endoscopic sclerotherapy or a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"       nadolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"       isosorbide mononitrate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/64\">",
"       64",
"      </a>",
"      ]. The dose of nadolol was titrated to achieve a resting heart rate of approximately 55",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      and the patients were followed for a median of 18 months. The actuarial probability of remaining free of variceal rebleeding was significantly higher with drug therapy compared with sclerotherapy (45 versus 75 percent). There was also a trend toward increased survival in the drug group.",
"     </li>",
"     <li>",
"      Similar results were observed in another report that included 95 patients who were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      (given as an initial dose of 20 mg TID and adjusted over a five-day period until the resting heart rate had been reduced by 25 percent or was less than 55 beats per minute) or propranolol plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"       isosorbide mononitrate",
"      </a>",
"      (progressively increased to a dose of 20 mg BID over a period of one week unless side effects appeared) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/65\">",
"       65",
"      </a>",
"      ]. The actuarial probability of rebleeding was lower in the combination therapy group after two years of follow-up (40 versus 57 percent), although the results did not achieve statistical significance. Statistical significance was achieved when stratifying the data by age or by adding an additional year of follow-up. Significantly more patients in the combination therapy group had to discontinue treatment due to side effects (15 versus 2 percent). There was no difference in patient survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above findings need to be validated by other large studies before the role of oral nitrates in the prevention of recurrent variceal bleeding can be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70340028\">",
"    <span class=\"h2\">",
"     Beta blockers plus oral nitrates versus band ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least five controlled trials comparing combination medical therapy to band ligation in the prevention of variceal rebleeding have reached disparate conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. One showed a benefit of combination medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/66\">",
"     66",
"    </a>",
"    ], while another showed a benefit of band ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/67\">",
"     67",
"    </a>",
"    ], and three others showed no difference [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. Several details regarding the study design and specific interventions may account for the variable conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/71\">",
"     71",
"    </a>",
"    ]. Thus, the relative benefits of these alternative approaches remain uncertain and each continues to have its proponents. As a general rule, we recommend strategies involving endoscopic variceal ligation. (See",
"    <a class=\"local\" href=\"#H70340076\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70340034\">",
"    <span class=\"h1\">",
"     TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transjugular intrahepatic portosystemic shunts (TIPS) decompress the portal vein similar to surgical portacaval shunts but avoid the risks of general anesthesia and major surgery (",
"    <a class=\"graphic graphic_figure graphicRef72311 \" href=\"UTD.htm?3/10/3239\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39511?source=see_link\">",
"     \"Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of clinical trials have evaluated the efficacy of TIPS versus endoscopic therapy for the prevention of recurrent variceal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/16,72-79\">",
"     16,72-79",
"    </a>",
"    ]. Most used endoscopic sclerotherapy and at least two used band ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. The heterogeneity of these studies limits their direct comparison. The studies varied in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sclerotherapy protocols used",
"     </li>",
"     <li>",
"      The severity of liver failure",
"     </li>",
"     <li>",
"      Patient randomization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While most studies randomized patients within 24 hours of admission, one trial, which found no benefit of TIPS, focused primarily on long-term rebleeding and randomized patients after a mean of 10 days compared with one to two days in the other reports [101]. The timing issue may be important since it has been suggested that TIPS is significantly better than sclerotherapy in preventing rebleeding only when it is performed less than one week after the initial bleed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies demonstrated a significant decrease in the risk of rebleeding in patients undergoing TIPS (",
"    <a class=\"graphic graphic_figure graphicRef52679 \" href=\"UTD.htm?16/2/16430\">",
"     figure 3",
"    </a>",
"    ).The differences across studies were due to the variable rebleeding rates after endoscopic treatment rather than after TIPS (which was approximately 20 percent). Despite the beneficial effects on bleeding, TIPS was associated with either no survival advantage or poorer survival in most of the studies (",
"    <a class=\"graphic graphic_figure graphicRef73392 \" href=\"UTD.htm?32/20/33102\">",
"     figure 4",
"    </a>",
"    ). In addition, hepatic encephalopathy occurred at least twice as frequently following TIPS in most of the studies. Advanced age, liver failure, shunt fraction (shunt diameter) and a history of encephalopathy prior to TIPS are all risk factors for worsening encephalopathy after TIPS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 11 controlled trials with a total of 811 patients concluded that, compared with endoscopic treatment, TIPS reduced the rate of rebleeding but did not improve overall survival, and increased the incidence of encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15448?source=see_link\">",
"     \"Complications of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cost-effectiveness of TIPS versus other forms of prophylaxis was evaluated in a decision analysis in which it was compared with sclerotherapy or band ligation; patients in the endoscopic therapy groups also received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/83\">",
"     83",
"    </a>",
"    ]. Compared with endoscopic therapy, TIPS was associated with a lower recurrent variceal bleeding rate and was more cost-effective. However, the cost-effectiveness depended upon the costs of TIPS and the TIPS restenosis rate; the majority of patients who undergo TIPS require multiple interventions over time.",
"   </p>",
"   <p>",
"    Subsequent controlled trials have been published that were not included in the meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. One trial compared TIPS to medical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endoscopic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/84\">",
"     84",
"    </a>",
"    ]. The study included 91 patients (Child-Pugh class B or C) who were randomly assigned to medical therapy (with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    plus isosorbide-5-mononitrate) or TIPS following an initial episode of variceal bleeding. Patients who did not tolerate propranolol underwent endoscopic treatment. Those who had previously failed pharmacologic therapy received both pharmacologic therapy and endoscopic treatment. The following observations were made during two years of follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The probability of rebleeding was significantly lower in the TIPS group (49 versus 13 percent)",
"     </li>",
"     <li>",
"      A similar number of reinterventions were required in both groups (angioplasty",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      restenting in the TIPS group or repeat endoscopic therapy in the medical therapy group)",
"     </li>",
"     <li>",
"      Encephalopathy was more frequent in the TIPS group (38 versus 14 percent)",
"     </li>",
"     <li>",
"      Child-Pugh class improved significantly more often in the medical therapy group (72 versus 45 percent)",
"     </li>",
"     <li>",
"      The probability of survival was identical (72 percent)",
"     </li>",
"     <li>",
"      TIPS was twice as expensive as medical therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A second trial included 63 patients with Child's B or C cirrhosis and acute variceal bleeding who were treated with vasoactive drugs and endoscopic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/85\">",
"     85",
"    </a>",
"    ]. The patients were assigned to either early TIPS (within 72 hours of randomization) or treatment with a nonselective beta blocker and long-term endoscopic band ligation. The patients were followed for a median of 16 months. Patients who underwent early TIPS had significantly higher rates of remaining free from rebleeding (97 versus 50 percent) and higher one-year survival (86 versus 61 percent). There were no significant differences noted between the groups with regard to serious adverse events.",
"   </p>",
"   <p>",
"    Considering the above data, the superiority of TIPS for prevention of rebleeding is offset by its failure to improve survival and increasing morbidity due to the development of liver failure and encephalopathy. For these reasons, TIPS is used primarily as a salvage therapy for those with recurrent bleeding despite an adequate trial of endoscopic and pharmacologic treatment. The precise definition of \"failure of endoscopic treatment\" remains controversial; we consider failure to be the recurrence of variceal hemorrhage despite at least two sessions of endoscopic treatment performed no more than two weeks apart.",
"   </p>",
"   <p>",
"    Whether there are subsets of patients in whom the balance would favor TIPS is still being clarified. One study suggested a benefit of TIPS in a subset of patients with an elevated hepatic venous pressure gradient (HVPG) following an episode of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/86\">",
"     86",
"    </a>",
"    ]. Patients with active variceal bleeding were managed by band ligation and then underwent hepatic venous pressure measurement within the first 24 hours. Those with an HVPG &gt;20 mmHg were randomly assigned to continue medical therapy or undergo urgent TIPS. In this setting, TIPS was dramatically superior to medical treatment. This study highlights the issue of timing of intervention in the overall efficacy of specific interventions for variceal bleeding. Additional studies are now required to validate the role of portal pressure measurement to guide the need for TIPS early after admission for bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70340040\">",
"    <span class=\"h2\">",
"     Recurrence of portal hypertension and stent stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal cause of rebleeding after TIPS is the recurrence of portal hypertension (",
"    <a class=\"graphic graphic_table graphicRef53289 \" href=\"UTD.htm?7/45/7899\">",
"     table 4",
"    </a>",
"    ). This may result from TIPS thrombosis, stent retraction and kinking, stent stenosis, or the development of right heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15448?source=see_link\">",
"     \"Complications of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TIPS thrombosis usually occurs within the first month and is more likely to occur in moribund individuals. Its development has been associated with the presence of a biliary-TIPS fistula. It has been proposed that systemic anticoagulation can prevent TIPS thrombosis, but this carries the risks of inducing hemorrhage; anticoagulation is rarely used in North America.",
"     </li>",
"     <li>",
"      Stent retraction into the parenchyma tissue tract and stent kinking can be avoided by careful attention to technique.",
"     </li>",
"     <li>",
"      Stent stenosis is the most common cause of recurrent portal hypertension. It is due to the ingrowth of tissue from the surrounding liver into the stent lumen eventually occluding it [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Virtually all long-term survivors after TIPS experience TIPS stenosis within the first two years when uncoated stents are used, necessitating surveillance by either Doppler sonography or angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/87\">",
"     87",
"    </a>",
"    ]. Doppler sonography is specific but somewhat insensitive depending upon the specific cutoffs used for the diagnosis of stent stenosis. Angiography is the gold standard for the detection of stent stenosis and is required for its treatment. A commonly used regimen is angiography at 6 and 12 months after TIPS and annually thereafter for the first three years. The propensity for development of stent stenosis decreases after four years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the introduction of coated stents, the risk of stent stenosis has been dramatically reduced and the shunt patency rates are substantially better than those with uncoated stents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/88\">",
"     88",
"    </a>",
"    ]. This has diminished the need for shunt revisions and thus reduced the costs associated with the procedure. We recommend that all TIPS be performed with a coated stent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70340046\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A vast body of literature exists on the value of surgical treatment for prevention of recurrent variceal hemorrhage. Surgical options at present are principally used in patients with continued bleeding despite endoscopic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharmacotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70340052\">",
"    <span class=\"h2\">",
"     Use as initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite its demonstrated efficacy in decreasing recurrent variceal hemorrhage, enthusiasm for surgery has declined over the last two decades, due in part to the more easily administered techniques of endoscopic therapy. Several other factors have also contributed to this decline:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The multitude of operations available and the degree of skill required to perform each one has left only a limited number of surgeons who consistently obtain outcomes comparable to those from centers in which these operations were developed.",
"     </li>",
"     <li>",
"      Several major randomized studies have shown that survival outcome after sclerotherapy is equal to or superior to those obtained with surgery. In the first study, 16 of 32 patients undergoing sclerotherapy survived the initial hospitalization for active hemorrhage compared with 14 of 32 patients randomized to emergent portacaval shunt [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/89\">",
"       89",
"      </a>",
"      ]; patient survival was similar during long-term follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another trial, 72 patients were randomized to either sclerotherapy or distal splenorenal shunt (DSRS) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/91\">",
"       91",
"      </a>",
"      ]. DSRS achieved control of bleeding more efficiently than sclerotherapy",
"      <span class=\"nowrap\">",
"       (34/35",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       15/37).",
"      </span>",
"      However, patient survival and liver function were better in the sclerotherapy arm (",
"      <a class=\"graphic graphic_figure graphicRef70811 \" href=\"UTD.htm?10/15/10494\">",
"       figure 1",
"      </a>",
"      ). Furthermore, the use of sclerotherapy initially followed by DSRS as salvage therapy if necessary was associated with the survival benefit in the sclerotherapy arm despite the poorer control of bleeding with sclerotherapy alone.",
"      <br/>",
"      <br/>",
"      Similar data have been obtained in two other trials of DSRS versus sclerotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/92,93\">",
"       92,93",
"      </a>",
"      ], while a third study found DSRS to be superior [",
"      <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70340058\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthotopic liver transplant (OLT) is the only treatment which corrects the portal hypertension and also corrects the liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/95\">",
"     95",
"    </a>",
"    ]. It can be performed even in those with active hemorrhage. The presence of a previous portacaval shunt does not affect survival after OLT, although it lengthens the time taken for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. A previously placed TIPS can be easily removed with the explant at the time of transplant in most instances; in occasional patients, however, the stent extends into the right atrium or superior mesenteric veins, rendering the surgery much more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival figures range from 80 to 90 percent at one year to 60 percent at five years after OLT. The value of transplantation as a sole treatment for prevention of recurrent hemorrhage is limited by the frequently long waiting period before an organ is available; during this time, all of the factors contributing to mortality remain operative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70340064\">",
"    <span class=\"h3\">",
"     Conclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the past decade, the frequency with which shunt operations have been performed has dwindled. This is related both to the increasing use of TIPS and liver transplantation. As a result, the number of surgeons who are experienced in shunt operations, especially the distal splenorenal shunt (Warren shunt) has decreased. Thus, shunt operations (particularly the Warren shunt, which is technically challenging) cannot be recommended unless a surgeon is available who has demonstrated consistently favorable outcomes.",
"   </p>",
"   <p>",
"    Although shunt operations continue to have a role in selected patients (at centers with appropriate surgical expertise), we prefer to use TIPS, especially since the long term patency problems with uncoated stents can be largely obviated by the use of coated stents. All TIPS should be performed with covered stents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15448?source=see_link\">",
"     \"Complications of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44578461\">",
"    <span class=\"h1\">",
"     USING HVPG TO GUIDE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some centers are basing treatment recommendations upon measurement of the hepatic venous pressure gradient (HVPG). Concerns related to this approach are the additional costs and risks associated with measurement of the HVPG. This is further complicated by a mixed picture of cost-effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/41,99\">",
"     41,99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\", section on 'Nonselective beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is one approach that has been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?17/23/17786/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44578468\">",
"    <span class=\"h2\">",
"     Child-Pugh class A or B cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measure the HVPG at baseline and then institute treatment with a beta blocker (with or without nitrates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endoscopic band ligation). The HVPG is then remeasured after one to three months. If there is a 20 percent reduction in the HVPG, then medical therapy is continued. If there is a less than 20 percent reduction in HVPG, treatment depends upon the patient's functional status:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Good functional status: Insertion of a distal splenorenal or low-diameter interposition shunt (see",
"      <a class=\"local\" href=\"#H70340046\">",
"       'Surgery'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Poor functional status:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Liver transplant candidate: Consider TIPS",
"     </li>",
"     <li>",
"      Not a liver transplant candidate: Endoscopic band ligation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44578475\">",
"    <span class=\"h2\">",
"     Child-Pugh class C cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Start with endoscopic band ligation (with or without a beta-blocker",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nitrate). If that fails, TIPS should be considered in transplant candidates.",
"   </p>",
"   <p>",
"    The algorithm above has to be considered in light of the local HVPG measurement costs and expertise, life expectancy, and rebleeding rates and should be adjusted for individual patients and centers according to those considerations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/40/8834?source=see_link\">",
"       \"Patient information: Esophageal varices (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/9/12434?source=see_link\">",
"       \"Patient information: Screening for esophageal varices (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70340076\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to the prevention of recurrent variceal hemorrhage in patients with cirrhosis is uncertain. Our approach is outlined below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that all patients with compensated cirrhosis who have bled from esophageal varices receive band ligation and beta blockers, unless beta blockers are contraindicated (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We usually perform band ligation seven days after initial endoscopic control of variceal hemorrhage and every one to two weeks thereafter until the varices are obliterated. Beta blockers are initiated at the time of discharge from the hospital. For patients with decompensated cirrhosis (eg, ascites, hepatic encephalopathy) we have a high threshold for",
"      <span class=\"nowrap\">",
"       starting/resuming",
"      </span>",
"      beta blockers due to evidence suggesting increased mortality in such patients. (See",
"      <a class=\"local\" href=\"#H70339974\">",
"       'Endoscopic band ligation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H70340004\">",
"       'Beta blockers plus band ligation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5066642\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For primary prophylaxis, our practice is to give beta blockers to patients with compensated cirrhosis and large varices. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link&amp;anchor=H4#H4\">",
"       \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\", section on 'Nonselective beta blockers'",
"      </a>",
"      .) If they subsequently bleed, we band aggressively until the varices are obliterated. If the patient is otherwise compensated, we resume beta blockers at the time of discharge from the hospital, but have a low threshold for stopping them. Patients with refractory ascites may have worse outcomes if placed on beta blockers, based upon the results of a prospective study, but further randomized studies are needed before beta blocker use can be considered specifically harmful in these patients. (See",
"      <a class=\"local\" href=\"#H5066642\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical portal decompression may be an option for patients with Child class A cirrhosis provided that the appropriate surgical expertise is available. (See",
"      <a class=\"local\" href=\"#H70340046\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with liver failure undergo evaluation for liver transplantation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"       \"Patient selection for liver transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with acute variceal bleeding despite adequate band ligation and beta blockers we recommend either TIPS or surgery as a bridge to transplantation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The choice of procedure should be individualized based upon the patient's condition and available expertise. (See",
"      <a class=\"local\" href=\"#H70340034\">",
"       'Transjugular intrahepatic portosystemic shunts'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H70340046\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other approaches have also been proposed based upon measurement of the hepatic venous pressure gradient and may be equally valid as the approach outlined above. (See",
"      <a class=\"local\" href=\"#H70340034\">",
"       'Transjugular intrahepatic portosystemic shunts'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H44578461\">",
"       'Using HVPG to guide treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/1\">",
"      Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/2\">",
"      Burroughs AK. The natural history of varices. J Hepatol 1993; 17 Suppl 2:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/3\">",
"      Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/4\">",
"      MacDougall BR, Westaby D, Theodossi A, et al. Increased long-term survival in variceal haemorrhage using injection sclerotherapy. Results of a controlled trial. Lancet 1982; 1:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/5\">",
"      S&ouml;derlund C, Ihre T. Endoscopic sclerotherapy v. conservative management of bleeding oesophageal varices. A 5-year prospective controlled trial of emergency and long-term treatment. Acta Chir Scand 1985; 151:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/6\">",
"      Terblanche J, Bornman PC, Kahn D, et al. Failure of repeated injection sclerotherapy to improve long-term survival after oesophageal variceal bleeding. A five-year prospective controlled clinical trial. Lancet 1983; 2:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/7\">",
"      Sclerotherapy after first variceal hemorrhage in cirrhosis. A randomized multicenter trial. The Copenhagen Esophageal Varices Sclerotherapy Project. N Engl J Med 1984; 311:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/8\">",
"      Westaby D, Macdougall BR, Williams R. Improved survival following injection sclerotherapy for esophageal varices: final analysis of a controlled trial. Hepatology 1985; 5:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/9\">",
"      Korula J, Balart LA, Radvan G, et al. A prospective, randomized controlled trial of chronic esophageal variceal sclerotherapy. Hepatology 1985; 5:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/10\">",
"      Kochhar R, Goenka MK, Mehta SK. Esophageal strictures following endoscopic variceal sclerotherapy. Antecedents, clinical profile, and management. Dig Dis Sci 1992; 37:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/11\">",
"      Garg PK, Sidhu SS, Bhargava DK. Role of omeprazole in prevention and treatment of postendoscopic variceal sclerotherapy esophageal complications. Double-blind randomized study. Dig Dis Sci 1995; 40:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/12\">",
"      Sarin SK, Nanda R, Sachdev G, et al. Intravariceal versus paravariceal sclerotherapy: a prospective, controlled, randomised trial. Gut 1987; 28:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/13\">",
"      Bhargava DK, Singh B, Dogra R, et al. Prospective randomized comparison of sodium tetradecyl sulfate and polidocanol as variceal sclerosing agents. Am J Gastroenterol 1992; 87:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/14\">",
"      Akriviadis E, Korula J, Gupta S, et al. Frequent endoscopic variceal sclerotherapy increases risk of complications. Prospective randomized controlled study of two treatment schedules. Dig Dis Sci 1989; 34:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/15\">",
"      Sarin SK, Sachdev G, Nanda R, et al. Comparison of the two time schedules for endoscopic sclerotherapy: a prospective randomised controlled study. Gut 1986; 27:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/16\">",
"      Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Intern Med 1997; 126:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/17\">",
"      Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995; 123:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/18\">",
"      Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 1997; 92:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/19\">",
"      Laine L, el-Newihi HM, Migikovsky B, et al. Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med 1993; 119:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/20\">",
"      Stiegmann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992; 326:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/21\">",
"      de la Pe&ntilde;a J, Rivero M, Sanchez E, et al. Variceal ligation compared with endoscopic sclerotherapy for variceal hemorrhage: prospective randomized trial. Gastrointest Endosc 1999; 49:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/22\">",
"      Lo GH, Lai KH, Cheng JS, et al. The additive effect of sclerotherapy to patients receiving repeated endoscopic variceal ligation: a prospective, randomized trial. Hepatology 1998; 28:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/23\">",
"      Pagliaro L, D'Amico G, S&ouml;rensen TI, et al. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med 1992; 117:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/24\">",
"      Lebrec D, Poynard T, Bernuau J, et al. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology 1984; 4:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/25\">",
"      Cerbelaud P, Lavignolle A, Perrin D, et al. Propranolol et prevention des recidives des ruptures de varice oesophagienne du cirrhotique. Gastroenterol Clin Biol 1986; 10:18A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/26\">",
"      Colman J, Jones P, Finch C, et al. Propranolol in the prevention of variceal hemorrhage in alcoholic cirrhotic patients. Hepatology 1990; 12:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/27\">",
"      Colombo M, de Franchis R, Tommasini M, et al. Beta-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: a multicenter randomized controlled trial. Hepatology 1989; 9:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/28\">",
"      Gatta A, Merkel C, Sacerdoti D, et al. Nadolol for prevention of variceal rebleeding in cirrhosis: a controlled clinical trial. Digestion 1987; 37:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/29\">",
"      Villeneuve JP, Pomier-Layrargues G, Infante-Rivard C, et al. Propranolol for the prevention of recurrent variceal hemorrhage: a controlled trial. Hepatology 1986; 6:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/30\">",
"      Garden OJ, Mills PR, Birnie GG, et al. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial. Gastroenterology 1990; 98:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/31\">",
"      Sheen IS, Chen TY, Liaw YF. Randomized controlled study of propranolol for prevention of recurrent esophageal varices bleeding in patients with cirrhosis. Liver 1989; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/32\">",
"      Kiire CF. Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis. BMJ 1989; 298:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/33\">",
"      Queuniet AM, Czernichow P, Lerebours E, et al. [Controlled study of propranolol in the prevention of recurrent hemorrhage in cirrhotic patients]. Gastroenterol Clin Biol 1987; 11:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/34\">",
"      Marbet UA, Straumann A, Gyr KE, et al. Reduction in early recurrence of variceal bleeding by propranolol. Scand J Gastroenterol 1988; 23:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/35\">",
"      Hayes PC, Davis JM, Lewis JA, Bouchier IA. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet 1990; 336:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/36\">",
"      P&eacute;rez-Ayuso RM, Piqu&eacute; JM, Bosch J, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 1991; 337:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/37\">",
"      Poynard T, Lebrec D, Hillon P, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding. Hepatology 1987; 7:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/38\">",
"      Valla D, Jiron MI, Poynard T, et al. Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. J Hepatol 1987; 5:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/39\">",
"      Sacerdoti D, Merkel C, Gatta A. Importance of the 1-month-effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis. J Hepatol 1991; 12:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/40\">",
"      Feu F, Garc&iacute;a-Pag&aacute;n JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/41\">",
"      Raines DL, Dupont AW, Arguedas MR. Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding. Aliment Pharmacol Ther 2004; 19:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/42\">",
"      Koshy A, Girod C, Lee SS, et al. Discrepancy between portal pressure and systemic hemodynamic changes after incremental doses of propranolol in awake portal hypertensive rats. Hepatology 1989; 9:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/43\">",
"      Serst&eacute; T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/44\">",
"      Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe? Hepatology 2010; 52:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/45\">",
"      Zipprich A, Garcia-Tsao G, Seufferlein T, et al. The presence of esophageal varices (EV), but not treatement with beta-blockers, is associated with a poorer survival in patients with cirrhosis and ascites. Hepatology 2011; 54:461A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/46\">",
"      Gonzalez R, Zamora J, Gomez-Camarero J, et al. Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med 2008; 149:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/47\">",
"      Ravipati M, Katragadda S, Swaminathan PD, et al. Pharmacotherapy plus endoscopic intervention is more effective than pharmacotherapy or endoscopy alone in the secondary prevention of esophageal variceal bleeding: a meta-analysis of randomized, controlled trials. Gastrointest Endosc 2009; 70:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/48\">",
"      Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/49\">",
"      Qureshi H, Zuberi SJ, Alam E. Efficacy of oral propranolol and injection sclerotherapy in the long-term management of variceal bleeding. Digestion 1990; 46:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/50\">",
"      Rossi V, Cal&egrave;s P, Burtin P, et al. Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: prospective controlled trial of propranolol and sclerotherapy. J Hepatol 1991; 12:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/51\">",
"      Andreani T, Poupon RE, Balkau GB, et al. Efficacite comparee du propranolol et de sclerose endoscopique de varices oesophagienned dans la prevention des recidives d'hemorragies digestives au cours des cirrhosis. Etude controlee. Gastroenterol Clin Biol 1991; 15(Suppl):A215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/52\">",
"      Alexandrino PT, Alves MM, Pinto Correia J. Propranolol or endoscopic sclerotherapy in the prevention of recurrence of variceal bleeding. A prospective, randomized controlled trial. J Hepatol 1988; 7:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/53\">",
"      Dasarathy S, Dwivedi M, Bhargava DK, et al. A prospective randomized trial comparing repeated endoscopic sclerotherapy and propranolol in decompensated (Child class B and C) cirrhotic patients. Hepatology 1992; 16:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/54\">",
"      Dollet JM, Champigneulle B, Patris A, et al. [Endoscopic sclerotherapy versus propranolol after hemorrhage caused by rupture of esophageal varices in patients with cirrhosis. Results of a 4-year randomized study]. Gastroenterol Clin Biol 1988; 12:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/55\">",
"      Fleig WE, Stange EF, Hunecke R, et al. Prevention of recurrent bleeding in cirrhotics with recent variceal hemorrhage: prospective, randomized comparison of propranolol and sclerotherapy. Hepatology 1987; 7:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/56\">",
"      Martin T, Taupignon A, Lavignolle A, et al. [Prevention of recurrent hemorrhage in patients with cirrhosis. Results of a controlled trial of propranolol versus endoscopic sclerotherapy]. Gastroenterol Clin Biol 1991; 15:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/57\">",
"      Ter&eacute;s J, Bosch J, Bordas JM, et al. Propranolol versus sclerotherapy in preventing variceal rebleeding: a randomized controlled trial. Gastroenterology 1993; 105:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/58\">",
"      Westaby D, Polson RJ, Gimson AE, et al. A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term management of variceal bleeding. Hepatology 1990; 11:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/59\">",
"      Pagliaro L, Burroughs AK, Sorensen TIA, et al. Therapeutic controversies and randomized controlled trials: Prevention of bleeding and rebleeding in cirrhosis. Gastroenterol Int 1989; 2:71.",
"     </a>",
"    </li>",
"    <li>",
"     Ferayorni, L, Polio, J, Groszmann, RJ. Drug therapy for portal hypertension: A 5 year review. In: Portal hypertension II: Proceedings of the Second Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies, DeFranchis, R (Eds), Blackwell Science, Oxford 1996. p.68.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/61\">",
"      D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/62\">",
"      Bernard B, Lebrec D, Mathurin P, et al. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. J Hepatol 1997; 26:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/63\">",
"      Merkel C, Sacerdoti D, Bolognesi M, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Hepatology 1997; 26:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/64\">",
"      Villanueva C, Balanz&oacute; J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/65\">",
"      Gournay J, Masliah C, Martin T, et al. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000; 31:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/66\">",
"      Villanueva C, Mi&ntilde;ana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/67\">",
"      Lo GH, Chen WC, Chen MH, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 2002; 123:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/68\">",
"      Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002; 123:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/69\">",
"      Garc&iacute;a-Pag&aacute;n JC, Villanueva C, Albillos A, et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut 2009; 58:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/70\">",
"      Kumar A, Jha SK, Sharma P, et al. Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology 2009; 137:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/71\">",
"      Groszmann RJ, Garcia-Tsao G. Endoscopic variceal banding vs. pharmacological therapy for the prevention of recurrent variceal hemorrhage: what makes the difference? Gastroenterology 2002; 123:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/72\">",
"      Jalan R, Forrest EH, Stanley AJ, et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology 1997; 26:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/73\">",
"      Pomier-Layrargues G, Villeneuve JP, Desch&ecirc;nes M, et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut 2001; 48:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/74\">",
"      Merli M, Salerno F, Riggio O, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology 1998; 27:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/75\">",
"      Cabrera J, Maynar M, Granados R, et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996; 110:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/76\">",
"      Cello JP, Ring EJ, Olcott EW, et al. Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial. Ann Intern Med 1997; 126:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/77\">",
"      Sauer P, Theilmann L, Stremmel W, et al. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology 1997; 113:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/78\">",
"      Garc&iacute;a-Villarreal L, Mart&iacute;nez-Lagares F, Sierra A, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage. Hepatology 1999; 29:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/79\">",
"      R&ouml;ssle M, Deibert P, Haag K, et al. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997; 349:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/80\">",
"      Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994; 20:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/81\">",
"      Pomier-Layrargues G. TIPS and hepatic encephalopathy. Semin Liver Dis 1996; 16:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/82\">",
"      Papatheodoridis GV, Goulis J, Leandro G, et al. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology 1999; 30:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/83\">",
"      Russo MW, Zacks SL, Sandler RS, Brown RS. Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. Hepatology 2000; 31:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/84\">",
"      Escorsell A, Ba&ntilde;ares R, Garc&iacute;a-Pag&aacute;n JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 2002; 35:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/85\">",
"      Garc&iacute;a-Pag&aacute;n JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/86\">",
"      Monescillo A, Mart&iacute;nez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/87\">",
"      Sanyal AJ, Freedman AM, Luketic VA, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/88\">",
"      Bureau C, Pagan JC, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int 2007; 27:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/89\">",
"      Cello JP, Grendell JH, Crass RA, et al. Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and variceal hemorrhage. N Engl J Med 1984; 311:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/90\">",
"      Cello JP, Grendell JH, Crass RA, et al. Endoscopic sclerotherapy versus portacaval shunt in patient with severe cirrhosis and acute variceal hemorrhage. Long-term follow-up. N Engl J Med 1987; 316:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/91\">",
"      Henderson JM, Kutner MH, Millikan WJ Jr, et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis. A prospective, randomized trial. Ann Intern Med 1990; 112:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/92\">",
"      Ter&eacute;s J, Baroni R, Bordas JM, et al. Randomized trial of portacaval shunt, stapling transection and endoscopic sclerotherapy in uncontrolled variceal bleeding. J Hepatol 1987; 4:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/93\">",
"      Kitano S, Iso Y, Hashizume M, et al. Sclerotherapy vs. esophageal transection vs. distal splenorenal shunt for the clinical management of esophageal varices in patients with child class A and B liver function: a prospective randomized trial. Hepatology 1992; 15:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/94\">",
"      Rikkers LF, Jin G, Burnett DA, et al. Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. Am J Surg 1993; 165:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/95\">",
"      Garrett KO, Reilly JJ Jr, Schade RR, van Thiel DH. Bleeding esophageal varices: treatment by sclerotherapy and liver transplantation. Surgery 1988; 104:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/96\">",
"      Bismuth H, Adam R, Raccuia JS. [Liver transplantation in the treatment strategy of portal hypertension]. Chirurg 1995; 66:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/97\">",
"      Esquivel CO, Klintmalm G, Iwatsuki S, et al. Liver transplantation in patients with patent splenorenal shunts. Surgery 1987; 101:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/98\">",
"      Shaked A, Goldstein RM, Klintmalm GB, et al. Portosystemic shunt versus orthotopic liver transplantation for the Budd-Chiari syndrome. Surg Gynecol Obstet 1992; 174:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/99\">",
"      Targownik LE, Spiegel BM, Dulai GS, et al. The cost-effectiveness of hepatic venous pressure gradient monitoring in the prevention of recurrent variceal hemorrhage. Am J Gastroenterol 2004; 99:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/23/17786/abstract/100\">",
"      Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med 2001; 345:669.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1252 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-29CCF0041E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17786=[""].join("\n");
var outline_f17_23_17786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H70340076\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70339949\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70339956\">",
"      AASLD GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70339962\">",
"      ENDOSCOPIC SCLEROTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70339968\">",
"      Technique and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70339974\">",
"      ENDOSCOPIC BAND LIGATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70339980\">",
"      Band ligation versus sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70339986\">",
"      Band ligation plus sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70339992\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70339998\">",
"      Nonselective beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5066642\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70340004\">",
"      Beta blockers plus band ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70340010\">",
"      Beta blockers versus sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70340016\">",
"      Beta blockers plus sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70340022\">",
"      Beta blockers plus oral nitrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70340028\">",
"      Beta blockers plus oral nitrates versus band ligation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70340034\">",
"      TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70340040\">",
"      Recurrence of portal hypertension and stent stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70340046\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70340052\">",
"      Use as initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70340058\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H70340064\">",
"      - Conclusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44578461\">",
"      USING HVPG TO GUIDE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44578468\">",
"      Child-Pugh class A or B cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44578475\">",
"      Child-Pugh class C cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70340076\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1252\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1252|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/15/10494\" title=\"figure 1\">",
"      DSRS v endosc sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/10/3239\" title=\"figure 2\">",
"      Transjugular intrahepatic portosystemic shunt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/2/16430\" title=\"figure 3\">",
"      EST v TIPS variceal rebleed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/20/33102\" title=\"figure 4\">",
"      EST v TIPS mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1252|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/35/35388\" title=\"table 1\">",
"      Sclerotherapy prevent rebleed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/41/34459\" title=\"table 2\">",
"      Complications of sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/21/8540\" title=\"table 3\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/45/7899\" title=\"table 4\">",
"      GI bleeding after TIPS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15448?source=related_link\">",
"      Complications of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=related_link\">",
"      Endoscopic variceal ligation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=related_link\">",
"      General principles of the management of variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/40/8834?source=related_link\">",
"      Patient information: Esophageal varices (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/9/12434?source=related_link\">",
"      Patient information: Screening for esophageal varices (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39511?source=related_link\">",
"      Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=related_link\">",
"      Treatment of active variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=related_link\">",
"      Uncommon causes of upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_23_17787="Reversibility of FEV1";
var content_f17_23_17787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessing impairment in patients with asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reversibility of FEV1 (percent FEV1",
"change)",
"       </td>",
"       <td class=\"subtitle1\">",
"        or",
"       </td>",
"       <td class=\"subtitle1\">",
"        Airway Hyperresponsiveness",
"(PC20 mg/mL or equivalent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &lt;10",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        &nbsp;",
"        <br/>",
"       </td>",
"       <td>",
"        &gt;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        10-19",
"       </td>",
"       <td>",
"        8-&gt;0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        20-29",
"       </td>",
"       <td>",
"        0.5-&gt;0.125",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        &ge;30",
"       </td>",
"       <td>",
"        &le;0.125",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from American Thoracic Society. Guidelines for the evaluation of impairment/disability in patients with asthma. Am Rev Respir Dis 1993; 147:1056.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17787=[""].join("\n");
var outline_f17_23_17787=null;
var title_f17_23_17788="Hodgkin immunophenotype";
var content_f17_23_17788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and classical Hodgkin lymphoma (HL): Morphologic and immunophenotypic features",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Classical HL",
"       </td>",
"       <td class=\"subtitle1\">",
"        NLPHL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pattern",
"       </td>",
"       <td>",
"        Diffuse, interfollicular, nodular",
"       </td>",
"       <td>",
"        Nodular, at least in part",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumor cells",
"       </td>",
"       <td>",
"        Diagnostic RS cells; mononuclear or lacunar cells",
"       </td>",
"       <td>",
"        \"L&amp;H\" or \"popcorn\" cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Background",
"       </td>",
"       <td>",
"        Lymphocytes, histiocytes, eosinophils, plasma cells",
"       </td>",
"       <td>",
"        Lymphocytes, histiocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrosis",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD15",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD30",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD20",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD45",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EMA",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EBV (in RS cells)",
"       </td>",
"       <td>",
"        + (&sim;50%)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oct2",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BOB.1",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Background lymphocytes",
"       </td>",
"       <td>",
"        T cells &gt; B cells",
"       </td>",
"       <td>",
"        B cells &gt; T cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD57+ Tcells",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ig genes (single-cell PCR)",
"       </td>",
"       <td>",
"        Rearranged, clonal, mutated, \"crippled\", no ongoing somatic hypermutation",
"       </td>",
"       <td>",
"        Rearranged, clonal, mutated, productive, ongoing somatic hypermutation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17788=[""].join("\n");
var outline_f17_23_17788=null;
var title_f17_23_17789="Causes persistent cough in children";
var content_f17_23_17789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of persistent cough in children*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Congenital anomalies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Connection of the airway to the esophagus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Laryngeal cleft",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Tracheoesophageal fistula",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Laryngotracheomalacia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Primary laryngotracheomalacia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Laryngotracheomalacia secondary to vascular or other compression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bronchopulmonary foregut malformation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Congenital mediastinal tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Congenital heart disease with pulmonary congestion or vascular airway compression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recurrent viral infection (infants and toddlers)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Persistent bacterial bronchitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chlamydial infection (infants)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Whooping cough-like syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <em>",
"        Bordetella pertussis",
"       </em>",
"       infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Chlamydial infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <em>",
"        Mycoplasma",
"       </em>",
"       infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cystic fibrosis (infants and toddlers)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Granulomatous infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Mycobacterial infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Fungal infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Suppurative lung disease (bronchiectasis and lung abscess)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cystic fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Foreign body aspiration with secondary suppuration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Ciliary dyskinesia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Immunodeficiency (primary or secondary, including HIV disease)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paranasal sinus infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Allergy and asthma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asthma and cough-dominant asthma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Allergic or vasomotor rhinitis and postnasal drip",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Aspiration (fluid material)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Dyskinetic swallowing with aspiration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       General neurodevelopmental problems",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       M&ouml;bius syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bottle-propping and bottle in bed (infants and toddlers)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastroesophageal reflux",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Foreign body aspiration (solid material)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Upper airway aspiration (tonsillar, pharyngeal, laryngeal)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tracheobronchial aspiration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Esophageal foreign body with an obstruction or aspiration resulting from dysphagia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Physical and chemical irritation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Smoke from tobacco products (active and passive)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Wood smoke from stoves and fireplaces",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dry, dusty environment (hobbies and employment)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Volatile chemicals (hobbies and employment)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Psychogenic or habit cough",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Iatrogenic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Angiotensin-converting enzyme inhibitors",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Longer than 3 weeks.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Taussing, LM, Landau, LI. Pediatric Respiratory Medicine, 2nd ed, Mosby, St. Louis, MO, 2008. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy; 2008 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17789=[""].join("\n");
var outline_f17_23_17789=null;
var title_f17_23_17790="Decision to intubate";
var content_f17_23_17790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The decision to intubate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 416px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17790=[""].join("\n");
var outline_f17_23_17790=null;
var title_f17_23_17791="PET-CT HSTL";
var content_f17_23_17791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PET/CT imaging of hepatosplenic T cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 294px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4ASYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKaxxTicCqWo3iQREkjNAD5rgx59KoSawIyd+MCsC/1rduVDzWHNfk5JPNAHWz+J1RtqKDRH4jZk3EKPrXCvMTJuPerPnARdaAOzg8QPKSvyZ7VpWmoGT7+K8yW5KvhTgmtKz1V4WAd+KAPS1kDDKmnCuc0jVorggBwTW/E4ccGgCWikpRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUGgCG6lCIa4jxJeOxKr0+tdFrc5jjbmuA1K6LyMWNAFCeRgODz3qKNjJ/Fk1BLP8Ae75plu/lqzN0oAt3O7ywQeRTUdtgUt0rFutVRcjJwDVvS7xblTigC1cs6BWHNEzmS3yCQwp9yrCLIGcVUhzuIk4BoAm8PX8lpdZZyRn1r0/w9q6XORxke9eXC0RB8p561ueEpjDdkE96APWlO4A+tKKrWMvmRr9KtA5zQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUj8KaWmS/6s0Acx4nnAQrmvOtSnVj5betdh4vkKnPavPbp1nviucY70AXmgUIHTuKqujtkdjViOTESqKoy3IWfaG6UAU5NP/dkMOpq5YQLBgelW+HUE8UFVC5xzQBYSYsCo70kkORu9KihOD70s5bBAagBHlXpnmrWnziKVWJxzXPRmQ3ZDEgCtCcnCFDzmgD2Tw5OJrRSDWzXK+CiwsY9w6iuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKhuX2xGpqguyvktmgDgvFz5U8Zrh2hAmMu2vQ9ftvMQleTXF3i4kKkYoApjpx3rDnt3W7LE8ZroJFQRhgaybpiZB6UAXQ+6FQh5FKXOMHrVCMMD+6yfWrIOF5Uk0AL5pVhipkuVZ9p+9WbIZCxKdaktIZSSz0AWZotsUj9xzVXTbk3ThB1Vqu5BiKseaNAsUbUNy9c0Aet+E0K2UWfSujFZOgJstkB9K1h3oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooNABmqV8PlPPWrlVLw5OKAMW+QeSxPYVw2pxoJGJ65rvLw8EHpXIa3AjRsY/vUAczdgiM7OcelZIjlumIjByO1b8UUiKdy5z1ohaOJ/3a/N3oAzILWeIfdx65plzK8eVGMCt6Qq6fNkVxfja9NnboYD8xNAGpZ7mBbbk+lWnWZTgDjGc0zwW5uNOWScfMRxW5csgic4GcUAci96qT7H65xXZeD7PzZfNxx1rk7LRHvdUDtnaWr1rQrFLSJFQdBzQB0unJthX2q7Ve2I8sAVYFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFBooNACVVvV+QsOtW8VHKu5SMdaAOM1vUY7chX69KyDGJhuXPPvXSa5osV5IN/HOayb3TjEyC3YqF9aAMW+V7KHfIvyVkRTW92++M4YHoK67VbcXGmeTJ94DrXn8Nt9ivcg8A0AdLPbMtrlFJ4rjde0hryWN5BjHau2u9WjttMjdxjNYrX0OoIHidWI6gGgCno5a0tPLUYGeDXQ6VE15GVmT6GsO5ZFgRF4Ocmuq8J3BmtzGcYHSgCeLTTaEYA9ciuj0ssyjNVljYDDcir1kPmG3gZ6UAblqPkqaorf7lSigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAppJzTqKAM69B3c8Vi3hAk5Nb98Dg8VzOro8aM4zQA6YR+QxIySK4fUUUzuwTgc1v2N60kMqNn2zWbcwBY2Zz1oA5TV71bq1aEqRhSFrzXwLc6pZ+K7uC4V2tS3yV60NLgml3b+c9K1o9AtYkEyxJ5h7gUAcpL532hyI2IrtPBC5iJZcGor2z2Wu5YzuxxxV3wxDIoO4EUAdVD87YrRtbYBgar2sPAIrThUjFAE6DaMU6kHvS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAZozSUUAGRTJJNvSmyyBaqTTg5oAdLMG61i6ww2FW6GtFTl+elUNXjDpkUAc+I1gjY+tZ2qsPLUEHB9KuXDFpBEegqOYxn923IFAGHZxxicfMck11dqqnucY4rDhtVjn3kcVs2kgMmF6UAaKxLImHwcVZtYEjXgCqoJUZFXrUswG7igDTtgcDHSr6DpVOHCgCrAkoAnNA6VD5lOEnFAEuaKj8wU7cPWgB1FNDinA5oAKKKKACiiigAooooAKKKKACiiigAooooASgUHimO2OnWgCSkqAzADJNRC5RicGgC4Tik31VM4A4NV5LxVbBPNAGgz8ZqJ5Tjg1VE4P8VSKw65oASQljUbQ7iD0pZ5ljIB61VnuwoO080AOu5FgjJzzXNXWsFi8RX8atXk8k799tZE8J+0OcDaBQBQnvY4518x/mccA1Ve8dQWwGwa8n+LnixtG8R2EMblUJ5robTVbqe3hkRgVZQ3WgDurO/a4JVgeKv2rusxIzXI2OsR2Fk89yyg81L4Q8WJrGpNHEQ3OOKAPRLB3c/P0rftoxtBwKw4l5DDIwcEGrsl4YIuP0oA2mUAA0uQcY7VlabfNOuXz1xV8P83HSgCdnAGScVCLhC2NxqnduWbAPFU5pktU3M1AF+7vTEQATTIdQLdc1VtLmG6U55qQwgE7aAJxqGyXDE81q29ysqjFc7Jbsx3Y5FW7IvHgGgDoAcigVVgmBNWhQAUUUUAFFFFABRRRQAUUUUAFFFI3SgCOSQCsnUL4xg7TzV25PPFZc8AeT5jQBBa3c0zYcELVgoQ/B60qxqhA/hqtqF0tsuRQAtzdCDh2qk7+edyNWDf3r30hWNjWtotpMIAZCSfegCZGmVuScVpQXJxhjSNbgKPm/Cq0jLv2oB+FAFmd/MIINVnK7sMamSI+WSeK53Vnulu1WLJXPWgDZm/uqvB71garPMjsAvBrejaRbdAw5xyapXzI+SYwcUAeDfFzwKdb8q9VmE6jJxUmkCGw0u2hmmy6IAQTXf+ItQTypAUwOlcDeWdnfYKybHzyB3oAx/iPrNna+FgolKyzZ2YNS/s4Ry3KT3o3HY2Mmud+JXgzVb61sprNWkhRmVV9BXqXws0STwf4LVZTiaUb2+poA9ahmdmKy9zmrmFdMZzXK6Bqct4MOMkdTW9bllYlnwD2oAuQSiEEAVMt4zBsdapNyvTmnRAqhIoAtqXkOWqvqli1xDhW7VJY3f7zbIua0sAqRjrQBylizaexRmzXQWN0siZNYGvIYXZgMAc1S0vVGzsB/CgDtBNGTyQKlWaI/dYVx811JI/BIqxZvJuB3HrQB2EBG7g1oRfdrFsm3AE9a2ISdvWgCWiiigAooooAKKKKACiiigApG6UppjmgCjdkAE965DUtVe3uSPwrrrjkkGuL1+zLylgO9AF221dWiHmEAmsrWr8Or5bgCs6Wzm2gLkVXvdMuplAXNAF7wugnkLHkZruY9seABwRXPeGtNNlAokHzEVu3kwjjB9KAEvJSFO0dqy9KSTz3eX8BUyTm4cY6VeEaqBtFAEuCwAHSoZ7YZBVc+tJ55U4FIZJWOexoAzdQuWiYIuSKQrmBiwHzCrF7E2C5XNUoZHKOHHFAHm3jy8g03i4IVTXF2klrPKJInBGc9a6r4uaTJqUAMCkt7VwXhvQLqFl83dx60Ad0urMtuqrhlXsRVmPU2vLIxnO7PAptvpu23XCZNWLK3hhul8wbcnpQB1/hGzMVsJXyCR0q9qHm+apiHFTWMgW2RY8bcc1b3ocZGTQA61zJCpYfNUoODgCpYNuzpio2dVY0ANj2CTIHIq/HcCXAU/MO1ZpdSTjgmpLG3Pmbt3egB2rWZu0KgZOMGuf0/Q3iuySPlrs1eNiFU5Ipyxqr7ttAGA1gFk6VZjtlXHFaV0oK7gOlVrc5bBFAF+1QKorSgPFZ8XC1ehORQBZooHSigAooooAKKKKACiijNACGo3PrUjVBOfl4oAp3TAnp0qhNCkoJK81Zlfk5FRyN+6J6UAY5jQzbABV+K3UKPlFZabmuyV55rZVsIM9aAFm2oQQMcVWvgHtxTr5mKjFVbiQi3x3oAjsNsbEflWmnTDd6y4Y/kD9+tXbackYcdKALKwKeSabKu0EqeO1IZS3G3ik6DJ6UAUprlt21hkVHI0bwuwwABS3s6Lnis28LLaSsh7UAcdr2oLLPLCoHyng1zFxLPHgINpPVhWF4u1WS31cJGTuLc10Wn3cE0EaycsRyKANzSXaa3j9T1PrUOqskT724Kniue1/xfbaDNBDgKCeat3l4mq6etzEeHGcCgD0Lw5dJPZqQ2T3rXRu/evPPCU7wRopJ613NncB5ApIzQBsCUeWCTg1XkcHJB5qG4LEnFNhU5G44oAN2GyauW1w+QF78ZqncLt5quLhoyu096AOjsbZxcby3HWtUr8tYuntK7KzMQDWyoyOtAEJGchuRVVh5cnAwKuP8ALVS+IVM0AWo2yoxV6AnFZNg4dOvStWE5HFAFtelLSKOBS0AFFFFABRRRQAUlLQaAE7Gq8/3DU56Gq85+Q0AZsnJqC5JEJAqckbjVa7fCkYoAo2kf70k1pjG0cVUtUDKSetXolyMUARTFS4XHas6+iMZz2NacyYfcRzWVqU5DDd2oAhglIbaelX44933aymOV8wD3q5p96WHzGgC+oKdaZNMBweBUu/cuc1Rv1DKcHmgDPv3UyZBqrNJiCVW7rVW48xZMnOBVbVbspZGRfvgc0AeXeIdGa51R5SP4uK1tI0dsKWOKkutUhkDEj5weaaurN5GIxQB498dWaDVIURjgHtXY/DXUFk0O0jmkyCvGa5L4s2VzqJS42nOeTWJBqk2jWVoYSSYxyBQB9EWzm3b5R8vUVs6TdPJOGJ4rkfCOrw61pEUhYCUgCo9U8Ww+GrpBdn9yxxmgD2GNgqBm5NTIyupIGMVzPh/X7PWbJZbORWXGeDmtrz1BGzlSOaAJJ5FKkd6yS3zgH1q1M20lvWqEsm2QFvu0Adjo7q6qPStpRleK5PQrgM4Cmuqhb5fegCOVDmqWpofJ/CtU4K5PWq91EJEwRQBi6JJlmU5rpbYjaMVztogguG4xW5ZvmgDRU8U6mrTqACiiigAooooAKDRQaAGnvVeflcd6naqs74oAz3JDciq07AsBVqYZbrVfyw0vNAD4oxj0q3CuKYqDgVYUACgCOVR3rE1eIE8Cth2O6szV3AjLY6UAZ9ntUFH79qiliML7lGAarLPzvBp63yyOFfpQBZgu8HaTVhmDg8c1RmCcMlRvdmOPJoAW5jIY5GR6VialGpR42GARWgt+spOegrMvZ1lLhfvUAeeanYeVePsGdxrUtLWFIE3EK3fPaszX5Lm2M8hQnHSsbwdqV7qk8sdwjKueDQBqeL9NjmsSFAYetcHaeHYbsSQtjdXpl7azPYSowOcfLmuJ8LaVqC+JT9oz5JP6UAcn4c1yXw1rDWc7nygxC5ro/HU1l4n0VF8xUkHKn3qf4t+C4xB9ssOXHzHbXHeDdOutUQQOWBjOOaANP4S3eraDqrxO7Pak4AzxXukeul2+RsLivJodOudGfJUkZ61tW+omBBMz5xztoA9Usr57hBu6etR6pN+7AXrXMaF4mtpo9jOqt6ZrQub4yL8jAigDsPCbZIJNdtASQMV5x4QuCbgAt3r0AahDAoV2ANAGmMFR60khAXFRwypKoZWBqRyAORQBk3KYkJxWhp5+UA9ar3a8Zos5f3gFAG4lSZqGJs1KKAFooooAKKKKACkJpaQ9KAGMfWqF03HFXZD8tZ8xyx9KAKcxwuT1ptu2Wz3qPUGwnFMs2IUHFAGog+YVZAUjjrUNsu4gmrBQJkigCrLtB561jeIHC2bEccVrzNgk1heJhu0x9pwcUActbSbs/N1qO7k8oblPesGy1JEkkjZhuU4xVh75HQliAvqTQBu2l+GTDkZqWe4WSLaa5ZruN+beVXx12mom1R1IQj8aANtyqIwjzzVe0UvcbuferGmKtwgbIJ9M0XckdjnJAJoAqeILaCWAlwPesC1ksNLjLxIFPeszx14njsbNm3gsPQ9ay/CmoR+KLPptNAHbzX0WowDy8celVYbVzJujXDdzT9J0kWsgw4IPbNdFcW/2WASKOCKAMOzsvt3m2t0AyngZrOtPCK6Vfs0CbYyc1tpqNvbv5jMobvWJr/jaKNisbqce9AFvU9OjuYmEm0GuPm0C4EjKgyh7+lULrxsJ3KbwHzxzWrofisbvJnwd3HNAHnfiaG/0DUUliDmMnk1qHxqbKCAyNlWxmtbxfdSXl4tt5GYX6NivN/Gmk3FlbhAjFc7gfagD6B+Gevx6lcKYWBPXFdB4k1G++2bYkY4PGK+b/gp4q/sTxAsV3IBHIQoLHvX2RpNtaX9pFcNGCX5Bx1oAb4KuLia1X7SpBB6V1z5K9OKrafbxQ/cUYq84BjOOtAGdc8piqNu22U59a05EyvvVFogH460Abdm4ZQasg1mWLYwK0QaAJKKRaWgAooooAKaTxSk4phPNAEE7YU1nsxOatXT4yKol8CgCrcjewFPiTaAKjRt8uT2NWgNzA0AaFoPlqZ+QaituFqZ+BQBSlTJ/GuZ8Xt5OnSnOOK6pyd3FcV4+zNYSxoSCRQB86a/4gfTtbkkLYi71w/ij4i3dwrQWUhVfUVo/Fa2kii2w5J/iNeTkEEK3GKAO08M+PNS02fE8pdGPeuxuvH0bpvMuHxnGa8Z7gDmp4rWadiFBYigD2rw18TCJ/LeYgE461Q8ffE67kmNjpbbxj5pK8pFhdICyowI9KglWSNv3iur+poA3bXUr/XL1YLu4JTvk16L4bvf7KsjHbPtK9SK8gtJnhuY3hILnjAr2HwRpwuolW++USCgDd0XxJdzajEnnEqWr2C/kd9ARw2SFyTXnOn+HtOspkmEy9c8mu01PUIB4bmhtpFZ/LO2gDyvVPEaC4mtzKM8ivNdb1pheODL8pNYGrXl1Frdw8zHcJDkdqgvriC4VXO7f3oAtXWoMsySLIetb9jrSho5DL8w964qaQOflHGMVGCR0JoA9fj8bQIq+eqvtHWsDxb4st9ZsWSLiTp+FcAWY9WNLGpd8LQBLYOyX1u0f3xICPzr73+Gl08nhjTzOfn2DrXwroFq0msWoeNtokBOB719y+BY9+jWfl5AVRQB6JbMGAK1bIyKoaagCAHPWtLHYUAUnOGNVHHz5NXZ0Oc1UlXvQA6M7DmtKB99ZasWTAAq7ZMRxQBfFLSClzQAUUUUAIxqCRvyqV6qXDbYzQBUuG3OearSjCe9OVtzfSm3A3cUAMhiwhbvU9vzSIMJUsCc5oAuxDinSdKWIYFJJ0NAFSRsZ5rznx9qPkwSDvXoF2dqMa8R+KGo4Lqp5oA8m8YXonV/NjDc151LHZTT/ALyHbnvXb6nIZYm3r1rhdZjEAaXccbulAGsNLsYbbKQgk9DVG1iS2ncngE1NY34Gm7mUtjtWe97Jcs22PaCeKAL0t/FDMAMEGtc2tpf2oaaNdvqK56K2UxlnGZOwqx586xCNeEFAFpNI06CcPCCWHIzV5tbuLHO3nHQCsdLyHp5nzjrWbqGplXwq7sUAdPN4gvpArGQgema3LLxNOluA75AU55rza3u5Z2LSZVRVwXiyRGON/noAydcuPtOpTy92Y1Qxjmp7qKSKRt4zu71FGpYkCgBgpaQgg4ooAWlUlWBHUUlHpQB6P8PL2yuruOGdFWQEcmvrrwSVXT4hGQUC8Yr4J0u9fT76OeM9CCa+v/gx4kGq6TEofkDpQB7fZSA7cVpCsaxccYrYQ5QUAMlGV6VTYBiQavMMrVKZcODQBWDeXJirkJwapSLhgauxDIFAGhGeKdUcXQVKaACiiigBrDNUb5cxnFXzVeVcnFAGRFGUyxppbc3FW7shUOKoW/QtQBaUZGKtQL2qCHBq7EuKAJAMCmS8CpscVBOfSgDL1PP2d8V85/EeRm1JkByCa+idWJ+yyfSvmvx6W/tVz/tUAcReJtBDHiuT1SyEkhIyyV0WuzN5LbeDWVZbltXmm5HTBoAyYiYYSjABRWbNdFbldo+TPatS9tnkVmUnbWSYzEp3jPpQBe+0GQjyuD60irMvm+a3BHFU8MQqpxnmrZnV0CMfm7igDnMkTnLHk8mtKEwqpydx96WawjM28HCmoXSOKXg5oAtSyZiwFAFZsUZa6+Uke4rQnmTywowCarcchCN1AEl8jYAyD7mqkIWAkuRk0xppA+HOcVfWz+1Qh41/KgDOkZCSeeaYc4zjiti004yyBHAGK1X0lWs5SFGVXPFAHIH2opxG0sPSkxjFACV7Z+zprLRas9pIwC9q8UrtvhFcm38aWwDYD8UAfeGlPmJW9a6CFtyiuY0Vw1lEc9hXRWjAr1oAt44qrcqAKtr05qrf/KlAFN+VFWYDxiqludwPNWIDQBfi6VMelVoyasKcigBaKKKAEbpVeQ81O5qrIck0AZmpk7cDvUdkpERBqS7YM4HvT4cAUAPhHNX4hVKDlq0IxigBz8Cqkr4arEzYFU5F3HOaAKWqYa2kz6V83fEKNY9Uds96+lLsBoWBGcivAfidYD7YxwcZoA8vv4lmQkYrOdB9maNgNtXryIxFsE7aynnUZBHHrQBUcqImiFYt4qseT92rl9ORKSi8Gsu4vYYlKuuS1AFeS6gVuGww702KNHczKxNZtzgSHA681Zs7grH5aj8aALcm7yiBTfsmIg7dakEi9HJ3VPqAJtl8s8EcmgDPkt/Mbep6VUmVopvQrzWnpljPMD5ZLDvSapZuSM4Vl4+tAFBLdp7cyIMsDzWrpavBatnIJp+mIlpbnewLHkiq+oXzH5LfnNAGhZyYD7j8/bNavh+V5fOhmHDjArj2e4jjWZ+MHpXfeDmj1OKIqoRlPOKAOC12yexv5FYEKxyKz69I+KWnpAIZVwflycV5ueTxQAldP8Og58WWbIOjDNcyOtehfBmya58SI4XIU0Afafh9sadb56lRXR2bjNc7o8ZW1hB4worctiFPWgDZHIWsvxFci2tzITgCtG3bcMHtXNePLO4u9MZbYncPSgCTRrkXFh5i85FWkdg4rI8G2c1lovl3PLYxzWmu4tQBrQyEgZq4hyKzoAcVei6UATUUZooAY9Up225q3IcVn3pJQ4oAyppMzn61aQ4QVmSK3nA+9a0YzEM0ASRPgitKM5QVlquGFacDfIKAGz9Kqk8VZueapSHaOKAIZzwa8p+Kdqq27SY5r1OUFl965bxppq32kyZGSooA+V9VmkDMmOCa52/laJdpHJru9fsRDPKpXkVxuriOREJGCOKAMMXG9yhXrVO/hijbMgzjpWv9nXOFqrd2ec5FAGBcBZV3dMUlnGgyxerV1Aqxt2qGGIMhANADJLlRKO6+tWFuFuF8tTisyVPLkZT2p1tnzkwCxz0oA9B8N2y2li7PzuFc74haQy5iGcHrXRWS3L6WNqEAD0qjb2zykiVeBQBzphnEQmYHkdKrQeal0pK5ya6t7Z5W8tE+XpWzovhJ7yZP3Z/KgDJg0ZtVt1XZyfSujGjT6FoUz2kZVghOa9M8OeDRptr5twvHatQaZHqMbQumY+mKAPmC4vr7UbC4a+ZmVF4zWBX0h498EWqeGrg2UQWQJngV85TRtFK8b/eU4NADK9v/AGcdOa41MyYOM56V4pFG00qRxrlmOBivsD4A+Gxp2hR3Eq7XYdxQB63bDYAvpVpZCGqu6fNkVaSPcgoA1rJ8x5qxIiuuG5zVS1XZHUxbigCKSJcbegpkcIzUhbmjODQBKi4qdOKhR+lSR8vQBYooooAhnqqw3Ag1am61EFoAzri1BKkHnNABVcCrsqgCqhYZxQAoOcVciY4xiqQGDmrEcuKAJrg44qv25FLLJvaoiWHXpQBDK+GwBVC/VXglQ8grmtKRQVJHWs69jIDn/ZoA+ePiAiW2oSYXKnNeZ6haG4dSpwvXFdt8ZtUmtb2RLdNxzXn2kvPcCN5iQ3XFAENxE0PLcEdqzbq7MysIhytbGtO0Epd+UYYrKOxId6KMdTQBifvpGO9Rt6c1o2ViIxuYZBrG1G73zHymKqOtdF4YtLjVIAqEk5xQBFPZWzsCV5Nbdho1lawLcyRHC85xXWaP8Nb65IkYHb1rpPE3hn+x9HRHQEkCgCr4TXTr3S280LF2AI61bbwxp7FvKkViegHeucLBLQJGmMdcV0HhS9t1lVbjcDkcGgDRt/BMEBRzjJ5HFdjpGgxWtusojGR7VaSKO7lQg4QDg10Fwix6ViM5IoAybw+bZFD8oArBsVkidinNaKzPMrKacsHlwMSOtADI7FdQglgfDF1xivEvGPwpuBq8ksETFHOcAV774TgD3LyYPFde1vDcf6yJSRQB8z+AvhYY9SSS6iOAQeR0r6L0W2jsLSOCNAqpx9atRWSxMWjjAqchcDd1oAnUbxkVcgBAAK1Wt0IAPatGJN4oAlU/LgUhPFI3yioWkzQA5iAc00Shz8vNRM2eKfaxhBQBajyOTViHrmoYwSeatouBmgCXFFFFAEUwzUA461bYZqtKmKAILgEocVmgPGSa1XG5fTFVp1+TigCBJ1bg0/cAciqaoVJNPJxQBZXk09hwKhgfJ6VYYg96AImHymqt6m+Ij/Zq7ngj2qGThTn0xQB82/FLTN1/IZBwWzXnnkhM+Xj5a9k+L8IiLyk/d7eteK2srPLIOgagDO1ZReqR3FYyBolaAjIPFdHeKiI4+6fWubS7RbzYx3GgCCHSIJpGQj5mr1r4V+EZFlRgp25zXnnhxPtetKgBGW4FfVfw800WltEXUHKjtQBv6Vpn2a3Xj7ornPGOkHV2CnAHv0r0F5EWJgF7Zrzzxd4hj0+F3RdxB/KgDmE8IQi4XzSuK0x4HtWUPER+FU7XxKLmDe0QHvT5fFoieNUBA9jQB1umWC20KQkcr3rSkhcx7QPlrO0S/W8iV8ctW2rYQDOfagDnLq0eObKDipVgEkeH4Nb6xq33lqnqMQQjYMUAT6XFFaxAgitBZEI3Kawo2Krzkin2s+2XaTxQBt/ascHvViPDqDWNO24rtNaNo+IwD1oA1IRkDFW14FVLQYU555q0xAFADZJMioN/UUrN7UKuaAHRLzViMZNRqpq1CnPWgCaNMYNWeopFXApwGKACiiigBKRgGFOpKAK7RcGoSuQc1eIzUEyUAZ8sYqo64NaLDrmq7xAnLUAVVO2nrKO9EidlqEKcHNAFyORScCnMm5KrwDAqcGgDyT4yaXJPp7ui9K+bC9xDcONvANfbPiTTk1HTZYsAkivm3xD4Nnh1aSNUO0knOKAPL7+aSbauOTVjTPB1zeXEUsSZzya9L8O/D95LtZLhcrnuK9W0Xwxa2agBARQBwPgjwFBCyXE8Q8xeeles2HlwRIiKQFGK0ILWKCNRGg6daq3kTFuBge1AC3l4I0yn3SK43XbWDUbUqqAljzXR3tuRCSTxWJPLBEFWUjb3AoA5NtNmihKRIMVRk0mXehePnNem6Zc6bKgUKDS6jPp0B3NtUUAReHrcw6cq7MNjg1edpUIOagtNVtJoSLeRTjsKt+YrAd80AWbWUv161TvvMadQOmav20aRDdjNOdkZs45oAyW+U4aljkRWGRxVjUCgTOKoJIrRlQPnoAuXl15aKUHHer2lyecAQeKzbCJ5twkHA9a2tOVYiABQBtwHbH70MxNNyAoxSrzQA4LmhTg0+MZFP2YNAD4iTir8CcZqkg6VoQsCKAJKKKKACiiigAoxRRQAUjdKWkbpQBUnWqxwRzVqaq5XNAEQUA1G6Ag44qwfl60x8YoAp4KkjNAfrnjFWGQEZrO1J/ItZHFAFXUNXWJhGvU8VmtZQ37b5EGeucVycl8ZtRJZjjdXe6KEez3DrQBny2aWsJ2ACsqS9McTYPIro9RXMRFcfrMBitZHU8tzQBtaNqPnp87Zx2rfZY5IA4xn0ryzw7qH2efbM3U13cl7st1ZDxjNAE2owBoXGea4DxRp0sUXmA5B7jtXUtrsTMY5etQaiqXsOFbK+lAHm2n3c1vcFSzVNrs09zb4Vyc1sahoRR/MUYqCLT5CyAjKg0AUfClndRRl3J45r0PQw0q4lB471mrbxwQptIGOorQsL6MOqIOaAN9QBFs6YNZ15fRwnbnLVPqV6lra7sgMRXFSXjT3is7DBbigDcuZ5Zfu9Km0+EyTBjwRS2ETSqBjIrbtrQRrkCgCGSWOFemPU0+01G080LvBJpNWtVFoW7kVwDiZLl3GQFNAHryssgBQgjFSwgkZxXHeE9XWc+W78g4rs4hkfKc0AWEUY4pR1pgbFSoQDQA9e4qW3b1qEDLcU5TtYUAXxRSIcrS0AFFFFABRRRQAU2Q4FOqGZsjigCAnJNJtoOKATQBEy80xkxUpBzTJc0AMCdeeMVla1D59oyA8mtYZ24NVbmMDg85oA8qvNPNtdZY45rrPD1zsiCE8VPrmkichwKwBHLY3Sqc7etAHXXq7wSOmK5nW4wLR93YV0NncpLCOecVzHje5MNmfLHAHNAHnQD3WobIc5B7V6Pp8T/2ePNPIXvXCeE3El2zEDcTwa7G+uXjgwpwMUAcV4hvzbaqQp4zzWraakzQgWzZYiqy6H/a10Zn4BPOa6C00KDTo/MXkgUAZVxq11jbJHwPaoYbm5uZwsQwlaFwQVY7BipdEtxM25PlbvmgC35GYBzlwOazYfMjuiRng1vXcRhT5eSetcxqt79mcMTigB+uX00rKGztFc7LfGO/j25xmuhgkS/t+OTjrWRdWAVycDcDxQB6V4WnE9mucZrfZOBt/KuJ8FXaJiJ25ruyyAfL3FAFO+TzIwGOK4/XrZfLYKcZ9K6y9c4O4jpxXOXqGUHg5oAreEtMZLpXBOK9ItlPl49K57wxamNQWxg106ptzigBydRU6LmoEFWI6AHhMUjcYp/NI/NAFiI5QVKKghPGKnoAKKKKACiiigBG6VWlPNWX6VWfBNAEdIaDTWNACE0g+ailXigAwBnPpVNss+T0q2xzmq7AZ4NAEZUODu6VjeILFTAXXqK2jgcUy5jEts69SRQB5vpupG3uHjkbvWf4rvfPiaNedw4rK8ZTS2GovHHwxPWsG21GWS8jjmJbBxzQBq+D7C5W8JKkrmuw1GynZ0GzjvWn4XsIxCsgAyRXQCFCDuGT70AcvpdqYYm+TBqUwyMCJB8hroEtgTkAYqC7gYoQtAHDSoRcFP4c10Wl6aqxB4+9K+nRu+7K5HUVpafNHCBGCDjtQBR1C2ZEGRkVw3ifTnu2URgjmvV54Uuk54J6VROkQhsnDH0NAHC6Zpr2FkCVJOKhlXzSCyd69Ekslkj8vYAPpWLd6MYtzAAqOaAOY0eP7LdtKeBXSQ62Xbb6VztxIQ7onUVReVo33EsCfSgDp9R1RpJEVDzmui0mx+0wq8o5PNc94Z05bsCV/mI55rvrWERwhRxigBkUKxAbRgLxVtWyAaQoAPWlReKAJFqVKjXpSgndQBYzTSeaO1LxQA+I81bHIqmn3hVwdBQAUUUUAFFFAoAZI2BVVjmrEvSq3agAPSozTz0pjDNADc4oHrTgMdaae9ADW5qMrzUhppoAjKZNO2qi5PSlFNnGYGz6UAeJfEiITa8xXgCuXiiwwkxyD1r0Lxdp3nzbl5fPNc7JYBECkUAd/4NuY201CT8wHSuhgYSgkYxXnWlGSz8vDHaeK7jRGMh2k9qAL5O0+1DjKHHWnyrxxUL5UZoA5++QRTEIxy3WpNNsCJBIWOT61dgtUknZpDk1fjQJ8oFABI/lpxjOOKiS4G7kHNPlhJbdnpUYgJbIoAuRkuO1VdSby7eXd0K1at4iBk9q5rxbqXWFPTBoA5NnQXkpzkZqpJmeZQq5GaktIwkzPIOGNdHYackmxlAAJzQB0/he1EVih24J610CqAOap6bH5dsqg9qvIMLzQBGMscCmq/wAxXvUmQuaYEJbdQBKp4pQeaFHFKBzQBKDxS80wnFOBoAkj+9zVtegqpH1q2v3aAFooooAKKKD0oAhlqA9amlYVATzQAhB9aTpRk0jk4oAQmk4xSHNJzigA4zTHwOaVjgGqJmLyFR2oAuI6PwDgioNRfbZyFeoFZ13efZpAR0PWqOpaqxhKqOCKAOUmu2lun8wng96raqsaRrMMY6modVMuC8Knk1Qkkd7NkuCQcdKANqzCXtn5qchOwrX0bUTBcbWIx05rm/C6y/Y5YoDlm6VpWOnPZwz3eoybVTLHJ4xQB28F1HKBmQVakVSuF5HrXkVp8SfDtzfvbW97GrocfMcDNbz+MIVVVS7Rw3RQetAHZQpmRugA7irKYJ+9muC/4TmG1kVZASG71rDxfpxj3+bGGxkrnkUAdPJ7EGnooA5Bz9a811P4n6NZM3mXMe5f4c9a5DT/AIw3OueJhp2nWUxhJx5gHH50Ae2anqcdrE+MAgetef3eoLc3LlsMCa3Do9zdQM0jNlhnk1xMljJaaiyzMQu6gDo7a1EwB6j0rSNyLUqo4xVawRowhXlCKydfuJYrkA8A9KAPS9Duxcwgitck+tcT4NvSICjH5sV1ENwznGaALbDPNOQkcUxHyMZ5qVQByaAHYNKtA5p2DQAhp4ppFOXmgCSPrVtfu1UXg1bQ/LQAtFFFABQehopG6UAVpetRmnv1phoAYabupXpEoANxpjnFS1HIM0AMJyvNYt9crbO5JrcUA4BrmfFdoy28kintQBzGq60JbjYjcio7TUjcP5RHPSuYiSQ37MxOCa6HSUhiu0dwDzQB1lhpcbRYmQc+tc14002AALANrj0rvoCskSlfSuE8bSPFfIR0J60AUvAEbpd4n4UcV3usaVFqWl3FjIoKyoRkVwmj3Hk3iMD1r0e1kEsaN3xyaAPmxv2ffL1qadZmFtuLR89KwdZ+E/ieC/d4NQkWBD8mD0FfWzuI48DAFZV8PMVggBHpigD5tg8H6qsKwz6g7zdBk1JP4A1uO2Z57to0I+/nk164+lkasJJVzzxW/r1o9xpgSMZwKAPnfw98LoLy+WTUJ3uVDc81774Q8G6bo1vE9laopA+8RzVXw7p32RQZEAOeuK7axZDEAuPpQBYWJViO0DFeYeN4TJebkG3ac/WvULiQRwOccAV5f4nulllYjkigDd8HrHe2gRuWWpfE3h0XJVoxyorM+HLP5r9cE13t+wjt3bA6UAcC88emQBVOHA5rV0XWo5FG9uTXD+IHmkvpMZ25rLXUzasiKxD560Ae3WsweUBDkHmtMAk4rmfCBa4s0lbJOOprplY8+tAEiVIajUEdaeORQAUqjAoXHegGgBynLVcj6VTXqKuR9KAHUUUUAFI3SlprdKAKz9aYae/WmGgCN6QEDrStTGGaAH7h60nHekCe9OI4oAZ1aqOsRefYyqRk4q8Vz04qCYfI6nmgDyqWwKXZ+tWYYAxwowQetbGpwBL7OOKk0uz8y53bfkoAu2ss0GmSMRyq1x73jayswkGWjPFektbobdkAGGGKyLTQLa1lkkwP3hyRQB51p8siXWxgcqa7jStUZQAemKmufD8Bm8yFcE1PaaMImyTQAXF3LKMKCc1c02FmjLSDnGasx2qrgYHFWB8q4GMUAcTqE5k1Aqo+6a3tJkM8YjIyPelbSozO0hxk1oWFqtt2oAiubRPLKgYNZgme1m2nOK35SpNV7iwSZ88A0AYWt6v5envlscV53KzXCvIckE8V3viHQJLhAEbg0aZ4YSKFAwBZecUAL4GtTBZmR1256Vq6nJJIpA6Yq7bQNBGECgAelLdwhoiVHOKAPMNfUxOxAyT1rj/ss1xqUf7s4LcV6JqduJLvDDjNXNI0VHvEcoMA0AdR4Wg+y6dErjHFbCgc1FAgRAuMY6VKB6UASDnrTxgUxaXODQA5/amDrTmNMzzQBKnUVdj6VSj6iryfdoAWiiigApOopaQdKAK8gqFqnkBqFwaAGYzTDjvTweoppHrQA0EVIDxUe3mndKAEY4qvIcgkdallziq6nH3qAOX1liLvGe9a+kRosGVXk1keIfluwfetjRATb57UAaHIXAqKRSTU+M9Kbj5vpQAwfJil2g8jrUdw/oaWNhxk0AP69etL5fHtT1XJyKmA4xQBRcc4qVMlADSOh8zpxUyIR24oAhMR3A9qmUd6kb7p4poIA5oAhmTJz6UkS4OTT3bnjpTXbCHFAD+c8UpUbGX2qOFsjmpSRg880AcNrKGK7J7ZrX8PNvwT2ql4gUPPgferS8ORbY8nigDeXmpADUKkgn61MjZFAEmzjimkHNSKTjmg80ARfWjHNDdaU9aAHxD5hV9Pu1Ttx1q6OlABRRRQAUZoooAik4FVzjPQ0UUAMHU801uD1oooATP1pGbkcn8qKKAI5m9c1WJG4daKKAOM8TSkX2FOSD6V0WgufsPLDPpiiigDVUnGcmmswCk8ZoooAziWaToMe1W4wBjOaKKALakYGM1Ih56miigAIGc5NODDb1oooAQkHjNNOMdTRRQBEwXPJNNYLtPJoooARSoHegtxuBGPeiigDitcvo01Daz9+wroPD7pLGCjA/UUUUAbanOcgD6VLHj1NFFAEuR6012AHXmiigCJWJPJqQMCetFFAFq3GQcVYoooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Combined positron emission tomography/computed tomography (PET/CT) imaging of a 66-year-old female with hepatosplenic T cell lymphoma demonstrates dramatically increased uptake in the liver and spleen. There was also increased uptake in the pituitary and some lymph nodes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Kindly provided by German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_23_17791=[""].join("\n");
var outline_f17_23_17791=null;
